

PHILIP EDWARD CASTLE

Office Address: National Cancer Institute/National Institutes of Health
9609 Medical Center Drive
Room 5E410
Rockville, MD 20850
USA

Phone: 240-276-7120
Fax: 240-276-7825
Email: philip.castle@nih.gov
Twitter: @NCICastle
Skype: philip.castle3

Web of Science Researcher ID: AAP-6395-2020

PROFESSIONAL INTERESTS

Epidemiology of human papillomaviruses (HPV) and cervical/anogenital cancer; science and translation of cancer prevention strategies; cancer screening; global health; health services research and delivery; and health disparities

I. EDUCATION

2000	M.P.H. (Epidemiology), The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA
1995	Ph.D. (Biophysics), The Johns Hopkins University, Baltimore, MD, USA. Thesis: <i>The Contraceptive Effects of Sperm-Agglutinating Monoclonal Antibodies in Rabbits</i>
1986	B.S. (Biological Sciences), Carnegie Mellon University, Pittsburgh, PA, USA

II. CURRENT EMPLOYMENT AND POSITIONS

2020—Present	Director, Division of Cancer Prevention, NCI, NIH, DHHS, Bethesda, MD, USA
--------------	--

Description: I lead the Division of Cancer Prevention (DCP) research portfolio and associated grants, contracts and programs in cancer prevention. I oversee the planning, direction, execution, and evaluation of a portfolio of research projects, research programs and other grant/awards, cooperative agreements, contracts, and interagency agreements related to the mission and mandates of DCP.

2020—Present	Senior (Tenured) Investigator, Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD, USA
--------------	--

Philip Edward Castle, Ph.D., M.P.H.
NCI Division of Cancer Prevention
9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
240-276-7120; philip.castle@nih.gov

Description: My research program and group are focused on discovery, development, and evaluation/validation of new technologies for the prevention of cancer. We are involved in the following studies: 1) natural history of anal and penile human papillomavirus (HPV) in men who have sex in men (MSM) living in Rwanda and Democratic Republic of Congo; 2) impact of prophylactic HPV vaccination of Rwandan women living with HIV (WLWH), 3) optimal cervical cancer screening strategies in Rwandan WLWH, 4) oral cavity cancer screening in Assam, India; 5) morphologic and genetic markers of gynecologic cancer; and 6) FDA registration trial for self-collection and HPV testing for cervical cancer screening in the US.

III. PROFESSIONAL HONORS AND RECOGNITIONS

2020	ASCCP Service Recognition Award
2017-18	NCI Cancer Prevention Fellowship Distinguished Alumni
2011	Clinical Cancer Advances 2011: Annual Report on Progress against Cancer from the American Society of Clinical Oncology. <i>J Clin Oncol</i> 2011 (Katki <i>et al.</i> , <i>Lancet Onc</i> , 2011)
2010	Arthur S. Flemming Award for Government Service in Applied Science, Engineering, and Mathematics (http://flemming.gwu.edu/) (also selected for Basic Sciences but can receive the award only in one category)
2010	American Society for Colposcopy and Cervical Pathology (ASCCP) Distinguished Scientific Achievement Award
2007	NIH Merit Award (for leadership in guiding the translation of human papillomavirus testing into cervical cancer screening for low-resource regions of the United States)
2006	European Research Organisation on Genital Infection and Neoplasia (EUROGIN) Distinguished Service Award
2003	Honorary Member of Argentina Association of Clinical Oncology
2002	Outstanding Research Paper by a Fellow (DCEG)
2001	Intramural Research Award for the proposal, "Cytokine Profiles in Cervical Secretions and their Relationship to HPV Persistence and Progression to Neoplasia"
1999	New Investigator Award, American Society of Reproductive Immunology
1991	Student Merit Award, American Society of Andrology

IV. EMPLOYMENT HISTORY

2014–20	Professor (with Tenure in 2019), Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
2015–20	Member, Albert Einstein Cancer Center, Bronx, NY, USA
2018–20	Visiting Professor, National University Health System of Singapore, Singapore
2019-20	Researcher, University of Oslo, Oslo, Norway
2015-17	Associate Investigator, Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH), DHHS, Bethesda, MD, USA
2012-16	Co-Founder and Executive Director, Global Cancer Initiative, Inc., Chestertown, MD, USA
2012-13	Director, Clinical Development, ImmuneXpress, Inc., Seattle, WA (part-time)

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

2012	Chief Scientific Officer, American Society for Clinical Pathology (ASCP), Washington, DC, USA
2011-12	Executive Director, ASCP Institute, Washington, DC
2010	Senior (Tenured) Investigator, DCEG, NCI, NIH, DHHS, Bethesda, MD, USA
2003-10	Tenure-Track Investigator, DCEG, NCI, NIH, DHHS, Bethesda, MD, USA
2002-13	Research Fellow, DCEG, NCI, NIH, DHHS, Bethesda, MD, USA
1999-02	Cancer Prevention Fellow, Division of Cancer Prevention (DCP), NCI, NIH, DHHS, Bethesda, MD, USA
1995-99	Post-Doctoral Fellow, Laboratory of Cellular and Developmental Biology, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, DHHS, Bethesda, MD, USA
1988-89	Research Assistant, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1986-88	Research Assistant, Sepracor, Inc., Marlborough, MA, USA

V. PAST ACADEMIC APPOINTMENTS

2014-16	Honorary Professor, University of New South Wales, Sydney, Australia
2011-18	Visiting Professor, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
2011-14	Visiting Professor in Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA

VI. CURRENT/RECENT ACTIVITIES

- Member, WHO Strategic Advisory Committee on in Vitro Diagnostics (SAGE IVD) (http://www.who.int/medical_devices/diagnostics/SAGE_IVD_2018_member_list/en/)
- Expert Advisor, American Cancer Society (ACS) Guideline Development Group (GDG) for Cervical Cancer Screening
- Member, WHO Thermoablation for Cervical Treatment Guidelines Group (<https://www.who.int/reproductivehealth/publications/thermal-ablation-for-cervical-pre-cancer-lesions/en/>)
- Consultant and Member of the Academic (Faglig) Panel for an implementation study of primary HPV testing of cervical cancer screening in 400,000 women living in Norway. The study is being directed by the Cancer Registry of Norway and Health Directorate of Norway (http://www.cancer.fi/rhs/006_2014_october/). (Ended March 30, 2020)
- Technical Advisor to Basic Health International and MOH of El Salvador for the implementation of HPV-based screening in El Salvador
- Official Advisor on Cervical Cancer Prevention and Control to the Vietnam Ministry of Health
- Official Advisor on Cervical Cancer Prevention and Control to the Haiti Ministry of Public Health and Population
- Consultant and Member of Executive Leadership for *New Mexico HPV Outcomes: Practice Evaluations and Surveillance (NM-HOPES)*; *Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)*; Steering Committee Member, NM HPV and Pap Registry (NMHPVPR)
- Co-Principal Investigator, KPNC Guidelines Cohort
- Principal Researcher/Investigator on COMPASS: A Randomised Controlled Trial of

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

Primary HPV Testing for Cervical Cancer Screening in Australia
<https://clinicaltrials.gov/ct2/show/NCT02328872>

- Co-Investigator, “Using Project ECHO Telementoring to Increase Access to Diagnosis and Treatment of Pre-invasive Cervical Disease Along the Texas-Mexico Border” (CPRIT)(Kathleen Schmeler, PI)
- Investigator, Best practices for prevention and control of cervical cancer. FRIDA Study (PI, Jorge Salmeron)
- Investigator, Rapid reduction of cervical cancer in Mexico: a demonstration trial. FRIDA 2 Study (PI, Jorge Salmeron)
- Participant, Bill & Melinda Gates Foundation meeting on cervical cancer screening and preventive treatment tools for low resource populations
- Consultant to Bill & Melinda Gates Foundation on cervical cancer screening and prevention
- Albert Einstein Cancer Center Representative, North American Consortium for Global Cancer Medicine
- Member of Mentoring Committee, Dr. Salina Marie Torres for “p16/Ki-67: A pilot study to evaluate the stability of liquid-based cytology (LBC) specimens for assessment of protein-based biomarker targets”
- Advisor, UOG-UHCC CPACHE (U54) Pilot: An Intervention to Increase Cervical Cancer Screening among Pacific Islanders Living in Guam (GU) and Hawaii (HI) (Dr. Neal Palafox, PI)
- AIDS Malignancy Consortium (AMC): Member (2016); Member, AMC HPV Working Group (2017); Member, Non-AIDS Defining Maligancies (2018); Steering Committee Member (2018-2020); Associate Chair of Cancer Prevention and Control (2019-2024)
- Technical Advisor on cervical cancer prevention to Rwanda, Uganda, Botswana, and Nicaragua
- Participant in WHO Expert Panel Meeting on HPV Testing and Prequalification (2017).
- Einstein/Rockefeller/CUNY (ERC)-CFAR (H. Goldstein, PI) Patient and Population Health Outcomes Research (PPHOR) Scientific Working Group and on the Clinical and Translational Investigations Core
- Member of HPV Test Characteristics Expert Panel for Cancer Care Ontario.
- Member and Chair, External Advisory Board, “Innovative Screening and Diagnosis of Oropharyngeal, Anal, and Cervical Cancers to Decrease the Morbidity, Mortality, and Costs of HPV-Related Cancer Care in Texas”. (CPRIT)(Kathleen Schmeler, PI)
- Member, Medical Advisory Board, Prevent Cancer Foundation (2018-2019)
- Co-Founder and CEO, Global Coalition Against Cervical Cancer, Inc., Arlington, VA, USA (2013-9)
- Member, Bronx Community Cancer Advisory Board (2019-)
- Advisor, CervicalScreen Singapore Advisory Committee, Health Promotion Board, Singapore https://www.sccps.org/wp-content/uploads/2019/03/CSS-Clinical-Mgt-Guidelines-2019_March-Release.pdf
- Participant, Screen and Treat Guideline Development Group, World Health Organization (2019-2020) (ended March 7, 2020)

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

VII. FORMER RESPONSIBILITIES

American Society for Clinical Pathology

I was functionally and then officially the Chief Scientific Officer for the ASCP, the largest membership organization for laboratory medicine in the world, during my tenure there. I developed a health service research and delivery program for evidence-based use of clinical diagnostics for healthcare decisions. Foci include but not limited to: 1) HPV testing and cytology in anogenital cancer screening; 2) molecular pharmacology; 3) systematic and methodologic errors in clinical laboratory testing; and 4) guideline development for use of laboratory diagnostics. During my time at ASCP, I was the acting PI of the PEPFAR contract for laboratory training in Africa. Accomplishments include directing ASCP's involvement in the Choosing Wisely Campaign, establishing a global pathology outreach program, leading several clinical guideline activities, and developing over 50 working relationships with science and medical organizations globally.

National Cancer Institute

The HPV Persistence and Progression Cohort (The PaP Cohort) (PI) (2007-present)

In collaboration with Kaiser Permanente Northern California, I initiated The PaP cohort, which is composed of approximately 35,000 carcinogenic HPV-positive women. The primary goal is to examine the HPV genotype-specific risk of, and other factors related to, persistence and progression to cervical precancer and cancer.

Anal Cancer Screening Study (PI) (2009-2010)

In collaboration with the KPNC (Dr. Stephen Follansbee, Kaiser PI), we are evaluating the natural history of HPV and screening strategies for detection of anal precancer and cancer in HIV-infected men.

Development of a New, Low-Cost Self-Collection Device ("SELF")

Provision patent 61/204,751 filed with the U.S. Patent and Trademark Office

Improvement in Screening and Management Practices for Cervical Cancer Prevention (PI) (2008-present)

I am collaborating with a number of colleagues to evaluate current and newly introduced screening and diagnostics assays and methods in the U.S. to identify best practices:

- An Evaluation of the Clinical Utility of Endocervical Curettage for Detection of Cervical Precancer and Cancer. Together with Dr. Maire Duggan at the University of Calgary and Calgary Lab Services, we are undertaking a rigorous evaluation of the clinical utility and adequacy of endocervical curettage, which was conducted on all women attending colposcopy in the Calgary Health region from 2003-7.
- Quality Assurance/Quality Control Biomarkers for Improving Histopathologic Diagnosis of Cervical Biopsies. Together with Dr. Mark Stoler at the University of Virginia, we are evaluating novel biomarkers using immunohistochemistry on a large case series of cervical biopsies to improve the diagnostic accuracy and reproducibility of cervical histopathology.

Cervical Cancer Prevention Activities and Outcomes (at Kaiser Permanente Northern California) (PI) (2008-present)

In collaboration with KPNC (Dr. Walter Kinney, Kaiser PI), we are evaluating the impact of introducing carcinogenic HPV testing into routine cervical cancer screening.

Project Itoju: A Study of Unusual Age Trends in HPV Prevalence in Nigeria. (Investigator) (2009-present)

A community-based cross-sectional study of ~1500 women in Southwestern Nigeria to

understand the epidemiology of HPV infection and cervical neoplasia in West Africa, as exemplified by Nigeria, and to analyze how HPV-based screening might be optimized to fit the epidemiologic pattern.

Low-Cost Molecular Cervical Cancer Screening Study (PI) (2010-present)

In collaboration with PATH and the Cancer Institute of the Chinese Academy of Medical Sciences (CICAMS; Beijing, China), I am conducting a study to 1) evaluate the clinical performance of two low-cost tests, careHPV and the Onco E6 Test, for detection of cervical precancer and cancer and 2) to determine the positive predictive value of visual inspection with acetic acid, the Onco E6 Test, and HPV16/18/45 detection among careHPV-positive women for cervical precancer and cancer.

HPV Testing to Improve Cervical Cancer Screening in the Mississippi Delta (Mississippi Delta Project) (PI) (2007-present)

In collaboration with the NCI Center for Reducing Cancer Health Disparities (CRCHD) and the University of Alabama, and with partial funding from CRCHD and the National Center for Minority Health and Health Disparities (NCMHD), my colleagues and I are developing strategies to implement sustainable HPV primary screening using self-collected cervicovaginal specimens for prevention of cervical cancer in underserved women living in the Mississippi Delta region.

Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening (PI) (2009-present)

In collaboration with the NCI Center for Reducing Cancer Health Disparities (CRCHD) and the University of Alabama, and with partial funding from CRCHD and the National Center for Minority Health and Health Disparities (NCMHD), we conducted a follow-up study to the Mississippi Delta Project to evaluate the preferences of under-screened women for two different approaches for participating in cervical cancer screening.

Cervical Immunity Study (PI) (2005-2008)

This was a study of ~400 women from Guanacaste, Costa Rica who exited The Guanacaste Project with oncogenic HPV infection. The primary goal of the study is to examine the relationships of cervical immunity to HPV clearance and persistence.

Portland Kaiser Study (Co-PI) (1989-2010)

I evaluated the results of a prospective study of ~20,000 women attending Northwest Kaiser Permanente in Portland, OR for incident cervical precancer and cancer.

ALTS Natural History (PI) (1997-2010)

ALTS was a randomized clinical trial of ~5,000 women to evaluate management strategies for women with equivocal or mildly abnormal cytology. I served as PI from 2008-2010.

VIII. PAST GRANTS/CONTRACTS/SUBCONTRACTS:

5U54CA190163-06 (Anastos, Mutesa, Castle) 09/01/2014 – 08/31/2020

Funding Agency: NCI/NIH

Project Title: HIV/HPV cancer prevention, treatment, & pathogenesis: Rwanda/Einstein consortium ("Optimal Methods for Cervical Cancer Prevention in HIV+ Women in Low-Income Settings")

Description: The major goals of this study of 7,200 HIV-infected women are to 1) determine the most effective and cost-effective methods of cervical cancer screening in HIV-infected Rwandan women, 2) investigate the prevalence of anal HPV genotypes in HIV-infected Rwandan men who have sex with men (MSM), and 3) build pathology and laboratory medicine capacity.

https://projectreporter.nih.gov/project_info_description.cfm?aid=9552733&icde=46523401

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

Role: Principal Investigator

5UH3CA189883-06 (Cremer)

05/14/2015 – 08/31/2020

Funding Agency: NCI/NIH

Project Title: CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting

Description: The major goal of this study of 1,000 women diagnosed with cervical precancer is to demonstrate the efficacy of a next generation, low resource-adapted CryoPen for the treatment.

https://projectreporter.nih.gov/project_info_description.cfm?aid=9553660&icde=46524096

Role: Co-Investigator

5UH3EB024965-03 (Alatise, Fedorak, Kingham) 04/15/2017 – 03/31/2022

Funding Agency: NIBIB/NIH

Project Title: Point-of-Care, Real-Time Urine Metabolomics Test to Diagnose Colorectal Cancers and Polyps in Low- and Middle-Income Countries

Description: The research, development, and validation of a urine metabolomics test to diagnosis colorectal cancer and polyps in high-risk patients such as those with bloody stools, first degree relatives of those diagnosed with colorectal cancer, and colorectal cancer survivors.

https://projectreporter.nih.gov/project_info_description.cfm?aid=9472322&icde=46524211

Role: Principal Investigator and Executive Committee Member

5P20CA210284-03 (Castle, Ntirenganya)

09/19/2017 – 08/31/2020

Funding Agency: NCI/NIH

Project Title: Building Research Capacity to Address the Challenge of Non-Communicable Diseases and Injuries in Rwanda – The GUKORANA Research Center

Description: Establish a center of excellence in non-communicable disease and injury in Rwanda in response to the RFA “Planning for Regional Centers of Research Excellence in Non-communicable Diseases in Low and Middle Income Countries (P20)” (RFA-CA-15-007)

https://projectreporter.nih.gov/project_info_description.cfm?aid=9580595&icde=46524233

Role: Principal Investigator

IPA Assignment (Castle)

03/26/2019 – 03/26/2020

Funding Agency: NCI

Project Title: The KPNC Guidelines Cohort

Description: This project will focus on planning, conducting, and reporting the most important needed guidelines-related analyses of HPV-based cervical cancer screening and prevention with KPNC and NCI colleagues.

Role: Principal Investigator

1R01CA230331-01 (Burk, Strickler)

8/01/2018 – 7/31/2023

Funding Agency: NCI/NIH

Project Title: Next Generation Cervical Disease and HPV Research in HIV+ Women

Description: The current project will for the first time use next-generation HPV DNA sequencing able to determine whether a given HPV type detected at two or more time points is the same exact viral infection versus different HPVs of the same type. These data will be used to comprehensively study: type-specific differences in HPV persistence and their relation with precancer; the occurrence of HPV reactivation and how often reactivated HPV persists and leads to precancer; the impact of immune status on each of these steps in HPV natural history; and whether HIV impacts precancer risk beyond its effects on HPV.

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

https://projectreporter.nih.gov/project_info_description.cfm?aid=9580595&icde=46524233

Role: Co-Investigator

1R01CA218195-03 (Cremer)

01/12/2018 – 12/31/2022

Funding Agency: NCI/NIH

Project Title: Development of an LMIC-Adapted Thermocoagulation Prototype for the Treatment of Cervical Pre-Cancer

Description: The major goal of this study of 1,000 women diagnosed with cervical precancer is to demonstrate efficacy of a next generation, low resources-adapted thermocoagulation system for ablative treatment.

https://projectreporter.nih.gov/project_info_description.cfm?aid=9470179&icde=46524225

Role: Co-investigator

NHMRC APP1104938 (Valley)

Funding Agency: National Health and Medical Research Council (Australia)

Project Title: Point-of-care HPV-DNA testing for cervical cancer screening in high-burden, low-resource settings

Description: A study of cervical cancer screening and treat strategies in 3,400 women living in Papua New Guinea

Role: Associate Investigator (no support)

NHMRC APP1109121 (Canfell)

Funding Agency: National Health and Medical Research Council (Australia)

Project Title: Effectiveness and Cost-Effectiveness of HPV Vaccination and HPV-Based Cervical Cancer Screening Strategies in China

Description: To evaluate the outcomes, resource utilisation, budget impact and cost-effectiveness of HPV vaccination, and the threshold per-dose price at which vaccination would be cost-effective. To evaluate the outcomes, resource utilisation, budget impact and cost-effectiveness of a range of primary HPV screening strategies in women aged 25-65 years.

Role: Chief Investigator (no support)

(Hansen)

Funding Agency: Norwegian Cancer Society

Project Title: Equalscreen: Increasing participation and reducing inequities in cervical cancer screening

Description:

Role: Unpaid Investigator

NHMRC APP1135172 (Canfell)

Funding Agency: National Health and Medical Research Council (Australia)

Project Title: Centre for Research Excellence in Cervical Cancer Control (C4)

Description:

Role: Chief Investigator (no support)

NCS #182675 (Tropé)

04/01/2017-03/31/2019

Funding Agency: Norwegian Cancer Society

Project Title: Incremental improvement of cervical cancer screening: the balance of benefits and harms

Description: evaluate the effect of different screening and management methods on both

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

benefits (cervical cancer preventive) and harms (such as premature labour) in order to improve future cervical cancer prevention strategy. Specifically, we will assess trends in the population of preventable cancer and detected precancerous lesions; the validity of different screening test methods and risk stratification algorithms; the effectiveness of post-diagnostic management protocols; and the harm-benefit profile of different treatment methods for precancerous lesions of the cervix. The project will capitalize on the unique data available at the Cancer Registry of Norway.

Role: Co-Investigator

(Victoria Mango, PI)

01/15/2019 – 01/15/2020

Funding Agency: Prevent Cancer Foundation

Project Title: Feasibility of breast cancer screening in high-risk Nigerian women using a novel low-cost device

Role: Co-Investigator

Expanding Cervical Cancer Screening and Preventive Therapy (CCS&PT) through Introducing New Technologies and Integrating with Voluntary Family Planning

(<http://sites.nationalacademies.org/pqa/peerccspt/index.htm>)

(Schmeler, PI)

04/01/2019 – 03/31/2022

Funding Agency: USAID

Project Title: Evaluating innovative technologies and approaches to addressing cervical cancer in the Republic of Mozambique

Description: A program to investigate best strategies for integrating cervical screening into volunteer family planning.

Role: Co-Principal Investigator

5UM1CA121947-13 (Mitsuyasu, PI)

09/01/2019 - 08/31/2020

Funding Agency: NCI

Project Title: AIDS Malignancy Consortium

Description: Clinical trials cooperative group

https://projectreporter.nih.gov/project_info_description.cfm?aid=9788273&icde=46525858

Role: Associate Chair, Cancer Prevention and Control

1R21CA239784-01 (Sutton, Omisore)

06/01/2019 – 05/31/2023 0.36 CM

Funding Agency: NCI

Project Title: Tablet-based mobile health ultrasound for point-of-care breast cancer diagnosis in Nigeria

Description: A study of developing and using tablet-based training for ultrasound detection breast cancer.

https://projectreporter.nih.gov/project_info_description.cfm?aid=9773812&icde=46520589

Role: Co-Investigator

U01CA238592 (Burk, Castle)

010/01/2019 – 09/30/2023

Funding Agency: NCI

Project Title: Investigations into the Molecular Pathogenesis of Cervical Glandular Neoplasias

Description: A study of the molecular epidemiology and natural history of cervical adenocarcinoma

Role: Co-Principal Investigator

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

R01CA239921 (Castle, Schmeler)

06/01/2019 – 05/31/2024

Funding Agency: NCI*Project Title:* A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical-Cancer Risk Reduction in HIV+ Women living in Mozambique*Description:* Dr. Castle will lead a clinical trial to compare two methods of cervical ablation, cryotherapy vs. thermocoagulation, for cervical cancer risk reduction in HIV+ women living in Mozambique.*Role:* Principal Investigator**(Burger)**

09/01/2019 – 08/31/2022

Funding Agency: Norwegian Cancer Society*Project Title:* Optimal Cervical Cancer Prevention Policies in the Era of HPV Vaccination (CC-PREVENT)*Description:* To optimize resource-use and benefit-harm trade-offs within and between cervical cancer prevention programs (i.e., vaccination and screening programs) that continue to reduce the burden of cervical cancer for all social groups in Norway.*Role:* Collaborator**(T. Peter Kingham, PI)***Funding Agency:* Prevent Cancer Foundation*Project Title:* The Feasibility and Efficacy of Fecal Immunochemistry for Colorectal Cancer Screening in Nigeria*Role:* Co-Investigator**R01 (Richards-Kortum)**

08/01/2020 – 07/31/2025

Funding Agency: NCI*Project Title:* Low-cost mobile colposcopy and confocal imaging for global prevention of cervical cancer*Description:* The major goal of this project is to develop a low-cost, point-of-care, accurate diagnostic to enable one-day screen, diagnosis, and treatment.*Role:* Co-Investigator**R01CA246620-01A1 (Kingham, Du, Alatise)**

10/01/2020 - 09/30/2025

Funding Agency: NCI*Project Title:* Determining the unique biology and risk factors for colorectal cancer in Nigeria*Description:* A study of the epidemiology of colorectal cancer in Nigeria*Role:* Co-Investigator**U54CA254568 (Anastos, Castle, Mutesa, Yotebieng, Adedimeji)**

10/01/2020 - 09/30/2025

Funding Agency: NCI*Project Title:* Rwanda/DRC/Einstein HIV-Associated HPV-Related Malignancies Research Center*Description:* A consortium of Albert Einstein College of Medicine (Einstein), the University of Rwanda (UR), the Rwanda Military Hospital (RMH), and the Congo Protestant University (CPU) to conduct HPV-related research projects, "Long-Term HPV Vaccination Effectiveness and Immunity in Rwandan Women Living with HIV" and "Prevalence and Incidence of HPV and Anal Disease in Rwandan and Congolese Men who have sex with Men".*Role:* MPI

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

1R01CA248757-01 (Hosgood, Castle, Rapkin)

04/01/2020 – 03/31/2025

1.50 CM

Funding Agency: NCI*Project Title:* Multilevel interventions to improve lung cancer screening uptake and guideline adherence*Description:* Multi-level interventions to increase the uptake of and adherence to low-dose spiral CT-based screening for lung cancer.*Role:* MPI**R21 (Richards-Kortum)**

04/01/2020-03/31/2022

0.48 CM

Funding Agency: NCI*Project Title:* Point-of-care HPV mRNA test for cervical cancer screening in low-resource settings*Description:* The major goal of this project is to develop a low-cost, point-of-care, prototype mRNA assay for HPV16 and HPV18.*Role:* Co-Investigator**R01 (Richards-Kortum)**

12/01/2020 – 11/30/2025

0.90 CM

Funding Agency: NCI*Project Title:* Sample-to-answer nucleic acid testing platform for use in low-resource settings*Description:* The major goal of this project is to develop a low-cost, point-of-care, accurate HPV test for use in lower-resource settings*Role:* Co-Investigator

Acting PI for # 5 U2G PS001285-03, CDC Cooperative Agreement for Supporting Laboratory Training and Quality Improvement for Diagnosis and Laboratory Monitoring of HIV/AIDS Patient in Resource Limited Countries. (2011-2)

Contraceptive Research and Development Program (CONRAD) Pilot Subproject Grant entitled "Pan-Semen Monoclonal Antibodies for Vaginal Contraception" (1994-5)

1007518 (Canfell)

09/01/2012 – 06/30/2013

Funding Agency: NHMRC (Australia)*Project Title:* Evaluation of Primary HPV Testing for Cervical Cancer Screening in Australia**Women's Interagency HIV Study (WIHS) (Anastos)**

01/01/2014 – 12/31/2014

Funding Agency: NIAID, NICHD, NCI, NIDA (NIH)*Description:* The major goal of this U.S. cohort is to study the impact of HIV infection on the health of women. Specifically, the cervical cancer component of this cohort is focused on understanding the influence of HIV on the natural history of cervical HPV infections as well as determining the optimal cervical cancer screening and management strategies for these higher risk women.*Role:* Co-Investigator**Pilot Collaborations with LMICs in Global Cancer Research or Global Health Research at NCI-Designated Cancer Centers (Schmeler)**

03/01/2014 – 02/28/2015

0.60 CM

Funding Agency: NCI/NIH

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

Project Title: A Low-Cost Optical Imaging Tool for Cervical Cancer Prevention

Description: The major goal of this project is to conduct a pilot study to compare the diagnostic accuracy of high-resolution microendoscope (HRME) to visual inspection after acetic acid and colposcopy for cervical precancer and cancer in 600 women with abnormal Paps.

Role: Consultant

OPP23519_01: START-UP Project (Jeronimo, Castle)

Funding Agency: Bill & Melinda Gates Foundation

Project Title: Low-Cost Molecular Cervical Cancer Screening Study (LMCCSS) (China); clinicaltrials.gov identifier: NCT01231945

Description: The major goal of this project was to evaluate performance lower-cost HPV DNA and novel HPV E6 tests and management strategies of HPV-positive women in a clinical study of 7,500 women living in rural China.

Role: PI of LMCCSS

1U54CA164336-01 (Wheeler)

06/01/2012 – 05/31/2016

Funding Agency: NCI/NIH

Project Title: New Mexico HPV Outcomes: Practice Evaluations and Surveillance (NM-HOPES); Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)

Description: The major goal, using a data from a statewide registry in New Mexico, is to assess real-world utilization health service delivery of cervical cancer screening and management.

Role: Consultant and Member of Executive Leadership

(Pål Halvorsen & Michael Riegler)

11/01/2015 – 05/30/2016

Funding Agency: Research Council of Norway

Project Title: Lighthouse Projects: DigSys Pillcam

(<http://www.forskningsradet.no/en/Funding/IKTPLUSS/1254004156292>)

Description: Planning grant to develop a clinical trial for evaluating the DigSys Pillcam for colorectal cancer screening.

Role: Co-Investigator

1R01 CA174634-01A1 (Strickler)

04/01/2013 – 03/31/2016

Funding Agency: NCI/NIH

Project Title: Molecular Methods to Improve Cervical Cancer Screening in HIV+ Women

Description: The major goal of this project is to investigate the use of new biomarkers to discriminate HPV infections associated with cancer risk from those benign HPV infections destined to clear in 1,000 HIV-positive women.

Role: Co-Investigator

ES543576 (Nygård)

Funding Agency: GLOBVAC

Project Title: Human papillomavirus vaccination as platform for adolescent sexual and reproductive healthcare delivery in Zambia

Description: A planning grant to develop a research project to use HPV vaccination as a platform to improve the health of Zambian adolescents.

Role: Investigator (unpaid)

3P30CA013148-43S2 (Scarinci)

07/01/2015 – 06/30/2016

Funding Agency: NIAID/NIH

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

Project Title: Self-collection & HPV testing in unscreened women: a feasibility study in Brazil

Description: The major goal of this pilot project is compare in a randomized clinical trial the participation of under-screened Brazilian women in Pap screening, self-collection and HPV testing, or a choice of either for cervical cancer screening.

Role: Co-Investigator

U54 EB015403-05 (R7K241) (Richards-Kortum, Castle, Schmeler)

06/01/2016 – 05/31/2017

Funding Agency: Center for Future Technologies in Cancer Care (CFTCC), Boston University College of Engineering (<http://www.bu.edu/cftcc/grants-and-funding/call-for-proposals/>)

Project Title: Lateral Flow HPV Test for Cervical Cancer Screening in Low-Resource Settings

Description: Research and development of a pump-free, lateral flow, point-of-care, HPV DNA test.

Role: Co-Principal Investigator

NHMRC APP1065892 (Canfell)

01/01/2014 – 12/31/2016

Funding Agency: National Health and Medical Research Council

Project Title: Evaluation of next generation human papillomavirus (HPV) vaccination and associated HPV-based cervical cancer screening strategies in Australia

Description: This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.

Role: Chief Investigator B (No Support)

PG0113 (Canfell)

06/30/2014 – 06/30/2015

Funding Agency: Prostate Cancer Foundation of Australia

Project Title: Epidemiological Modelling for PSA Testing and Management of Test-Detected Prostate Cancer

Description: To develop an Australian model for the ongoing epidemiologic and economic evaluation of changes in the detection, management and treatment of prostate cancer, and of the interactive effects of these changes on outcomes (including cancer incidence, mortality, and treatment-related morbidity) and costs.

Role: Associate Investigator G (No Support)

COMPASS (Canfell)

12/18/2012 – 12/31/2015

Funding Agency: Roche Molecular Systems, Inc. and Ventana Medical Systems, Inc.

Project Title: Compass Trial of Primary HPV Screening for Cervical Cancer in Australia

Description: Conduct a Pilot for a randomised controlled trial of Primary HPV DNA testing for cervical cancer screening in Australia.

Role: Chief Investigator (No Support)

PP150012 (Schmeler)

01/01/2015 – 12/31/2017

Funding Agency: CPRIT

Project Title: Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley through Public Outreach, Patient Navigation, and Telementoring

Description: We are proposing to implement two innovative, evidence-based, complementary interventions in the LRGV to increase public participation in cervical cancer screening and expand the professional capacity for accurate diagnosis and treatment of precancerous lesions.
Role: Unpaid Collaborator

(Sen)

Funding Agency: Nordic Information for Action eScience Center of Excellence (NIASC)

Project Title: SOIGNONS: SOcietal Games to Nudge people intO attending cervical caNcer Screening

Description: Developing and applying gamification strategies to improve participation of women living in Norway and Iceland in cervical cancer screening. The result has been the development of the “Fight HPV” App.

Role: Unpaid Collaborator



Special Community Grant Application June 2015 (Castle)

Funding Agency: Prevent Cancer Foundation

Project Title: Optimizing for Cervical Cancer Prevention for HIV-Infected Women in Low-Resource Settings

Description: Evaluation of a smart-phone based digital colposcope in Rwanda cohort of 7,200 HIV-infected women.

Role: Principal Investigator

3P30CA013330-43S1A (Castle)

10/01/2015 – 09/30/2018

Funding Agency: NCI/NIH

Project Title: Cervical Cancer Screening Strategies in HIV-Infected Women Living in Cameroon

Description: A pilot study in 800 HIV-infected and 400 HIV-uninfected women living in Limbé, Cameroon examine cervical cancer screening and management strategies and build research and health service delivery capacities there.

Role: Project Co-Leader

5U01CA078527-19 (Burk)

07/01/2014 – 06/30/2018

Funding Agency: NCI/NIH

Project Title: Persistent HPV Infection in Women at Risk for Cervix Cancer

Description: The major goal of this project is evaluate the relationship of viral genetic and epigenetic variation and the cervicovaginal microbiome on the risk of HPV-positive women developing cervical precancer and cancer.

Role: Co-Investigator

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

RSG-16-168-01-CPPB (Scarinci) 01/01/2017 – 12/31/2019 1.38 CM
Funding Agency: American Cancer Society
Project Title: Self-Sampling for HPV Testing in African American Women - Mississippi Delta
Description: A cluster-randomization trial to compare participation of underserved women living in the Mississippi Delta in two community-based outreach interventions for cervical cancer screening, Pap only or a choice between Pap or self-sampling and HPV testing.
<https://clinicaltrials.gov/ct2/show/NCT03713710>
Role: Co-Investigator

5R01CA186132-05 (Richards-Kortum) 09/01/2014 – 08/31/2019 0.80 CM
Funding Agency: NCI/NIH
Project Title: High resolution imaging & HPV oncoprotein detection for global prevention of cervical cancer
Description: The major goals of this study to 1) validate the use of a portable high-resolution microendoscope (HRME) for in situ diagnosis of cervical neoplasia in 3,000 women living in El Salvador and 2) develop a HPV E7-specific ELISA.
https://projectreporter.nih.gov/project_info_description.cfm?aid=9324154&icde=46523433
Role: Co-Investigator

5UH3CA189910-05 (Richards-Kortum, Schmeler) 07/22/2014 – 08/31/2019 3.00 CM
Funding Agency: NCI/NIH
Project Title: Point-of-Care Diagnostic Tools to Improve Global Cervical Cancer Control Programs
Description: The major goal of this study of 10,000 women living in Barretos, Brazil is demonstrate accurate diagnosis of cervical precancer and cancer using high-resolution microendoscopy (HRME).
https://projectreporter.nih.gov/project_info_description.cfm?aid=9553660&icde=46524096
Role: Co-Investigator

5U01CA078527-20 (Burk) 07/1/2014 – 06/30/2019 0.54 CM
Funding Agency: NCI/NIH
Project Title: Persistent HPV in Women at Risk for Cervix Cancer
Description: The major goal of this project is to evaluate the relationship of viral genetic and epigenetic variation and the cervicovaginal microbiome on the risk of HPV-positive women developing precancer and cancer.
Role: Co-Investigator

IX. FELLOWSHIPS AND SCHOLARSHIPS

1989-95 NIH Pre-doctoral Fellowship, The Johns Hopkins University
 2004-7 NIH General Research Scholarship

X. PREVIOUS SCIENTIFIC CONSULTATIONS/COLLABORATIONS

- CDC's Cervical Cancer Study (C3): An Intervention Pilot Study of HPV in Illinois National Breast and Cervical Cancer Early Detection and Prevention. Centers for Disease Control and Prevention (Dr. Vicki Benard and Dr. Mona Saraiya, PIs) (2006-8)
- Bill & Melinda Gates Foundation: Global HPV Vaccine Policy Model. Harvard University (Dr. Sue Goldie, PI)

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- Department of Health and Human Services, National Vaccine Program Office: Development of a Rapid HPV Antibody Test. Program for Appropriate Technology in Health (Roger Peck, PI)
- NCI Supplemental Funding for the AIDS International Training and Research Program at the Albert Einstein College of Medicine (AECOM): Capacity building in cervical cancer research in HIV-infected Rwandan women; Capacity building in investigating mucosal immunity and HPV disease in Rwanda; and Developing a Population-Based Cancer Registry in Rwanda (Dr. Kathy Anastos, PI)
- Collaborator, The New Mexico HPV and Pap Registry (Dr. Cosette Wheeler, PI)
- Collaborator, Role of the insulin/IGF-axis in incident CIN-2+ (Dr. Howard Strickler, PI)
- Field Trial of HPV Screening for Cervical Cancer in Chile (Dr. Catterina Ferreccio, PI)
- Developing Rwandan Research Capacity in Cervical Cancer and other AIDS Malignancies (Dr. Kathryn Anastos, PI)
- Co-Applicant, Risk of cervical intraepithelial neoplasia following an incident high risk human papillomavirus (HR-HPV) infection among older women, Grant Application to Canadian Institutes of Health Research (Dr. Marie-Helene Mayrand, PI)
- Unpaid collaborator, Comparative and Cost-Effectiveness of Preventing HPV-Related Diseases (Dr. Jane Kim, PI)
- Chief Investigator, Evaluation of Primary HPV Testing for Cervical Screening in Australia. National Health and Medical Research Council. Project Grant: 2011-13. (Dr. Karen Canfell, PI)
- Chief Investigator, COMPASS: A Randomized Controlled Trial of Primary HPV Screening (<http://www.compasstrial.org.au/main/about-compass/investigators-main>). (Dr. Karen Canfell, PI)
- Consultant, Cytology vs. at home HPV screening for detection of CIN 2, 3, CIS, NCI R01 (Dr. Shalini Kulasingham, PI) (2011)
- Improving Cervical Cancer Prevention among HIV-Infected Women Using Novel HPV-Based Biomarker Assays, NIH Intramural-to-India (I-to-I) program (Dr. Vikrant Sahasrabudde, PI)
- Development and evaluation of a human papillomavirus (HPV) methylation assay to study risk of cervical precancer, PI Innovation Award (Dr. Nicolas Wentzensen, PI)
- Consultant for Center for Global Health, U.S. National Cancer Institute on Cervical Cancer Research (2012)

XI. MENTORING

Ms. Michelle Khan (NCI) (2003-5)
 Dr. Aimee Kreimer (NCI) (2005-7)
 Dr. Melinda Butsch-Kovacic (NCI) (2005-6)
 Dr. Mahboobeh Safaeian (NCI) (2006-7)
 Dr. Nicolas Wentzensen (NCI) (2007-9)
 Dr. Jing Li (NCI) (2008)
 Dr. Laura Reimers (NCI) (2008)
 Dr. Julia Gage (NCI) (2008-10)
 Dr. Nicole Gastineau Campos (Harvard) (2008-present)
 Dr. Lauren Wilson (NCI) (2009-10)
 Dr. Hannah Yang (NCI) (2009-10)
 Dr. Hormuzd Katki (NCI) (2010)

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

Dr. Morgan Marks (JHU) (2010)
 Dr. Vikrant Sahasrabuddhe (NCI) (2010)
 Dr. Kate Rendle (NCI) (2015-6)
 Dr. Haejin In (Albert Einstein College of Medicine) (2017-2020)
 Ms. Dana Hashim (Norwegian Cancer Registry) (2017-2019)
 Dr. Diep Nguyen (University of New South Wales and New South Wales Cancer Council, Australia) (2015-9)
 Dr. Gad Murenzi (RMH) (2016-*present*)
 Ms. Kathryn Kunrod (Rice University)(2018-*present*)
 Mr. Brady Hunt (Rice University)(2017-2020)
 Dr. Dean Hosgood (2018-2020)

XII. ACTIVE PROFESSIONAL MEMBERSHIPS

- International Papillomavirus Society (IPVSOC)
- African Organization for Training and Research on Cancer (AORTIC)
- International Cancer Screening Network (ICSN)
- American Society for Colposcopy and Cervical Pathology (ASCCP)

XIII. JOURNAL EDITORIAL SERVICE

2002-2009	Editorial Board, Journal of Applied Research
2007-2012	WHO SDI Website Literature Reviews
2008-2020	Editorial Board and Associate Editor, Journal of Lower Genital Tract Disease https://journals.lww.com/jlqtd/Pages/editorialboard.aspx
2004-2016	Editorial Advisory Board, Journal of Infectious Diseases
2015-2020	Editorial Board, Papillomavirus Research
2015-2020	Editorial Board, Cancer Prevention Research http://cancerpreventionresearch.aacrjournals.org/site/misc/edboard.xhtml
2016-2018	Editorial Board, Journal of Global Oncology

Reviewer for professional journals: American Journal of Epidemiology; American Journal of Obstetrics and Gynecology; Annals of Internal Medicine; BMC Medicine; Journal of Cancer; British Medical Journal; Cancer; Cancer Cytopathology; Cancer Epidemiology, Biomarkers, and Prevention, Epidemiology; Cancer Research; Cancer Prevention Research; Clinical Infectious Diseases; EBioMedicine; Gynecologic Oncology; International Journal of Cancer; International Journal of Gynecological Pathology; JAMA; JAMA Internal Medicine; Journal of Clinical Microbiology; Journal of Clinical Oncology; Journal of Infectious Diseases; Journal of Investigative Dermatology; Journal of Global Oncology; Journal of Lower Genital Tract Disease; Journal of the National Cancer Institute; Journal of Virological Methods; Lancet Infectious Diseases; Lancet Oncology; Lancet Global Health; Nature Clinical Practice Oncology; New England Journal of Medicine; Proceedings of the National Academy of Sciences of the United States of America; Obstetrics and Gynecology; Sexually Transmitted Diseases

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

XIV. SCIENTIFIC LEADERSHIP AND SERVICE

NCI/NIH

2002-03	DCEG Technical Evaluation of Protocols Committee
2003-04	NCI Cancer Nanotechnology Working Group
2004-05	DCEG Committee of Scientists
2004-15	Annual Lecturer, Principles and Practice of Cancer Prevention and Control Course, Cancer Prevention Fellowship Program: Cervical Cancer Epidemiology and Prevention
2005-09	NIH Academy Preceptor and Lecturer on Cervical Cancer Epidemiology and Prevention
2005-10	Mentor and Lecturer, Undergraduate Scholarship Program
2005-10	Co-mentor, NIH Women's Health Postdoctoral Fellowship
2006	Co-chair (with Douglas Lowy), Symposium entitled "HPV and Cervical Cancer: From Pathogenesis to Prevention", NIH Research Festival
2006	NCI/NIH delegate to the ASCCP Consensus Guidelines Meeting
2006-08	DCEG Biospecimen Repository Committee
2008-10	DCEG Technology Transfer Committee
2009-10	DCEG Representative, Geographic Management of Cancer Health Disparities Program (GMAP), Center for Reducing Cancer Health Disparities
2009-10	DCEG Representative, NCI Strategic Plan (2009-13) for Reducing Cancer Health Disparities
2009-10	Member, Center for Reducing Cancer Health Disparities' Global Cancer Health Disparities Working Group

Other

2002-05	Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group
2004-08	Consultant/Member of the technical advisory group of START (Screening technologies to advance rapid testing for cervical cancer prevention) launched by PATH (Program for Appropriate Technology in Health), Seattle, WA, USA
2005-06	NIH-ASCCP Research Group
2005-10	Lecturer and Consultant to the FDA on HPV natural history and diagnostics
2006-11	EUROGIN Scientific Committee and Faculty: 2006 (Paris, France), 2007 (Monte Carlo, Monaco), 2008 (Nice, France), 2010 (Monte Carlo, Monaco), and 2011 (Lisbon, Portugal). Resigned from service as of 2012
2006-20	International Papillomavirus (IPV) Conference Scientific/Organizing Committee: 23 rd (Prague, Czech Republic, 2006), 24 th (Beijing, China, 2007), 25 th (Malmö, Sweden, 2009), 26 th (Montreal, Canada, 2010), 27 th (Berlin, Germany, 2011), 28 th (San Juan, Puerto Rico, 2012), 30 th (Lisbon, Portugal, 2015), 31 st (Capetown, South Africa, 2017), 32 nd (Sydney, Australia, 2018), and 33 rd (Barcelona, Spain, 2020)
2006-07	Member, Ralph Lauren Cancer Center's Harlem HPV Vaccine Task Force
2007-Present	Member, New Mexico HPV Pap Registry Steering Committee
2007	Co-host, Meeting to Build Consensus on Approaches to Improving Cryotherapy Service Delivery
2008	Invitee, NCI Translates: the NCI Translational Science Meeting

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

2008	Founding Member, Practice Improvement in Cervical Cancer Screening and Management (PICSM), ASCCP
2008	Reviewer, European Guidelines for Quality Assurance in Cervical Cancer Screening – Supplements on HPV testing and HPV vaccination
2009	Presenter and Participant, PICSM Symposium on Cervical Cancer Screening and Management of Cervical Abnormalities in Adolescents and Young Women
2010	Senior Advisory Group, Evaluation and impact of screening and treatment approaches for the prevention of cervical neoplasia in HIV-positive women in Burkina Faso and South Africa: HPV in Africa Research Partnership (Dr. Phillippe Mayaud, PI)
2011	Advisor and technical consultant for the development of cervical cancer prevention program in Rwanda
2010	Cervical Cancer Initiative Advisory Group, Union for International Cancer Control (UICC) http://www.uicc.org/cervicalcancer
2011-14	Data & Safety Monitoring Committee, Merck Next Generation HPV Vaccine Program
2012-16	Member, Centers for Disease Control and Prevention's (CDC) National Breast and Cervical Cancer Early Detection and Prevention (NBCCEDP) Advisory Committee
2014-Present	Member at Large, Board of Directors, American Society for Colposcopy and Cervical Pathology; Member of the Ethics Committee and Developmental Committee
2014	Technical Advisor, World Health Organization, Point-Of-Care Diagnostic Tests for Sexually Transmitted Infections
2014	Member, Pink Ribbon Red Ribbon (PRRR) SQS Task Group

XV. NATIONAL/PROFESSIONAL GUIDELINE DEVELOPMENT

2006	American Cancer Society HPV Vaccine Guideline Workgroup
2006	Member, HPV Working Group, ASCCP Consensus Guidelines Meeting
2009-12	Steering Committee Member and Evidence Review Data Committee Co-Chair, ACS/ASCCP Guideline Development for Cervical Cancer Screening and Prevention: The Role of Molecular Testing
2011-12	Work Group 5, Implications and Implementation of Standardization of Terminology for Squamous Neoplasia in the Lower Anogenital Tract: The LAST Project – Lower Anogenital Squamous Terminology. ASCP Delegate
2011-12	ASCP Representative and Steering Committee Member, ASCP/CAP/AMP Guidelines for Use of Molecular Markers for Colorectal Cancer
2012	Delegate, ASCCP Consensus Guidelines Meeting
2013	Member, expert work group meeting on cervical cancer screening in the U.S. Territories and Pacific Island Jurisdictions
2015-18	Panel and Steering Committee Member, American Society for Clinical Oncology (ASCO) resource-stratified guidelines on the secondary prevention of cervical cancer
2018-20	Steering Committee Member and Co-Chair of the Surveillance Group, ASCCP Management Guidelines Committee,

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

XVI. GRANT REVIEWER

Cancer Research UK
 Danish Cancer Society
 Medical Research Council UK
 U.S. NIH Study Sections

- Epidemiology of Cancer Study Section [EPIC] (*ad hoc*): 2012, 2013
- AIDS and Related Research IRG [AARR] (*ad hoc*): 2013
- Prevention of HPV-related Cancers in HIV-infected individuals (U54) (*ad hoc*): 2019

XVII. PROGRAM REVIEWER

MRC National Institute for Medical Research (NIMR) UK

XVIII. PRESENTATIONS

Invited Chair/Moderator

- 2005 *Clinical Utility of Genomic HPV Testing*. 22nd International Papillomavirus Conference, Vancouver, BC, Canada
- 2006 *Current Knowledge and Clinical Use of HPV Genotyping; Molecular Markers of CIN and Cervical Carcinoma; and Genotyping for Clinical Practice*. EUROGIN 2006, Nice, France
- 2006 *Epidemiology: HPV and HIV Infection*. 23rd International Papillomavirus Conference, Prague, Czech Republic
- 2006 *Human Papillomavirus (HPV) and Cancer: From Pathogenesis to Prevention*. NIH Research Symposium, Bethesda, MD, USA
- 2007 *HPV Genotyping and Genotyping*. EUROGIN 2007, Monte Carlo, Monaco
- 2007 *HPV Genotyping*. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China
- 2008 *Genotyping*. EUROGIN 2008, Nice, France
- 2008 *Understanding and Eliminating Cervical and Ovarian Cancer Health Disparities*. NIH Science of Eliminating Health Disparities Summit, Baltimore, MD, USA
- 2009 *HPV-based screening II*. 25th International Papillomavirus Conference, Malmö, Sweden
- 2010 *Recent Advances and Major Gaps in Basic HPV Research; Genotyping; and CDC/NIH*. EUROGIN 2010, Monte Carlo, Monaco
- 2010 *Workshop on CIN2*. 26th International Papillomavirus Conference, Montreal, Canada
- 2011 *Recent advances and gaps in research*. EUROGIN 2011, Lisbon, Portugal
- 2011 *Natural History of HPV*, 27th International Papillomavirus Conference, Berlin, Germany
- 2011 *Short Course on Laboratory Diagnostic Error*. 4th Diagnostic Errors in Medicine, Chicago, IL, USA
- 2012 *Should Anal Cancer Screening Be Standard of Care For All Women with HPV?* Debate Moderator, ASCCP Biennial Meeting, San Francisco, CA, USA
- 2012 *Community-Based Cancer Screening Programs – Breast and Cervical Cancer*. Cancer Prevention, Biomarkers and Screening Research in China and the United States: Opportunities for Collaboration. A Workshop Organized by: Cancer Institute/Hospital of the Chinese Academy of Medical Sciences & National Cancer Institute. Beijing, China
- 2012 *Co-Chair, Epidemiology and Public Health Track; Management of Abnormal Cytology and Histology; Workshop on Building Capacity for Cervical Cancer Prevention*. 28th

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- International Papillomavirus Conference, San Jose, Puerto Rico
- 2013 Panelist, Session on Integrating Cervical Cancer Prevention and Control with Other Health Interventions, Global Forum on Cervical Cancer Prevention, Kuala Lumpur, Malaysia
- 2014 Co-Chair, *New Screening Technologies*. AOGIN, Beijing, China
- 2015 *Session Chair, Diagnostics and Screening*, 30th International Papillomavirus Conference, Lisbon, Portugal
- 2017 Co-Chair, Public Health Track: *Screening Programs: Implementation, Evaluation, and Impact II*. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Moderator, *Screening/Diagnosis in low-income countries Part 1: Challenges and Successes*, IFCCP 2017 World Congress, Orlando, FL, USA
- 2017 Moderator, *Research from Latin America*, IFCCP 2017 World Congress, Orlando, FL
- 2018 Moderator, Plenary –*Underscreened/Underserved Populations*, ASCCP Annual Meeting, Las Vegas, NV, USA
- 2018 Co-Chair, *HPV testing in LMIC: providing hope to the pre-HPV vaccination cohorts*. International Papillomavirus Conference, Sydney, Australia
- 2019 Co-Chair, *Cervical Cancer Screening Guidelines: U.S. and Beyond*, ASCCP Annual Meeting, Atlanta, GA, USA
- 2020 Chair, *Global Factors Involved in Reducing Cancer Incidence, Advances in the Science of Cancer Health Disparities*, San Diego, CA, USA

Invited Talks/Lectures

- 1998 *Sperm Numbers and Fertility in Rabbits*. New Models for Preclinical Evaluation of Vaginal Contraceptives, NIH, Bethesda, MD, USA
- 2002 *Cervical Immunity and Protection against Cervical Neoplasia*. Gynecologic Oncology Group, New Orleans, LA, USA
- 2002 *Where the Rubber Meets the Road: the Role of the Cervical Microenvironment in Cervical Carcinogenesis*. University of Arizona, Division of Cancer Prevention and Control, Tucson, AZ, USA
- 2002 *HPV Immunology: Can We Prevent Cervical Cancer?* Grand Rounds, Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY, USA
- 2002 *Where the Rubber Meets the Road: the Role of the Cervical Microenvironment in Cervical Carcinogenesis*. University of Louisville Cancer Center, Louisville, KY, USA
- 2002 *Cervical Microenvironment and Cervical Cancer*. NCI meeting on the Epidemiology of HPV, Bethesda, MD, USA
- 2002 *Cytokine profiling of cervical secretions*. HPV Immunology Workshop, NCI/NIH, Bethesda, MD, USA
- 2002 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer*. DCEG, NCI, Bethesda, MD, USA
- 2002 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer*. The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 2002 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer*. University of Maryland School of Medicine, Baltimore, MD, USA
- 2002 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer*. LCDI, CCR, NCI, Bethesda, MD, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer*. Scientific Session, Gynecologic Oncology Group, Savannah, GA, USA

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
- 2003 *Human Papillomavirus Infection and Immunity.* HIV and Cancer Virology Faculty and Vaccine Working Group, "Future Vaccines for Papilloma and AIDS Viruses", NCI/NIH, Bethesda, MD, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* Department of Preventive Medicine & Community Health, Virginia Commonwealth University, Richmond, VA, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* Department of Epidemiology, Emory University, Atlanta, GA, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* Department of Obstetrics and Gynecology, Medical College of GA, Augusta, GA, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* Department of Obstetrics and Gynecology, University of Texas Southwestern, Dallas, TX, USA
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* The University of New Mexico, Albuquerque, NM, USA
- 2003 *Cervical Cancer Risk Factors and HPV Vaccines.* Oncología, UICC Symposia on Cervical Cancer, Córdoba, Argentina
- 2003 *Human Papillomavirus and the Development of Cervical Pre-Cancer and Cancer.* India Health Study and Rare Cancers, Rockville, MD, USA
- 2003 *HPV and Cervical Cancer: Traveling the Road from Etiology to Prevention.* University of Hawaii, Honolulu, HI, USA
- 2004 *Practical Applications Concerning HPV Carcinogenesis in Screening and Development: Vaccine Development.* International Association of Dental Research, Honolulu, HI (2004)
- 2004 *Immune Responses to HPV.* EUROGIN: International Expert Meeting on HPV Infection and Cervical Cancer Prevention. Nice, France
- 2005 *Developing Cervical Cancer Screening Programs For Underserved U.S. Populations Based On HPV DNA Testing.* All-Hands Meeting, Center for Disease Control and Prevention, Atlanta, GA, USA
- 2005 *Natural History of HPV Infection and the Role of the Cervical Microenvironment.* Brigham and Womens' Hospital, Harvard University, Boston, MA, USA
- 2005 *New Strategies for Cervical Cancer Prevention.* Community Networks Cancer Health Disparities Summit 2005, Rockville, MD, USA
- 2005 *HPV DNA testing in Cervical Cancer Screening.* Centers for Disease Control and Prevention, Atlanta, GA, USA
- 2005 *HPV Testing to Reduce Cervical Cancer Burden.* West Virginia Infectious Disease Conference. Charleston, WV, USA
- 2005 *Natural History of HPV and Cervical Cancer.* HPV Therapeutic Needs Assessment, Wyeth, McLean, VA, USA
- 2005 *Cervical Cancer. Epidemiology and Prevention.* NIH Academy, Bethesda, MD
- 2006 *Impact of HPV Type in the NCI Cohorts.* ASCCP Biennial Conference, Las Vegas, NV, USA
- 2006 *The Clinical Utility of HPV DNA Testing in Cervical Cancer Screening.* International Infectious Diseases Society for Obstetrics and Gynecology, Washington, DC, USA
- 2006 *Current Concepts in HPV Testing and Technology.* Post-Graduate Course, The American College of Obstetricians and Gynecologists Annual Meeting, Washington, DC, USA

- 2006 *Biomarkers for Cervical Cancer Testing*. Post-Graduate Course, The American College of Obstetricians and Gynecologists Annual Meeting, Washington, DC, USA
- 2006 *A Shot in the Arm? Cervical Cancer Prevention in the HPV Vaccine Era*. Grand Rounds, Obstetrics and Gynecology, University of South Dakota, USA
- 2007 *Cervical Cancer Prevention*. Grand Rounds, Obstetrics and Gynecology, Emory University, Atlanta, GA, USA
- 2007 *Updating Current Management Strategies: the Role of Genotyping and Molecular Markers; HPV Prophylactic Vaccines in Clinical Practice: Prophylactic vs. Therapeutic Effects; and Clinical utility of HPV Genotyping*. EUROGIN: International Expert Meeting on HPV Infection and Cervical Cancer Prevention. Monte Carlo, Monaco
- 2007 *A Shot in the Arm? Cervical Cancer Prevention in the HPV Vaccine Era*. AACR Frontiers in Cancer Prevention Research Conference, Philadelphia, PA, USA
- 2008 *Entering the Molecular Age of Cervical Cancer Prevention: What's New and How Do We Bring Order to the Chaos?* American Society of Cytopathology, USCAP Companion Meeting, Denver, CO, USA
- 2008 *Using Knowledge of HPV Natural History to Guide the Application of New Cervical Cancer Prevention Technologies*. Albert Einstein College of Medicine, Bronx, NY
- 2008 *Cervical Cancer Etiology and Prevention: It is all about (HPV) Persistence*. NIH Summer Lecture Series, Bethesda, MD, USA
- 2008 *Using Natural History of HPV to Guide Cervical Cancer Prevention Strategies*. Cervical Cancer Conference, American Cancer Society, Research Park, NC, USA
- 2008 *New Biomarkers for Detection of Cervical Precancer and Cancer; Risk Assessment of Cervical Cancer: Practical issues; and Self-Collection*. EUROGIN, Nice, France
- 2009 *Using HPV Natural History to Guide Cervical Cancer Prevention Strategies*. Distinguished Lecture Series, University of Miami Cancer Center, Miami, FL, USA
- 2009 *Getting the Most Bang for the Buck: How Our Understanding of HPV can Inform Cervical Cancer Prevention*. Second AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Carefree, AZ, USA
- 2009 *Using HPV Natural History to Guide Cervical Cancer Prevention Strategies*. New York Academy of Sciences, New York, NY, USA
- 2009 *HPV Testing for the Triage of ASCUS and LSIL; Principles and Results*. 25th International Papillomavirus Conference, Malmö, Sweden
- 2010 *New Molecular Tests for Cervical Cancer Screening in Low-Resources Settings; Combined HPV-Cytology Screening (Co-testing) Versus Human Papillomavirus (HPV)-Only Based Screening; and HPV Testing: Which Test is the Best Choice for HPV Testing Technology for Clinical Practice Cervical Cancer Risk Stratification*. EUROGIN 2010, Monte Carlo, Monaco
- 2010 *Practice Improvement in Cervical Screening and Management (PICSM) Moving Forward: Update from the NIH and Risk Management: Principles and Practice*. ASCCP Biennial Meeting, Las Vegas, NV
- 2010 *New molecular markers for cervical cancer screening: distinguishing hype from hope (Plenary Speaker); HPV Testing for the Triage of ASCUS and LSIL; Principles and Results; and Integrating new technologies such as genotyping and molecular markers in the screening/diagnostic algorithm*. 26th International Papillomavirus Conference, Montreal, Canada
- 2010 *Exporting Cervical Cancer Prevention to the Developing World: The Promise and the Challenges*. Next Generation Dx Summit, Washington DC, USA
- 2011 *Preventing Cervical Cancer: What Are We Waiting For?* University of Arizona Cancer

- Center Cancer Prevention and Control Seminar, Tucson, AZ, USA
- 2011 *An Overview of Women's Cancers in Africa and Rwanda: the Opportunity for Prevention and HPV Testing in the Prevention of Cervical Cancer.* Women Cancer Summit, Kigali, Rwanda
- 2011 *Separating the Wheat from the Chaff: The Paradigm of Human Papillomavirus (HPV) and Cervical Cancer. The Henderson Lecture,* Department of Obstetrics and Gynaecology Research Day, University of Toronto, Toronto, Canada
- 2011 *Management of Cyto-Negative / HPV-Positive Women; Significance of Molecular Testing/Markers and Age of Exposure to HPV; and Moving from Algorithms to Risk-Based Management: Is it of Value for the Clinician? Yes.* EUROGIN 2011, Lisbon, Portugal
- 2011 *Population Application of HPV Testing.* Canadian Network on HPV Prevention's HPV Webinar on HPV Testing Technologies: Current Evidence and New Advancements
- 2011 *A 21st Century Road Map for Cervical Cancer Prevention?* National Women's Hospital, Auckland, New Zealand and New South Wales Cancer Center, Sydney, Australia
- 2011 *A Brave New World? The Rationale for, and Barriers to, Adopting Molecular Testing for Cervical Cancer Prevention and Using Population Risks to Guide the Implementation of New Algorithms for Cervical Cancer Prevention. Keynote Speaker,* Preventing Cervical Cancer 2011. Melbourne, Australia
- 2011 *Risk Management and Assessment using HPV Genotyping and A Risk-Based Model for Integrating New Technologies: HPV Vaccination and New Biomarkers.* 2nd Colposcopy and Cervical Pathologies Congress, Antalya, Turkey
- 2012 *Talking the Talk, Walking the Walk: How Do Make Global Cervical Cancer Prevention a Reality?* Global Oncology Lecture, MD Anderson, Houston, TX, USA
- 2012 *HPV Molecular Diagnostics and Cervical Cytology.* ASCCP Biennial Meeting, San Francisco, CA, USA
- 2012 *The Natural History of HPV as the Rationale Basis for Cervical Cancer Prevention.* Papanicolaou Society of Cytopathology Symposium, USCAP Annual Meeting, Vancouver, Canada
- 2012 A presentation to USCAP's Friends of Africa on the ASCP's plans for capacity building for pathology services in Africa. USCAP Annual Meeting, Vancouver, Canada
- 2012 *Global Prospective of Cervical Cancer Prevention and Control and The U.S. Screening Guidelines and the Use of HPV Genotyping in Clinical Management. Keynote Speaker,* Chinese National Cervical Cancer Consortium Annual Conference, Beijing, China
- 2012 *Biomarkers of Cervical Cancer.* Cancer Prevention, Biomarkers and Screening Research in China and the United States: Opportunities for Collaboration. A Workshop Organized by: Cancer Institute/Hospital of the Chinese Academy of Medical Sciences & National Cancer Institute. Beijing, China
- 2012 *Cervical Cancer Screening: A 2012 Update.* Grand Rounds, Duke University, Rayleigh, NC, USA
- 2012 *U.S. Cervical Cancer Screening Guidelines.* 2012 Annual Meeting of the Italian Cervical Cancer Screening Society, L'Aquila, Italy
- 2012 *The Half-Paved Road from Etiology to the Prevention of Cervical Cancer.* Institute for Oncology and Radiology, Belgrade, Serbia
- 2012 *Delivering on the Promise of Cervical Cancer Prevention. Keynote Speaker,* Asian Pacific Regional Conference of the International Federation of Midwives, Hanoi, Vietnam
- 2012 President's Cancer Panel, Chicago, IL, USA
- 2012 *A User-Friendly Guide for Cervical Cancer Prevention.* Maryland State Council on Cancer Control Annual Cancer Conference, MD, USA

- 2013 *Natural History and Epidemiology of Cervical Cancer*. Prevent Cancer Foundation – Dialogue for Action, Baltimore, MD, USA
- 2013 *We have Effective Vaccines and Screening: Why Continue to Study Cervical Cancer?* McKelvey Lectureship in Gynecologic Oncology, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA
- 2013 *Here, There, Everywhere---Cervical Cancer as a Model for Global Cancer Health*. GAP Conference, MD Anderson Cancer Center, Houston, TX, USA
- 2013 *We have Effective Vaccines and Screening: Why Continue to Study Cervical Cancer?* MRC National Institute of Medical Research, London, England
- 2013 *The Storm Before the Calm: The Rapid Evolution in Cervical Cancer Prevention*. Society of Canadian Colposcopists and Society of Obstetricians & Gynecologists of Canada. Calgary, Alberta, Canada
- 2013 *International Perspectives on Cervical Cancer Prevention*. Asociacion Antioqueña de Obstetricia y Ginecologia, Medellin, Colombia and Instituto Nacional de Cancerologia, Bogota, Colombia
- 2014 *Advancing cervical cancer prevention by targeting the necessary cause – human papillomavirus*. 8th All-Russia Research and Practical Conference with international participation "MOLECULAR DIAGNOSTICS 2014". Moscow, Russia
- 2014 *The implementation of the screening technologies in developing countries*. AOGIN, Beijing, China
- 2014 *The Paradigm Shift from Pap to Molecular HPV and Biomarker Testing for Cervical Cancer Screening*. The 18th Japan-Korea-Taiwan Joint Conference for Gynecological Pathology. Taipei, Taiwan
- 2014 *Equal Management for Equal Risk: Using Risk to Guide Optimal Clinical Management of Screen-Positive Women*. The 18th Japan-Korea-Taiwan Joint Conference for Gynecological Pathology. Taipei, Taiwan
- 2014 *A Paradigm Shift from Pap to HPV Testing for Cervical Cancer Screening: The Good, the Bad, and the Ugly*. Southern Ob/Gyn Conference, Asheville, NC, USA
- 2014 *Equal Management for Equal Risk: Using Risk to Guide Optimal Clinical Management of Screen-Positive Women*. Southern Ob/Gyn Conference, Asheville, NC, USA
- 2014 *Cervical Cancer Prevention: Screen 1st, Vaccinate 2nd*. EIP 2014 Conference, Dubai, UAE
- 2015 *CERVIVOR School: Global Impact of Cervical Cancer (& Shouldn't We Do Something About It?!)*. Austin, TX, USA
- 2015 *Quality and Safety Monitoring of the Renewed Program*. PCC2015 Conference, Melbourne, Australia
- 2015 *Global Cervical Cancer Control*, PCC2015 Conference, Melbourne, Australia
- 2015 *Natural History and Epidemiology of Cervical Cancer: The Case for Global Cervical Cancer Prevention*. 2015 Dialogue for Action on Cancer Screening, The Prevent Cancer Foundation, Baltimore, MD, USA
- 2015 *Risk-based approach to cervical cancer screening and management*. 63rd Annual Meeting of the American Society of Cytopathology, Chicago, IL, USA
- 2015 *Epidemiology of human papillomaviruses (HPV) and cervical/anogenital cancer - from science to cancer prevention strategies*. 7th Annual Meeting of the Excellence in Pediatrics, London, UK
- 2016 *Natural History and Epidemiology of Cervical Cancer: The Case for Global Cervical Cancer Prevention*. 2016 Dialogue for Action on Cancer Screening, The Prevent Cancer Foundation, Baltimore, MD, USA
- 2016 *Cervical cancer prevention—HPV vaccination and screening*, 68th Annual Japanese Society for Obstetrics and Gynecology, Tokyo, Japan

- 2016 *HPV Primary Screening Strategy and Algorithm in LMIC*, 14th Annual Meeting of National Cervical Cancer Consortium, Beijing, China
- 2016 *The Promise of Global Cervical Cancer Prevention*, Annual Oration of the Society of Colposcopy and Cervical Pathology Singapore (SCCPS), Singapore
- 2016 *Perspective Lecture: Challenges of Cervical Cancer Prevention Beyond Medical Innovations*. AOGIN, Singapore
- 2016 *The Case for Primary HPV Testing*. AOGIN, Singapore
- 2016 *Safety, efficacy and barriers for implementation of HPV vaccine*. 5th Jornadas de Investigación en Cáncer. Cali, Colombia
- 2016 *Challenges of implementation of HPV-based screening in low-middle income countries*. 5th Jornadas de Investigación en Cáncer. Cali, Colombia
- 2016 *Cervical Cancer Prevention: State of the Art and State of the "Union"*. I Workshop Brasil-Estados Unidos Em Auto Coleta Para O Cervical Cancer. Maringá, Brazil
- 2016 *Globalization of Cervical (Pre)Cancer Screening as a Model for Addressing Global Cancer Health Disparities. Survivorship, Outcomes, and Risk (SOAR) Program*, Memorial Sloan Kettering Cancer Center, NY, NY, USA
- 2016 *HPV Vaccination: Facts, Fiction, and Why a Pediatrician Should Care*. 8th Excellence in Pediatrics. London, England
- 2017 HPV Vaccination Challenges and Solutions; Africa: Opportunities, IFCPC 2017 World Congress, Orlando, FL, USA
- 2017 Stratifying Risk in Cervical Cancer Screening, IFCPC 2017 World Congress, Orlando, FL
- 2017 Closing Keynote: *Mobilizing for Global Prevention and Early Detection of Cervical Cancer*. 2017 Dialogue for Action on Cancer Screening, The Prevent Cancer Foundation, Vienna, VA, USA
- 2017 *Global Eradication of Cervical Cancer. Why Not?* Annette L. Boman Cancer Research Symposium, University of Minnesota Duluth, Duluth, MN, USA
- 2018 *Evidence for 1 vs. 2 vs. 3 Doses*, ASCCP Annual Meeting, Las Vegas, NV
- 2018 *Should we be using Self-Collection in the U.S.? (Con)*, ASCCP Annual Meeting, Las Vegas, NV, USA
- 2018 *Epidemiology of Health Disparities*, ASCCP Annual Meeting, Las Vegas, NV
- 2019 *HPV and Cytology Cotesting vs. HPV Testing for Secondary Cervical Cancer Prevention: Is the Juice Worth the Squeeze?* Dialogue for Action, Prevent Cancer Foundation, Arlington, VA, USA
- 2019 *Cervical cancer prevention in the age of modern antiretrovirals and the AIDS Malignancy Consortium*, The CIHR Canadian HIV Trials Network Semi-Annual Meetings, Saskatoon, Saskatchewan, Canada
- 2020 *Globalization of Cervical Cancer Prevention*, Grand Rounds, Department of Obstetrics and Gynecology, Montefiore Medical Center

Oral Presentations (Abstracts)

- 1991 **Castle PE**, Whaley KJ, Moench TR, Hildreth JE, Saltzman WM, Radomsky ML, Hoen TE, Cone RA. Monoclonal IgM antibodies against rabbit sperm for vaginal contraception. American Society of Andrology, Montreal, Canada
- 1999 **Castle PE**, Dean J. Mice with "humanized" zona pellucida: a model for zona pellucida-targeted immunocontraception. 19th Annual Meeting of the American Society of Reproductive Immunology, Cooperstown, NY, USA
- 2000 **Castle PE**, Schiffman MH, Hillier SL, Rabe L, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, et al. Inflammation and co-infection with STDs other than HPV

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- as risk factors for progression of HPV infections to high-grade squamous intraepithelial lesions and cervical cancer. 18th International Papillomavirus Conference, Barcelona, Spain
- 2001 **Castle PE**, Sherman ME, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Schiffman M. The diagnostic and prognostic value of a single HPV DNA test for CIN3+ in a 10-year prospective study. 19th International Papillomavirus Conference, Florianopolis, Brazil
- 2002 **Castle PE**, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Anthony J, Schiffman M. A comparison of Hybrid Capture 3 to Hybrid Capture 2 for the detection of oncogenic HPV DNA. 20th International Papillomavirus Conference, Paris, France
- 2002 **Castle PE**, Schiffman M, Bratti MC, Hildesheim A, Herrero R, Rodríguez AC, Sherman ME, Wacholder S, Schussler JE, Burk RD. HPV type-specific persistence and progression to high-grade cervical neoplasia. 20th International Papillomavirus Conference, Paris, France
- 2002 **Castle PE**, Escoffery C, Schachter J, Rattray C, Schiffman M, Moncada J, Sugai K, Brown C, Cranston B, Hanchard B, Stephens RS, Palefsky JM, Burk RD, Hutchinson ML, Strickler HD. *C. trachomatis*, HSV-2 and HTLV-I are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. 20th International Papillomavirus Conference, Paris, France
- 2004 **Castle PE**, Schiffman M, Herrero R, Hildesheim A, Bratti MC, Wacholder S, Pfeiffer R, Rodríguez AC, Burk RD. Type-specific HPV DNA age patterns and determinants: evidence for phylogenetic clade-specific tropism for epithelial cell types. 21st International Papillomavirus Conference, Mexico City, Mexico
- 2005 **Castle PE**, Solomon D, Schiffman M, Wheeler CM. HPV16 infection and the two-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. 22nd International Papillomavirus Conference, Vancouver, Canada
- 2005 **Castle PE**, Dasgupta A, Wheeler CM, Solomon D, Schiffman M. A comparison of the Line Blot Assay and Hybrid Capture 2 in ALTS. 22nd International Papillomavirus Conference, Vancouver, Canada
- 2007 **Castle PE**, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. A comparison of Line Blot Assay and Linear Array. EUROGIN: International Expert Meeting on HPV Infection and Cervical Cancer Prevention. Monte Carlo, Monaco
- 2007 **Castle PE**, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. A comparison of Linear Array and Line Blot Assay for Detection of Cervical Precancer. 24th International Papillomavirus Conference, Beijing, China
- 2007 **Castle PE**, Cox JT, Solomon D, Schiffman M. A descriptive analysis of carcinogenic human papillomavirus DNA-negative cervical precancers in ALTS. 24th International Papillomavirus Conference, Beijing, China
- 2009 **Castle PE**, Rodríguez AC, Burk RD, Herrero R, Hildesheim A, Sherman ME, Solomon D, Alfaro M, Morales J, Guillen D, Wacholder S, Schiffman M. Negative screening tests and colposcopy do not provide absolute reassurance against cervical cancer. 25th International Papillomavirus Conference, Malmö, Sweden
- 2014 Zhao F-H, Katki H, Kinney W, Cheung L, Schiffman M, Fetterman B, Poitras N, Lorey T, **Castle PE**. Cervical cancer risk for following multiple rounds of human papillomavirus and cytology cotesting in a one million-women cohort. 29th International Papillomavirus Conference, Seattle, WA, USA
- 2015 **Castle PE**, Zhao F-H, Kinney W, Cheung L, Schiffman M, Fetterman B, Poitras N, Lorey T, Katki H. Cervical cancer risk for following multiple rounds of human papillomavirus

- and cytology cotesting in a one million-women cohort. Annual Meeting on Women's Cancers, Society of Gynecologic Oncology, Chicago, IL, USA
- 2015 Burger EA, **Castle PE**, Kim JJ. The optimal age for vaccinated women to initiate cervical cancer screening in the United States. 30th International Papillomavirus Conference, Lisbon, Portugal
- 2015 **Castle PE**, Yap P-S, Behrens C. Cervical precancer and cancer risk by human papillomavirus status and cytologic interpretation: implications for risk-based management. 30th International Papillomavirus Conference, Lisbon, Portugal
- 2015 Campos NG, Jeronimo J, **Castle PE**, Tsu V, Mvundura M, Lee K, Geng F, Kim JJ. Optimizing performance characteristics of careHPV in Uganda: a cost-effectiveness analysis. 30th International Papillomavirus Conference, Lisbon, Portugal
- 2015 Schiffman M, Vaughan L, Raine-Bennett T, Wilhelm P, Malinowski D, Katki H, Gage J, **Castle PE**, Wentzensen N. Cohort study of combined HPV testing and focalpoint cytology for automated cervical cancer screening and triage: "equal management of equal risk". 30th International Papillomavirus Conference, Lisbon, Portugal
- 2015 Keller MJ, Burk RD, Massad LS, Eltoun IE, Hessol N, **Castle PE**, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Palefsky JM, Strickler HD. Cervical precancer risk in HIV-infected women who test positive for oncogenic human papillomavirus despite a normal Pap test. 30th International Papillomavirus Conference, Lisbon, Portugal
- 2015 Cremer M, Alfaro K, Maza M, Morales M, Masch M, Kim JJ, Gage JC, **Castle PE**, Felix JC. Programmatic results of phase 2 of HPV testing implementation in El Salvador. 30th International Papillomavirus Conference, Lisbon, Portugal
- 2016 Engesæter B, van Diermen Hidle B, Hansen M, Moltu P, Staby KM, Borchgrevink-Pedersen S, Vintermyr O, Eide ML, Lönnberg S, Nygård M, Janssen EAM, **Castle P**, Christiansen IK. Quality assurance of HPV testing in the implementation of HPV primary screening in Norway. EUROGIN 2016, Salzburg, Austria
- 2017 Yeager M, Cullen M, Boland JF, Wentzensen N, Burdett L, Yu K, Dean M, Yang Q, Chen Z, Bass S, Steinburg M, Raine-Bennett TR, Lorey T, **Castle PE**, Gonzalez P, Hildesheim A, Kreimer AR, Burk RR, Schiffman M, Mirabello L. Limited HPV16 genetic variability within women with multi-site infections, and large variability between women. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Mirabello L, Yeager M, Wentzensen N, Clifford C, Cullen M, Boland JF, Yu K, Xiao Y, Chen Z, Yang Q, Bass S, Steinberg M, Raine-Bennett T, Lorey T, Franceschi S, Walker J, Zuna R, **Castle PE**, Burk RD, Schiffman M. E7 conservation is critical to HPV16 carcinogenicity. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Campos NG, Jeronimo J, Tsu V, **Castle PE**, Mvundura M, Kim JJ. The Cost-Effectiveness of Visual Triage of Human Papillomavirus-Positive Women in Three Low- and Middle-Income Countries. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Burger EA, Kim JJ, Sy S, **Castle PE**. Exposing the Insulting Infection: Leveraging Models to Explore the Natural History of the Cancer-Causing Human Papillomavirus (HPV) Infection. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Clarke MA, Fetterman B, Demarco M, Gage JC, Raine-Bennett TR, Silver M, Hyun N, Lorey T, Poitras N, **Castle P**, Befano B, Wentzensen N, Schiffman M. Clarifying the role of obesity in HPV natural history and multi-stage cervical carcinogenesis. 31st International Papillomavirus Conference, Capetown, South Africa
- 2017 Wentzensen N, Fetterman B, Bremer R, **Castle P**, Tokugawa D, Poitras N, Hosfield E, Marlowe E, Lorey T, Schiffman M, Kinney W. Evaluation of p16/Ki-67 dual stain and

HPV16/18 genotyping in a large population of HPV-positive women. 31st International Papillomavirus Conference, Capetown, South Africa

Conference Abstracts (Posters) (Last 5 Years)

- Wright TC, **Castle PE**, Apple R, Sharma A, Behrens CM, Huh WK. Risk of \geq CIN3 After 3 years of Follow-up of 42,209 Screened Women: End of Study Results from ATHENA. Society for Gynecologic Oncology, Las Angeles, CA, USA (2013)
- Campos NG, Castle PE, Wright TC, Kim JJ. Cervical Cancer Screening in Resource-Limited Settings: Evaluating Tradeoffs between Test Performance and Programmatic Considerations. The 35th Annual Meeting of the Society for Medical Decision Making (2013)
- Cremer M, Gage J, Maza M, Alfaro K, Rosenbaum A, Ditzian L, Felix J, **Castle PE**. Adherence to recommended follow-up among women testing careHPV+: a comparison of two follow-up strategies. (2013)
- Alfaro K, Gage J, Rosenbaum A, Ditzian L, Maza M, **Castle PE**, Cremer M. Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador. (2013)
- Rosenbaum A, Gage J, Alfaro K, Ditzian L, Maza M, Scarinci I, **Castle PE**, Cremer M. Acceptability of self-collected vs. provider-collected sampling for HPV DNA testing among women in El Salvador. (2013)
- Schiffman M, Boyle S, Raine-Bennett T, Katki H, Gage JC, Wentzensen N, Kornegay J, Apple R, Aldrich C, Tam T, Befano B, **Castle PE**. A Large-Scale Validation Study of the Roche cobas™ HPV Assay. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Schiffman M, **Castle PE**, Raine-Bennett T, Katki H, Gage JC, Befano, Wentzensen N, Vaughan L. A Study of HPV Typing by BD Onclarity™ for the Triage of HPV-Positive ASC-US. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Zhao F-H, Katki H, Kinney W, Cheung L, Schiffman M, Fetterman B, Poitras N, Lorey T, **Castle PE**. Cervical Cancer Risk for Following Multiple Rounds of Human Papillomavirus and Cytology Cotesting in a One Million-Women Cohort. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Gage JC, Schiffman M, Katki HA, **Castle PE**, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK. Potential safety of Primary HPV Testing: Evidence from 1 Million Women Undergoing HPV and Pap Testing in Routine Cervical Cancer Screening since 2003. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Katki HA, Schiffman M, **Castle PE**, Fetterman B, Lorey TS, Poitras NE, Cheung LC, Raine-Bennett TR, Gage JC, Kinney WK. How cervical precancer and cancer risks based on 1 million women were used to develop the new 2013 US screening and management guidelines incorporating HPV testing. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Ndiaye C, Trottier H, Schiffman M, Coutlée F, Ptaszynski S, Gage J, **Castle PE**, Burke, Raine Bennett TR, Mayrand MH. Risk of High-Grade Squamous Intraepithelial Lesions in Older Women Newly Infected by High-Risk Human Papillomaviruses. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Cullen M, Boland J, Mirabello L, Mitchell J, Bass S, Zhang X, Yeager M, Andersen M, Osentoski M, Laptewicz M, Wentzensen N, Yu K, Chen Z, Raine-Bennett TR, **Castle PE**, Schiffman M, Burk RD. High Depth HPV16 Whole Genome Sequencing of 830 PaP Cohort Specimens using Crude Exfoliated Cervical Exacts. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Cremer M *et al.* Introducing careHPV into a Public Sector Screening Program in El Salvador. 29th International Papillomavirus Conference, Seattle, WA (2014)

- Maza M, Alfaro K, Gage JC, **Castle P**, Morales M, Velis JM, Kim J, Felix J, Cremer M.A
Demonstration of Population-Based Screening in El Salvador Using careHPV.
- Cheung LC, Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, **Castle PE**,
Kinney WK. Age-Stratified 5-Year Risks of Cervical Precancer and Cancer among Women
with Enrollment and Newly Detected HPV Infection. 29th International Papillomavirus
Conference, Seattle, WA (2014)
- Sahasrabudde VV, Gravitt PE, Dunn TS, Robbins D, Brown D, Allen RA, Eby YJ, Smith KM,
Zuna RE, Zhang RR, Gold MA, Schiffman M, Walter JL, **Castle PE**, Wentzensen N.
Evaluation of Two Urine-Based HPV Assay in Comparison to Cervical HPV Detection and
High-Grade CIN among Women Attending a Colposcopy Clinic. 29th International
Papillomavirus Conference, Seattle, WA (2014)
- Wentzensen N, Bee K, Schiffman M, Hariri A, Mirabello L, Wacholder S, Raine-Bennett T,
Castle PE, Kinney W, Burk RD. Methylation of Six Carcinogenic HPV Types is Associated
with Cervical Precancer. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Wentzensen W, Fetterman B, **Castle PE**, Wood S, Stiernerling E, Tokugawa D, Poitras N, Lorey
T, Schiffman M, Kinney W. Evaluation of p16/Ki-67 Cytology for Triage of HPV-Positive
Women in a Large Population of Women undergoing Co-Testing. 29th International
Papillomavirus Conference, Seattle, WA (2014)
- Silver, J, Berard-Bergery, M, Mahoney, C, Tajan, E, Theobald, J, Yim, A, **Castle, PE**, Jeronimo,
J, Qiao, YL, Lu, P, Schweizer, J. Clinical Performance of the OncoE6™ Cervical Test and 8-
HPV Type E6/E7 Prototype. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Mirabello L, Schiffman M, Yu K, Cullen M, Boland J, Wentzensen N, Yang Q, Zhang X, Raine-
Bennet T, **Castle PE**, Chen Z, Yeager M, Burk R. Novel HPV16 Genetic Polymorphisms are
Associated with an Increased Risk of CIN3+ in Women Infected with European Lineage (A)
Variants. 29th International Papillomavirus Conference, Seattle, WA (2014)
- Mirabello L, Schiffman M, Yu K, Cullen M, Boland J, Wentzensen N, Yang Q, Zhang X, Raine-
Bennet T, **Castle PE**, Chen Z, Yeager M, Burk R. Mirabello L, Schiffman M, Yu K, Cullen M,
Boland J, Wentzensen N, Yang Q, Zhang X, Raine-Bennet T, Castle PE, Chen Z, Yeager M,
Burk R. Detection of HPV16 Variant Lineage Co-Infections of the Cervix using a Sensitive
Next-Generation Sequencing Method. 29th International Papillomavirus Conference, Seattle,
WA (2014)
- Castle PE**, Zhao F-H, Kinney W, Cheung L, Schiffman M, Fetterman B, Poitras N, Lorey T,
Katki H. Cervical Cancer Risk for Following Three Rounds of Human Papillomavirus and
Cytology Cotesting in a One Million-Women Cohort. Society for Gynecologic Oncology Annual
Meeting on Women's Cancers, Chicago, IL (2015)
- Schmeler KM, Fregnani JHTG, Grant B, Resende JP, Scapulatempo-Neto C, Macedo G, Stoler
MH, **Castle PE**, Richards-Kortum R. High-Resolution Microendoscopy (HRME): A low-cost,
point-of-care alternative to colposcopy and biopsies? Society for Gynecologic Oncology
Annual Meeting on Women's Cancers, Chicago, IL (2015)
- Mills A, Paquette C, **Castle P**, Stoler M. The Risk Stratification By p16 Immunostaining of CIN1
Biopsies: A report from the Gardasil Vaccine trials database. USCAP Annual Meeting, Boston,
MA (2015)
- Canfell K, Darlington Brown J, **Castle P**, Gertig D, Brotherton J, Heley S, Wrede D, Tan J,
Caruana M, Saville M. COMPASS: Phase I findings from a randomized controlled trial of
primary HPV screening in unvaccinated and vaccinated women in Australia. EUROGIN,
Seville, Spain (2015)
- Eldridge RC, Pawlita M, Wilson L, **Castle PE**, Waterboer T, Gravitt PE, Schiffman M,
Wentzensen N. AACR, Philadelphia, PA, USA (2015)

- Ramírez AT, López C, Posada G, Buitrago CA, Castañeda M, Agudelo MC, Barrera L, Baena A, **Castle PE**, Sánchez GI. p16/Kki-67 staining of conventional cytology for reflex testing of HPV-positive women referred to colposcopy in Medellín, Colombia. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Gage JC, Katki HA, Wentzensen N, Fetterman B, **Castle PE**, Cheung LC, Boyle S, Raine-Bennett T, Burk R, Stiemerling E, Tokugawa D, Poitras NE, Lorey T, Schiffman M. Improving clinical management of women screening HPV-positive/cytology negative: The U.S. experience using risk benchmarking to evaluate new biomarkers. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Mirabello L, Yeager M, Yu K, Wentzensen N, Cullen M, Boland JF, Zhang X, Yang Q, Mitchell J, Roberson D, Bass S, Burdette L, Feldman A, Wacholder S, Raine-Bennett T, Lorey T, **Castle PE**, Burk R, Schiffman M. Using next-generation whole-genome sequencing of 3500 HPV16-infected women to extend understand of cervical HPV16 epidemiology and carcinogenesis. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Gage JC, Raine-Bennett T, Schiffman M, Katki HA, Fetterman B, **Castle PE**, Poitras NE, Lorey T, Befano B, Wentzensen N. Rationale and Design of a Large Prospective Cohort Study to Evaluate Biomarkers for Cervical Cancer Screening. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Gage J, Felix J, Morales M, Maza M, Alfaro K, **Castle PE**, Kim J, Masch R, Cremer M. Histopathology variability in a regional cervical cancer screening program in El Salvador. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Canfell K, Caruana M, **Castle PE**, Brotherton J, Gertig D, Heley S, Darlington-Brown J, Garland S, Tan J, Wrede D, Savile M. First evidence of a fall in prevalence of vaccine-included HPV types in women 25+ years: Results from the Compass trial in Australia. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Yeager M, Schiffman M, Machado M, Yu K, Wentzensen N, Cullen M, Boland JF, Zhang X, Yang Q, Mitchell J, Roberson D, Bass S, Burdett L, Wacholder S, Raine-Bennett T, Lorey T, **Castle PE**, Burk R, Mirabello L. HPV16 variant risk lineage is modified by a women's ancestry. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Nygård M, Lönnberg S, **Castle PE**, on behalf of the expert group on HPV in primary screening in Norway. Randomized implementation of changes primary HPV testing for in cervical cancer screening in Norway. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Wentzensen N, Lahrmann B, Wood S, Zuna R, Walker J, **Castle PE**, Schiffman M, Grabe N. Automated evaluation of p16/Ki-67 stained cervical and anal cytology slides. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Cullen M, Boland JF, Zhang X, Yang Q, Mitchell J, Roberson D, Bass S, Wagner S, Wentzensen N, Dunn ST, Zuna R, Walker J, Braunlin M, Raine-Bennett T, Lorey T, **Castle PE**, Schiffman M, Burk R, Mirabello L, Yeager M. Development of a universal HPV whole genome sequencing assay targeting the 13 high-risk types. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Saville M, Caruana M, Castle P, Brotherton J, Gertig D, Heley S, Darlington-Brown J, Hawkes D, Tan J, Wrede CD, Canfell K. Will starting HPV screening at age 25 increase colposcopy referrals after HPV vaccination? Results from the COMPASS trial in Australia. 30th International Papillomavirus Conference, Lisbon, Portugal (2015)
- Adedimeji AA, Sinayobye JD, Asiimwe-Kateera B, Gitembagara A, Chaudhry J, Murenzi G, Zawadi T, Murchison L, Mugenzi P, Patel V, **Castle PE**, Mutesa L, Palefsky J, Anastos KA, for the Rwanda-Einstein Research Consortium. The social context of concurrent and multiple partnerships among Rwandan Men who have Sex with Men (MSM): Implications the spread of for HIV/HPV and other STIs. 21st International AIDS Conference, Durban, South Africa (2016)

- Adedimeji AA, Asiimwe-Kateera B, Sinayobye JD, Gitembagara A, Chaudhry J, Murenzi G, Zawadi T, Murchison L, Mugenzi P, Patel V, **Castle PE**, Anastos KA, Mutesa L, Palefsky J, for the Rwanda-Einstein Research Consortium. 21st International AIDS Conference, Durban, South Africa (2016)
- Chaudhry J, Sinayobye JD, Asiimwe-Kateera B, Gitembagara A, Murenzi G, Zawadi T, Murchison L, Mugenzi P, Patel V, **Castle PE**, Palefsky J, Anastos KA, Mutesa L, Adedimeji AA, for the Rwanda-Einstein Research Consortium. An exploratory qualitative investigation into the uses and role of social media for designing public health interventions among Rwandan Men who have Sex with Men. 21st International AIDS Conference, Durban, South Africa (2016)
- Sinayobye JD, Asiimwe-Kateera B, Gitembagara A, Murenzi G, Zawadi T, Murchison L, Mugenzi P, Gatsinzi V, Mutamuliza J, **Castle PE**, Palefsky JM, Anastos K, Mutesa L, Adedimeji A, for the Rwanda-Einstein Research Consortium. Exploring the socio-structural context, determinants, barriers and facilitators for the prevention and control of anal human papillomavirus (HPV) among Rwandan men who have sex with men (MSM). 21st International AIDS Conference, Durban, South Africa (2016)
- Campos NG, Maza M, Alfaro K, Gage JC, **Castle PE**, Felix JC, Cremer M, Kim JJ. Cervical Cancer Prevention in El Salvador: Costs and Cost-Effectiveness of careHPV testing in a public sector program. Internation. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Castle PE**, Kinney WK, Cheung LC, Gage JC, Barbara Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Schiffman M. Cervical cancer screening by triennial HPV and Pap cotesting: program performance among a million women at Kaiser Permanente Northern California, 2003-2013. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Castle PE**, Kinney WK, Cheung LC, Gage JC, Barbara Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Schiffman M. Impact of a History of Negative Cotests on Positive Screening Test Performance. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Gage JC, Raine-Bennett TR, Demarco M, Silver M, Clarke M, Hyun N, Lorey T, Fetterman B, Poitras N, **Castle PE**, Wentzensen N, Befano B, Schiffman M. Racial/ethnic variation in risks associated with HPV16 infection vs. other high risk genotypes in a large U.S. population. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Kinney W, Fetterman B, Poitras N, Lorey, **Castle P**. Secondary triage of abnormal results will be essential for screening of vaccinated women. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Demarco M, Hyun N, Katki H, Befano B, Cheung L, Raine-Bennett TR, Lorey T, Fetterman B, Poitras N, Gage JC, **Castle P**, Wentzensen N, Schiffman M. Risk-based clinical management of HPV-infected women: which predictors are worth considering? 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Demarco M, Hyun N, Katki H, Befano B, Cheung L, Raine-Bennett TR, Lorey T, Fetterman B, Poitras N, Gage JC, **Castle P**, Wentzensen N, Schiffman M. Independent validation of Onclarity (BD) partial typing. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Engesæter B, Berland J, Tropé A, **Castle P**, Nygård M. Evaluation of cancer cases identified in a randomized implementation of primary HPV testing in the Norwegian cervical cancer screening programme. 31st International Papillomavirus Conference, Capetown, South Africa (2017)

- Wentzensen N, Lahrmann B, Fetterman B, Zuna R, Kinney W, Lorey T, Tokugawa D, Walker J, **Castle PE**, Schiffman M, Grabe N. An integrated system for automated evaluation of p16/Ki-67 stained cytology slides (Cytoreader). 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Arbyn M, Poljak M, Meijer C, Cuschieri K, Heard I, Bogers J-P, Bonde J, Tommasino M, Iftner T, Sasieni P, Wentzensen N, Castle P, de Sanjosé S, Qiao Y-L, Williamson A-L, Saville M, Canfell K, Quint W, Franco E, Dillner J. Update of the list of HPV assays that fulfill requirements for primary cervical cancer screening. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Adedimeji A, Kampambwe S, Sen S, Ruiz-Lopez T, **Castle P**, Nygard M. Using mobile gaming application as an educational platform for increasing human papillomavirus vaccination and improving sexual health among Zambian adolescents. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, Xiao Y, Yu K, Yang Q, Steinberg M, Bass S, Burdett L, Raine-Bennett T, Lorey T, **Castle PE**, Burk R, Schiffman. HPV31 genetic variation using 2,001 whole-genome sequences and associations with cervical carcinogenesis. 31th International Papillomavirus Conference, Capetown, South Africa (2017)
- Killen J, Simms K, Nguyen D, Caruana M, Smith M, **Castle P**, Canfell K. Impact of maternal cervical cancer mortality on childhood deaths in low resource settings. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Nguyen D, Simms K, Hughes S, Egger S, **Castle P**, Canfell K. Systematic review and meta-analysis of childhood mortality after maternal death in low-resource settings: implications for cervical cancer prevention. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Simms K, Nguyen D, Caruana M, Smith M, Bray F, **Castle P**, Canfell K. The projected 50-year global burden of cervical cancer given alternate HPV vaccination and cervical cancer screening scenarios: by human development index. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Canfell K, Caruna M, Gebiski V, Darlington-Brown J, Heley S, Brotherton J, Jennett C, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M. Effectiveness of primary HPV screening with partial genotyping compared to cytology-based screening: baseline findings from the COMPASS trial. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Smith M, Caruna M, Hawkes D, Tan G, Castle P, Saville M, Canfell K. Clinical performance of dual-stained cytology for triage of HPV-positive women in a partially vaccinated population: data from the COMPASS trial. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Silver MI, Gage JC, Kinney WK, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett TR, **Castle PE**. Clinical outcomes after conservative management of CIN2 in 2,035 women aged 21-39 years. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Nygård M, Engesæter B, **Castle PE**, Troupe A. Randomized implementation of primary high-risk papillomavirus testing for cervical cancer screening in Norway. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Murenzi G, Sinayobye JD, Mugenzi P, Dusingize JC, Murangwa A, Rurangwa T, Anastos K, Mutesa L, Adedimeji A, Asiimwe-Kateera B, Zawadi T, **Castle PE**. Optimal methods for cervical cancer prevention in HIV-infected women in low-income settings. 31st International Papillomavirus Conference, Capetown, South Africa (2017)

- Final phase of a public sector HPV testing-based cervical cancer screening project in El Salvador. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Depth of necrosis using different ablation techniques in health cervical tissue. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Pain with different ablation techniques in health cervical tissue. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- Bench testing comparing a standard cryotherapy device and the Cryopen® adapted for low- and middle-income countries. 31st International Papillomavirus Conference, Capetown, South Africa (2017)
- 1, 2, 3....The American Society for Clinical Oncology's Resource-Stratified Guidelines for Primary, Secondary, and Tertiary Prevention of Cervical Cancer. **Castle PE**, de Sanjose S, Chuang LT. AORTIC, Kigali, Rwanda (2017)
- Keane A, Shi J, Simms K, Liu Y, Lew J, Mazariego C, Yuill S, Jeronimo J, **Castle P**, Qiao Y, Canfell K. Strategies for cervical cancer prevention in urban China, using Shenzhen City as an example. 32nd International Papillomavirus Conference, Sydney, Australia
- Killen J, Nguyen D, Simms K, Caruana M, Smith M, Canfell K, **Castle P**. The added benefit of scaling up HPV vaccination in GAVI eligible countries: flow-on effects of loss of a mother on the family. 32nd International Papillomavirus Conference, Sydney, Australia
- Liu Y, Keane A, Simms K, Lew J, Shi J, Mazariego C, Yuill S, **Castle P**, Jeronimo J, Qiao Y, Canfell K. Development and application of a framework to estimate health care costs in China: the cervical cancer example. 32nd International Papillomavirus Conference, Sydney, Australia
- León-Maldonado L, Salmerón J, Lazcano-Ponce E, Torres-Ibarra L, Bosch F, Cuzick J, Lörincz A, Wheeler C, **Castle P**, Allen-Leigh B, Huerta-Ávila E, Bruni L, FASTER-Tlalpan Study Group. HPV vaccine acceptability within an HPV-based cervical cancer screening program in Mexico City. 32nd International Papillomavirus Conference, Sydney, Australia
- Salmerón J, Lazcano-Ponce E, León-Maldonado L, Torres-Ibarra L, Bosch F, Cuzick J, Lörincz A, Wheeler C, **Castle P**, Huerta-Ávila E, Bruni L, FASTER-Tlalpan Study Group. Methods of the FASTER-Tlalpan study in Mexico. 32nd International Papillomavirus Conference, Sydney, Australia
- Cremer M, Alfaro K, Maza M, Zevallos A, Taxa L, Diaz A, **Castle P**, Alonzo T, Masch R, Conzuelo- Rodriguez G, Soler M, Gage J, Felix J. Development of an LMIC-adapted thermoablator. 32nd International Papillomavirus Conference, Sydney, Australia
- Clarke M, **Castle P**, Lorey T, Tokugawa D, Gage J, Darragh T, Hare B, Wentzensen. Long-term performance of HPV genotyping, HPV E6/E7 mRNA expression, and p16/Ki-67 cytology for detection of anal precancer in HIV+ MSM. 32nd International Papillomavirus Conference, Sydney, Australia
- Velentzi L, Smith M, Simms K, Hall M, Brotherton J, Skinner S, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland S, Hammond I, Guy R, Arbyn M, **Castle P**, Saville M, Armstrong B, Canfell K. Maximizing the future impact of interventions on cervical cancer in Australia through modelling: the pathways-cervix program. 32nd International Papillomavirus Conference, Sydney, Australia
- A. Tropé A, Hashim D, Engesaeter B, **Castle P**, Nygård M. Risk-based evaluation of the cervical cancer screening algorithm in Norway. 32nd International Papillomavirus Conference, Sydney, Australia
- Pinheiro N, Schiffman M, Yeager M, Cullen M, Joseph B, Raine-Bennett T, Wentzensen N, Steinberg M, Bass S, Difei W, Xiao Y, Yu K, Zhu B, Chen Z, Dean M, Roberson D, Lorey T, **Castle P**, Burk R, Mirabello L. HPV whole-genome sequencing of 6,096 women with cervical HPV infections: insights into alpha 9 carcinogenesis. 32nd International Papillomavirus Conference, Sydney, Australia

Sinayobye J, Adedimeji A, Viraj V, Hae Y, Donald R, Qiuhu S, **Castle P**, Mutesa L, Murenzi G, Mugenzi P, Munyaneza A, Anastos K, Palefsky J. Anogenital human papillomavirus (HPV) infection in HIV-infected and HIV-uninfected men who have sex with men (MSM) in Rwanda. 32nd International Papillomavirus Conference, Sydney, Australia

XIX. BIBLIOGRAPHY

(<http://www.ncbi.nlm.nih.gov/sites/myncbi/1-q0ng545uq5g/bibliography/41662611/public/?sort=date&direction=ascending>)

XIX.A. Peer-Reviewed Articles

1. Luby-Phelps K, **Castle PE**, Taylor DL, Lanni F. Hindered diffusion of inert tracer particles in the cytoplasm of mouse 3T3 cells. *Proc Natl Acad Sci USA* 1987;84:4910-3. PMID: 3474634
2. **Castle PE**, Whaley KJ, Hoen TE, Moench TR, Cone RA. Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits. *Biol Reprod* 1997;56:153-9. PMID: 9002644
3. Rankin TL, Tong ZB, **Castle PE**, Lee E, Gore-Langton R, Nelson LM, Dean J. Human ZP3 restores fertility in Zp3 null mice without affecting order-specific sperm binding. *Development* 1998;125:2415-24. PMID: 9609824
4. **Castle PE**, Hoen TE, Whaley KJ, Cone RA. Contraceptive testing of vaginal agents in rabbits. *Contraception* 1998;58:51-60. PMID: 9743897
5. Zeitlin L, **Castle PE**, Whaley KJ, Moench TR, Cone RA. Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. *J Reprod Immunol* 1998;40:93-101. PMID: 9862259
6. Greenhouse S, **Castle PE**, Dean J. Antibodies to human ZP3 induce reversible contraception in transgenic mice with 'humanized' zonae pellucidae. *Hum Reprod* 1999;14:593-600. PMID: 10221681
7. Saltzman WM, Sherwood JK, Adams DR, **Castle P**, Haller P. Long-term vaginal antibody delivery: delivery systems and biodistribution. *Biotechnol Bioeng* 2000;67:253-64. Erratum in *Biotechnol Bioeng* 2001;75:495. PMID: 10620255
8. **Castle PE**, Zemlo TR, Burk RD, Scott DR, Sherman ME, Lorincz AT, Kurman RJ, Glass AG, Rush BB, Liaw K-L, Schiffman M. Cervical HPV DNA detection as a predictor of a recurrent SIL diagnosis among untreated women. *J Low Genit Tract Dis* 2001;5:138-43. PMID: 17050958
9. Hildesheim A, Herrero R, **Castle PE**, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodríguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. *Br J Cancer* 2001;84:1219-26. PMID: 11336474
10. **Castle PE**, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodríguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). *Cancer Epidemiol Biomarkers Prev* 2001;10:1021-7. PMID:

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

11588127

11. **Castle PE**, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. *Sex Transm Dis* 2002;29:182-7. PMID: 11875380
12. **Castle PE**, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, Schussler JE, Schiffman M. Results of human papillomavirus DNA testing with the Hybrid Capture 2 assay are reproducible. *J Clin Microbiol* 2002;40:1088-90. PMID: 11880448
13. El-Mestrah M, **Castle PE**, Borossa G, Kan FW. Subcellular distribution of ZP1, ZP2 and ZP3 glycoproteins during folliculogenesis and demonstration of their topographical disposition within the zona matrix of mouse ovarian oocytes. *Biol Reprod* 2002;66:866-76. PMID: 11906903
14. **Castle PE**, Hildesheim A, Bowman FP, Strickler HD, Walker JL, Pustilnik T, Edwards RP, Crowley-Nowick PA. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. *J Clin Immunol* 2002;22:23-7. PMID: 11958590
15. **Castle PE**, Karp D, Zeitlin L, Garcia-Moreno EB, Moench TR, Whaley KJ, Cone RA. Human monoclonal antibody stability and activity at vaginal pH. *J Reprod Immunol* 2002;56:61-76. PMID: 12106884
16. Lorincz AT, **Castle PE**, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. *Lancet* 2002;360:228-9. PMID: 12133661
17. **Castle PE**, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD. Comparisons of HPV DNA detection by MY09/11 PCR methods. *J Med Virol* 2002;68:417-23. PMID: 12226831
18. **Castle PE**, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. *J Natl Cancer Inst* 2002;94:1406-14. PMID: 12237286
19. Schiffman M, Wheeler CM, **Castle PE**; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. *J Infect Dis* 2002;186:1169-72. PMID: 12355370
20. **Castle PE**, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F, Schiffman M. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. *Cancer* 2002;95:2145-51. PMID: 12412168
21. **Castle PE**, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. *Cancer Epidemiol Biomarkers Prev* 2002;11:1394-9. PMID: 12433717
22. Hildesheim A, Ryan RL, Rinehart E, Nayak S, Wallace D, **Castle PE**, Niwa S, Kopp W. Simultaneous measurement of several cytokines using small volumes of biospecimens. *Cancer Epidemiol Biomarkers Prev* 2002;11:1477-84. PMID: 12433730

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

23. Sherman ME, Lorincz AT, Scott DR, Wacholder S, **Castle PE**, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. *J Natl Cancer Inst* 2003;95:46-52. PMID: 12509400
24. Schiffman MH, **Castle P**. Epidemiologic studies of a necessary causal risk factor: human papillomavirus (HPV) infection and cervical neoplasia. *J Natl Cancer Inst* 2003;95:E2. PMID: 12644550
25. **Castle PE**, Solomon D, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Rodríguez AC, Alfaro M, Hutchinson ML, Dunn ST, Kuypers J, Schiffman M. Stability of archived liquid-based cervical cytologic specimens. *Cancer* 2003;99:89-96. PMID: 12704688
26. **Castle PE**, Escoffery C, Schachter J, Rattray C, Schiffman M, Moncada J, Sugai K, Brown C, Cranston B, Hanchard B, Palefsky JM, Burk RD, Hutchinson ML, Strickler HD. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotropic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. *Sex Transm Dis* 2003;30:575-80. PMID: 12838087
27. Rankin TL, Coleman JS, Epifano O, Hoodbhoy T, Turner SG, **Castle PE**, Lee E, Gore-Langton R, Dean J. Fertility and taxon-specific sperm binding persist after replacement of mouse sperm receptors with human homologs. *Dev Cell* 2003;5:33-43. PMID: 12852850
28. Pinto LA, Edwards J, **Castle PE**, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *J Infect Dis* 2003;188:327-38. PMID: 12854090
29. Jeronimo J, **Castle PE**, Herrero R, Sherman ME, Bratti MC, Hildesheim A, Alfaro M, Morales J, Hutchinson ML, Burk RD, Lorincz A, Wacholder S, Rodríguez AC, Schiffman M. Right-sided ectocervical lesions may be associated with false-negative cytology among women with histologic cervical intraepithelial neoplasia 2 or 3. *J Low Genit Tract Dis* 2003;7:175-83. PMID: 17051065
30. **Castle PE**, García-Closas M, Franklin T, Chanock S, Puri V, Welch R, Rothman N, Vaught J. Effects of electron-beam irradiation on buccal-cell DNA. *Am J Hum Genet* 2003;73:646-51. Erratum in *Am J Hum Genet* 2003;73:1477. PMID: 12917795
31. **Castle PE**, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. *J Clin Microbiol* 2003;41:4022-30. PMID: 12958220
32. Heselmeyer-Haddad K, Janz V, **Castle PE**, Chaudhri N, White N, Wilber K, Morrison LE, Auer G, Burroughs FH, Sherman ME, Ried T. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. *Am J Pathol* 2003;163:1405-16. PMID: 14507648
33. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodríguez AC, **Castle PE**, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. *Br J Cancer* 2003;89:1248-54. PMID: 14520455

Philip Edward Castle, Ph.D., M.P.H.
NCI Division of Cancer Prevention
9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
240-276-7120; philip.castle@nih.gov

34. **Castle PE**, Hildesheim A, Schiffman M, Gaydos CA, Cullen A, Herrero R, Bratti MC, Freer E. Stability of archived liquid-based cytologic specimens. *Cancer* 2003;99:320-2. PMID: 14579301
35. Jeronimo J, **Castle PE**, Herrero R, Burk RD, Schiffman M. HPV testing and visual inspection for cervical cancer screening in resource-poor regions. *Int J Gynaecol Obstet* 2003;83:311-3. PMID: 14643047
36. Rodríguez AC, **Castle PE**, Smith JS, Bratti C, Hildesheim A, Schiffman M, Viscidi R, Burk RD, Ashley RL, Castellsagué X, Herrero R. A population-based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. *Sex Transm Infect* 2003;79:460-5. PMID: 14663121
37. **Castle PE**, Phillips TM, Hildesheim A, Herrero R, Bratti MC, Rodríguez AC, Morera LA, Pfeiffer R, Hutchinson ML, Pinto LA, Schiffman M. Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. *Cancer Epidemiol Biomarkers Prev* 2003;12:1449-56. PMID: 14693736
38. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, **Castle PE**, Bratti MC, Rodríguez AC, Sherman ME, Wang S, Clayman B, Burk RD. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. *Cancer Epidemiol Biomarkers Prev* 2004;13:324-7. PMID: 14973086
39. **Castle PE**, Rodríguez AC, Bowman FP, Herrero R, Schiffman M, Bratti MC, Morera LA, Schust D, Crowley-Nowick P, Hildesheim A. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. *Clin Diagn Lab Immunol* 2004;11:399-405. PMID: 15013994
40. Tanaka Y, Pfeiffer R, Yeo AET, Mizokami M, Edlin BR, **Castle P**, O'Brien TR, Alter HJ, Shih JW-K. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. *J Med Virol* 2004;73:123-30. PMID: 15042659
41. Pastrana DV, Buck CB, Pang YY, Thompson CD, **Castle PE**, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. *Virology* 2004;321:205-16. PMID: 15051381
42. Rodríguez AC, Morera LA, Bratti C, Herrero R, Cox JT, Morales J, Alfaro M, Hutchinson M, **Castle PE**, Hildesheim A, Schiffman M. Performance of direct visual inspection of the cervix with acetic acid and magnification in a previously screened population. *J Low Genit Tract Dis* 2004;8:132-8. PMID: 15874851
43. **Castle PE**, Schiffman M, Bratti MC, Hildesheim A, Herrero R, Hutchinson ML, Rodríguez AC, Wacholder S, Sherman ME, Kendall H, Viscidi RP, Jeronimo J, Schussler JE, Burk RD. A population-based study of vaginal human papillomavirus in hysterectomized women. *J Infect Dis* 2004;190:458-67. PMID: 15243917
44. **Castle PE**. Re: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. *J Natl Cancer Inst* 2004;96:1181-2. PMID: 15292390
45. **Castle PE**, Wheeler CM, Solomon D, Schiffman M, Peyton CL; ALTS Group. Interlaboratory reliability of Hybrid Capture 2. *Am J Clin Pathol* 2004;122:238-45. PMID: 15323141

46. **Castle PE**, Schiffman M, Wheeler CM, ALTS Group. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. *Am J Obstet Gynecol* 2004;191:1590-7. PMID: 15547529
47. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodríguez AC, Bratti MC, Wheeler CM, Burk RD; PEG Group; **ALTS Group**. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *J Natl Cancer Inst* 2005;97:147-50. PMID: 15657345
48. **Castle PE**, Schiffman M, Herrero R, Hildesheim A, Rodríguez AC, Bratti MC, Wacholder S, Kendal H, Breheny AM, Prior A, Pfeiffer R, Burk RD. PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection. *Cancer Epidemiol Biomarkers Prev* 2005;14:256-60. PMID: 15668503
49. Bergen AW, Qi Y, Haque KA, Welch RA, García-Closas M, Chanock SJ, Vaught J, **Castle PE**. Effects of electron-beam irradiation on whole genome amplification. *Cancer Epidemiol Biomarkers Prev* 2005;14:1016-9. PMID: 15824182
50. **Castle PE**, Garcia-Meijide M, Holladay EB, Chuke R, Payne J, Long A, Siefers H, Demuth F, Lorincz AT. A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by Hybrid Capture II. *Am J Clin Pathol* 2005;123:250-5. PMID: 15842050
51. **Castle PE**, Schiffman M, Herrero R, Hildesheim A, Rodríguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. *J Infect Dis* 2005;191:1808-16. PMID: 15871112
52. **Castle PE**. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. *J Low Genit Tract Dis* 2004;8:224-30. PMID: 15874868
53. Herrero R, **Castle PE**[†], Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodríguez AC, Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. *J Infect Dis* 2005;191:1796-807. [†]Co-1st author. PMID: 15871111
54. Pinto LA, **Castle PE**, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. *Vaccine* 2005;23:3555-64. PMID: 15855014
55. **Castle PE**, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1311-4. PMID: 15894692
56. McIntyre-Seltman K, **Castle PE**[†], Guido R, Schiffman M, Wheeler CM, ALTS Group. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. *Cancer Epidemiol Biomarkers Prev* 2005;14:1165-70. [†]Corresponding author. PMID: 15894667

57. Schiffman M, Herrero R, DeSalle R, Hildesheim A, Wacholder S, Rodríguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, **Castle PE**, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. *Virology* 2005;337:76-84. PMID: 15914222
58. **Castle PE**, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. *Int J Cancer* 2005;117:1007–12. PMID: 15986443
59. **Castle PE**, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *J Natl Cancer Inst* 2005;97:1066-71. PMID: 16030304
60. Khan MJ, **Castle PE**[†], Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J Natl Cancer Inst* 2005;97:1072-9. [†]Corresponding author. PMID: 16030305
61. McGlynn KA, Devesa SS, Graubard BI, **Castle PE**. Increasing incidence of testicular germ cell tumors among black men in the United States. *J Clin Oncol* 2005;23:5757-61. PMID: 16110032
62. **Castle PE**, Ashfaq R, Ansari F, Muller CY. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. *Cancer Lett* 2005;229:245-52. PMID: 16112431
63. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, **Castle PE**; ALTS Group. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. *Am J Clin Pathol* 2005;124:722-32. PMID: 16203281
64. Jeronimo J, Long R, Neve L, Ferris D, Noller K, Spitzer M, Mitra S, Guo J, Nutter B, **Castle P**, Herrero R, Rodríguez AC, Schiffman M. Preparing digitized cervigrams for colposcopy research and education: determination of optimal resolution and compression parameters. *J Low Genit Tract Dis* 2006;10:39-44. PMID: 16378030
65. **Castle PE**, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC, Hildesheim A, Wacholder S, Long LR, Neve L, Pfeiffer R, Burk RD. Age-related changes of the cervix influence human papillomavirus type distribution. *Cancer Res* 2006;66:1218-24. PMID: 16424061
66. Sherman ME, **Castle PE**, Solomon D; ALTS group. Cervical cytology of atypical squamous cells—cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. *Cancer* 2006;108:298-303. PMID: 16544318
67. Atkins KA, Jeronimo J, Stoler MH; ALTS group (including **Castle PE**). Description of patients with squamous cell carcinoma in the Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study. *Cancer* 2006;108:212-21. PMID: 16680733
68. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler CM, **Castle PE**. Human papillomavirus testing following loop electrosurgical excision procedure

- identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. *Cancer Epidemiol Biomarkers Prev* 2006;15:908-14. PMID: 16702369
69. **Castle PE**, Aftab A, Saint-Jean G, Mendez L. Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. *J Clin Microbiol* 2006;44:2158-9. PMID: 16757614
 70. **Castle PE**, Sadorra M, Garcia F, Holladay EB, Kornegay J. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. *J Clin Microbiol* 2006;44:3915-7. PMID: 16971652
 71. Wheeler CM, Hunt WC, Schiffman M, **Castle PE**; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. *J Infect Dis* 2006;194:1291-9. PMID: 17041856
 72. Kovacic MB, **Castle PE**, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodríguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, Burk RD. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. *Cancer Res* 2006;66:10112-9. PMID: 17047075
 73. **Castle PE**, Schiffman M, Glass AG, Rush BB, Scott DR, Wacholder S, Dunn A, Burk RD. Human papillomavirus prevalence in women who have and have not undergone hysterectomies. *J Infect Dis* 2006;194:1702-5. PMID: 17109342
 74. Kreimer AR, Katki HA, Schiffman M, Wheeler CM, **Castle PE**; ASCUS-LSIL Triage Study Group. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3. *Cancer Epidemiol Biomarkers Prev* 2007;16:11-6. PMID: 17220326
 75. **Castle PE**, Sadorra M, Garcia FAR, Cullen AP, Lorincz AT, Mitchell AL, Whitby D, Chuke R, Kornegay JR. Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. *Cancer Epidemiol Biomarkers Prev* 2007;16:840-3. PMID: 17416781
 76. **Castle PE**, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. *Am J Clin Pathol* 2007;127:805-15. PMID: 17439841
 77. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, González P, Bratti MC, Rodríguez AC, **Castle P**, Costa Rican Vaccine Trial Group. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. *J Clin Microbiol* 2007;45:1447-54. PMID: 17344361
 78. Moore LE, Bergen AW, Haque KA, Qi Y, **Castle P**, Chanock SJ, Egan K, Newcomb P, Titus-Ernstoff L, Alguacil J, Rothman N, Garcia-Closas M. Whole genome amplification of buccal cytobrush DNA collected for molecular epidemiology studies. *Biomarkers* 2007; 12:303-12. PMID: 17453743
 79. Plummer M, Schiffman M, **Castle PE**, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. *J Infect Dis* 2007;195:1582-9. PMID: 17471427

80. **Castle PE**, Dockter J, Giachetti C, Garcia FAR, McCormick MK, Mitchell AL, Holladay EB, Kolk DP. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. *Clin Cancer Res* 2007;13:2599-605. PMID: 17473189
81. Safaeian M, Solomon D, Wacholder S, Schiffman M, **Castle P**. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. *Obstet Gynecol* 2007;109:1325-31. PMID: 17540804
82. Pratt MM, Sirajuddin P, Poirier MC, Schiffman M, Glass AG, Scott DR, Rush BB, Olivero OA, **Castle PE**. Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. *Mutat Res* 2007;624:114-23. PMID: 17583755; PMCID:PMC4383290
83. Jeronimo J, Massad LS, Schiffman M; National Institutes of Health/American Society for Colposcopy and **Cervical Pathology (NIH/ASCCP) Research Group**. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. *Am J Obstet Gynecol* 2007;197:47.e1-8. PMID: 17618753
84. **Castle PE**, Rodríguez AC, Porras C, Herrero R, Schiffman M, Gonzalez P, Hildesheim A, Burk RD. A comparison of cervical and vaginal human papillomavirus. *Sex Transm Dis* 2007;34:849-55. PMID: 17621246; PMCID:PMC3962831
85. Solomon D, Stoler M, Jeronimo J, Khan M, **Castle P**, Schiffman M. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities. *Obstet Gynecol* 2007;110:288-95. PMID: 17666602
86. LaMere BJ, Kornegay J, Fetterman B, Sadorra M, **Castle PE**; PaP Cohort Study Group. Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort. *J Virol Methods* 2007;146:80-5. PMID: 17673302; PMCID:PMC2683347
87. Mariategui J, Santos C, Taxa L, Jeronimo J, **Castle PE**. Comparison of depth of necrosis achieved by CO₂- and N₂O-cryotherapy. *Int J Gynaecol Obstet* 2008;100:24-6. PMID: 17897647
88. Schiffman M, **Castle PE**, Jeronimo J, Rodríguez AC, Wacholder S. Human papillomavirus and cervical cancer. *Lancet* 2007;370:890-907. PMID: 17826171
89. Jeronimo J, Massad LS, **Castle PE**, Wacholder S, Schiffman M; National Institutes of Health (NIH)-American Society for Colposcopy and Cervical Pathology (ASCCP) Research Group. Interobserver agreement in the evaluation of digitized cervical images. *Obstet Gynecol* 2007;110:833-40. PMID: 17906017
90. Seamans Y, Loesel C, Jeronimo J, Sellors J, **Castle PE**. Effect of cough technique and cryogen gas on temperatures achieved during simulated cryotherapy. *BMC Womens Health* 2007;7:16. PMID: 17908317; PMCID:PMC2048944
91. **Castle PE**, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the Atypical Squamous Cells of Undetermined Significance and Low-grade Squamous Intraepithelial Lesion Triage Study. *J Clin Microbiol* 2008;46:109-17. PMID: 17989194; PMCID:PMC2224265

92. **Castle PE**, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. *Am J Obstet Gynecol* 2007;197:356.e1-e6. PMID: 17904958; *J Low Genit Tract Dis* 2008;12:1-7. PMID: 18162804; PMCID:PMC2128712
93. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, **Castle PE**, Solomon D, Burk RD, Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. *J Natl Cancer Inst* 2008;100:513-7. PMID: 18364507; PMCID:PMC3705579
94. **Castle PE**, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M. An analysis of high-risk human papillomavirus DNA-negative cervical precancer in the ASCUS-LSIL Triage Study (ALTS). *Obstet Gynecol* 2008;111:847-56. PMID: 18378743
95. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, **Castle PE**. A comparison of Linear Array and Hybrid Capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS LSIL Triage Study. *Cancer Epidemiol Biomarkers Prev* 2008;17:1248-54. PMID: 18483347; PMCID:PMC2705141
96. Massad LS, Jeronimo J, Schiffman M; National Institutes of Health (NIH)-American Society of Colposcopy and Cervical Pathology (ASCCP) Research Group (including **Castle PE**). Interobserver agreement in the assessment of components of colposcopic grading. *Obstet Gynecol* 2008;111:1279-84. PMID: 18515509
97. Galgano MT, **Castle PE**, Stoler MH, Solomon D, Schiffman M. Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? *Am J Clin Pathol* 2008;130:65-70. PMID: 18550472
98. LaMere BJ, Howell R, Fetterman B, Shieh J, **Castle PE**; PaP Cohort Study Group. Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping. *J Virol Methods* 2008;151:298-300. PMID: 18571737; PMCID:PMC2577906
99. **Castle PE**, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. *J Clin Microbiol* 2008;46:2595-604. PMID: 18579716; PMCID:PMC2519476
100. **Castle PE**, Cox JT, Solomon D, Schiffman M. Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology. *Obstet Gynecol* 2008;112:637-45. PMID: 18757663; PMCID:PMC2634751
101. Meijer CJLM, Berkhof J, **Castle PE**, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *Int J Cancer* 2009;124:516-20. PMID: 18973271; PMCID:PMC2789446
102. **Castle PE**, Porras C, Quint WG, Rodríguez AC, Schiffman M, Gravitt PE, González P, Katki H, Silva S, Freer E, Van Doorn L-J, Jiménez S, Herrero R, Hildesheim A; CVT Group. Comparison of two PCR-based human papillomavirus genotyping methods. *J Clin Microbiol* 2008;46:3437-45. PMID: 18716224; PMCID:PMC2566086
103. **Castle PE**, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. *Obstet Gynecol* 2009;113:18-25. PMID: 19104355; PMCID:PMC2694845
104. Xi LF, Koutsky LA, **Castle PE**, Wheeler CM, Galloway DA, Mao C, Ho J, Kiviat NB.

- Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. *J Natl Cancer Inst* 2009;101:153-61. PMID: 19176451; PMCID:PMC2724855
105. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, **Castle PE**. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. *Cancer Epidemiol Biomarkers Prev* 2009;18:792-800. PMID: 19258470
 106. **Castle PE**, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Pap test cotesting. *Obstet Gynecol* 2009;113:595-600. PMID: 19300322; PMCID:PMC2747731
 107. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, **Castle PE**. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. *J Natl Cancer Inst* 2009;101:475-87. PMID: 19318628; PMCID:PMC2664090
 108. Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, **Castle PE**. Detection of precancerous cervical lesions is differential by human papillomavirus type. *Cancer Res* 2009;69:3262-6. PMID: 19351830; PMCID:PMC3155840
 109. **Castle PE**, Kreimer AR, Wacholder S, Wheeler CM, Koutsky LA, Rydzak G, Buckman DW, Graubard B, Schiffman M. Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. *J Infect Dis* 2009;199:1612-20. PMID: 19405865; PMCID:PMC2790913
 110. Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, **Castle PE**. A study of Amplicor human papillomavirus DNA detection in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study. *Cancer Epidemiol Biomarkers Prev* 2009;18:1341-9. PMID: 19423515; PMCID:PMC2804087
 111. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Mutimura E, Cajigas A, Bigirimani V, Cai X, Rwamwejo J, Vuolo M, Cohen M, **Castle PE**. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. *J Infect Dis* 2009;199:1851-61. PMID: 19435429; PMCID:PMC2814215
 112. **Castle PE**, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W. Age-appropriate use of human papillomavirus vaccines in the U.S. *Gynecol Oncol* 2009;114:365-9. PMID: 19464729; PMCID:PMC2729751
 113. Massad LS, Jeronimo J, Katki H, Schiffman M; National Institutes of Health (NIH)-American Society for Colposcopy and Cervical Pathology Research Group (including **Castle PE**). The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. *J Low Genit Tract Dis* 2009;13:137-44. PMID: 19550210; PMCID:PMC2921444
 114. **Castle PE**, Rodríguez AC, Burk RD, Herrero R, Hildesheim A, Solomon D, Sherman ME, Jeronimo J, Alfaro M, Morales J, Guillen D, Hutchinson ML, Wacholder S, Schiffman M. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. *Int J Cancer* 2009;125:1649-56. PMID: 19569231; PMCID:PMC2766540
 115. **Castle PE**, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D, Schiffman M, Proyecto Epidemiológico Guanacaste (PEG)

- Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. *BMJ* 2009;339:b2569. PMID: 19638649; PMCID:PMC2718087
116. **Castle PE**, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. *J Clin Microbiol* 2009;47:3344-7. PMID: 19675214; PMCID:PMC2756930
 117. Arbyn M, Ronco G, Cuzick J, Wentzensen N, **Castle PE**. How to evaluate emerging technologies in cervical cancer screening? *Int J Cancer* 2009;125:2489-96. PMID: 19626591; PMCID:PMC2790915
 118. Maucourt-Boulch D, Plummer M, **Castle PE**, Demuth F, Safaeian M, Wheeler CM, Schiffman M. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. *Int J Cancer* 2010;126:684-91. PMID: 19609952
 119. Xi LF, Koutsky LA, **Castle PE**, Edelstein ZR, Meyers C, Ho J, Schiffman M. Relationship between cigarette smoking and human papillomavirus types 16 and 18 DNA load. *Cancer Epidemiol Biomarkers Prev* 2009;18:3490-6. PMID: 19959700; PMCID:PMC2920639
 120. **Castle PE**, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. *Am J Epidemiol* 2010;171:155-63. PMID: 20007673; PMCID:PMC2878104
 121. **Castle PE**, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. *Obstet Gynecol* 2010;115:243-8. Erratum in: *Obstet Gynecol*. 2010;116:775-7. PMID: 20093895
 122. **Castle PE**, Wentzensen N, Wheeler CM, Rydzak G, Schiffman M. Effect of the number of biopsies on the subsequent acquisition of new human papillomavirus infections. *Obstet Gynecol* 2009;114:1057-62. PMID: 20168107
 123. Schiffman M, Rodríguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Solomon D, **Castle PE**, Burk RD. A population-based prospective study of carcinogenic human papillomavirus (HPV) variant lineages, viral persistence, and cervical neoplasia. *Cancer Res* 2010;70:3159-69. PMID: 20354192; PMCID:PMC2855741
 124. Moore G, Fetterman B, Cox JT, Poitras N, Lorey T, Kinney W, **Castle PE**. Lessons from practice: risk of CIN3 or cancer associated with HPV-positive ASC-US or LSIL screening result in women aged 21-24. *J Low Genit Tract Dis* 2010;14:97-102. PMID: 20354416; PMCID:PMC2907060
 125. Scarinci I, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Day JL, **Castle PE**. Cervical cancer prevention: new tools and old barriers. *Cancer* 2010;116:2531-42. PMID: 20310056; PMCID:PMC2876205
 126. **Castle PE**. Do selective estrogen receptor modulators treat cervical precancer and cancer? *Int J Cancer* 2011;128:997-8. PMID: 20473883; PMCID:PMC2944904
 127. **Castle PE**, Fetterman B, Cox JT, Shaber R, Poitras N, Lorey T, Kinney W. The age-specific relationships of abnormal cytology and HPV DNA results with the risk of cervical precancer and cancer. *Obstet Gynecol* 2010;116:76-84. PMID: 20567171

128. Gage JC, Schiffman M, Solomon D, Wheeler CM, **Castle PE**. Comparison of measurements of human papillomavirus persistence for post-colposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiol Biomarkers Prev* 2010;19:1668-74. PMID: 20615884; PMCID:PMC2919053
129. **Castle PE**, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Human papillomavirus genotypes detected at the time of cervical intraepithelial neoplasia grade 3 diagnoses. *Cancer Epidemiol Biomarkers Prev* 2010;19:1675-81. PMID: 20615885; PMCID:PMC2901898
130. **Castle PE**, Bulten J, Confortini M, Klinkhamer P, Pellegrini A, Siebers AG, Ronco G, Arbyn M. Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomized clinical trials. *BJOG* 2010;117:1067-73. PMID: 20604775; PMCID:PMC2915792
131. Gage JC, Schiffman M, Solomon D, Wheeler CM, **Castle PE**. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiol Biomarkers Prev* 2010;19:1668-74. PMID: 20615884; PMCID:PMC2919053
132. Galgano MT, **Castle PE**, Atkins KA, Brix WK, Nassau S, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. *Am J Surg Pathol* 2010;34:1077-87. PMID: 20661011; PMCID:PMC2921638
133. Gage JC, Duggan MA, Nation JG, Gao S, **Castle PE**. Detection of cervical precancer and cancer by endocervical curettage in 13,467 colposcopically-guided biopsy examinations. *Am J Obstet Gynecol* 2010; 203:481.e1-9. PMID: 20800216; PMCID:PMC2975767
134. Schweizer J, Lu PS, Berard-Bergery M, Bisht A, Labiad Y, Ho M, Mahoney C, Ramasamy V, Silver JE, Peck RB, Lim J, Jeronimo J, Howard R, Gravitt PE, **Castle PE**. A feasibility study of a human papillomavirus E6 oncoprotein test for detection of cervical precancer and cancer. *J Clin Microbiol* 2010;48:4646-8. PMID: 20926711; PMCID:PMC3008434
135. Wentzensen N, Wilson L, Wheeler CM, Carreon JD, Gravitt PE, Schiffman M, **Castle PE**. Hierarchical clustering of HPV genotypes patterns in the ASCUS-LSIL triage study. *Cancer Res* 2010;70:8578-86. PMID: 20959485; PMCID:PMC2970748
136. Anastos K, Hoover DR, Cajigas A, Burk RD, Shi Q, Singh DK, Mutimura E, Bigirimani V, Cai X, Rwamwejo J, Cohen M, **Castle PE**. Risk factors for cervical precancer and cancer in HIV-infected, HPV-positive Rwandan women. *PLoS ONE* 2010;5:e13525. PMID: 20976000; PMCID:PMC295812
137. Xi LF, Koutsky LA, **Castle PE**, Edelstein ZR, Huibert A, Schiffman M, Kiviat NB. Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for proper understanding of type-specific persistent infections. *J Infect Dis* 2010;202:1667-70. PMID: 20977339; PMCID:PMC3107552
138. Zhao F-H, Lin MJ, Hu S-Y, Chen F, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao Y-L, **Castle PE** (and CCSG). Performance of high-risk human papillomavirus DNA testing as a primary screening tool for cervical cancer: a pooled analysis of 17 population-based studies from China. *Lancet Oncol* 2010;11:1160-71. PMID: 21075054
139. Littell RD, Kinney W, Fetterman B, Cox JT, Shaber R, Poitras N, Lorey T, **Castle PE**. Short-term risk of cervical precancer and cancer in women aged 30 and older with a

- human papillomavirus-negative low-grade squamous intraepithelial lesion screening result. *J Low Genit Tract Dis* 2011;15:54-9. PMID: 21192178
140. Campos NG, Rodriguez AC, **Castle PE**, Herrero R, Hildesheim A, Katki H, Kim JJ, Wacholder S, Morales J, Burk RD, Schiffman M. Persistence of concurrent infections with multiple human papillomavirus types: A population-based cohort study. *J Infect Dis* 2011;203:823-7. PMID: 21257737; PMCID:PMC3071138
 141. **Castle PE**, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, Morales J, Rydzak G, Schiffman M; For the Proyecto Epidemiológico Guanacaste (PEG) Group. Long-term human papillomavirus persistence in the absence of detectable cervical precancer and cancer. *J Infect Dis*. 2011;203:814-822. PMID: 21343148; PMCID:PMC3071125
 142. **Castle PE**, Fetterman B, Poitras N, Lorey T, Shaber R, Schiffman M, Demuth F, Kinney W. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. *Obstet Gynecol* 2011;117:650-6. PMID: 21343769
 143. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, **Castle PE**. Characteristics of 44 cervical cancers diagnosed following Pap negative, high risk HPV positive screening in routine clinical practice. *Gynol Oncol* 2011;121:309-13. PMID: 21276605; PMCID:PMC3081890
 144. Xi LF, Hughes JP, **Castle PE**, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NA, Schiffman M. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. *J Infect Dis* 2011;203:1425-33. PMID: 21415020; PMCID:PMC3080901
 145. **Castle PE**, Shaber R, LaMere B, Kinney WK, Fetterman B, Poitras N, Lorey T, Schiffman M, Dunne A, Ostolaza JM, McKinney S, Burk RD. Human Papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. *Cancer Epidemiol Biomarkers Prev* 2011;20:946-53. PMID: 21415357; PMCID:PMC3117227
 146. **Castle PE**, Rausa A, Walls T, Gravitt PE, Partridge EE, Olivio V, Niwa S, Morrissey K, Tucker L, Katki H, Scarinci I. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. *Prev Med* 2011;52:452-5. PMID: 21497619; PMCID:PMC3114876
 147. Nuño T, **Castle PE**, Harris R, Estrada A, Garcia F.A.R., for the Yuma Project Technical Team. Breast and cervical cancer screening utilization among older Hispanic women living near the U.S.-Mexico border. *J Women's Health (Larchmt)* 2011;20:685-93. PMID: 21428792
 148. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, **Castle PE**. Cervical cancer risk for over 330,000 women undergoing screening by HPV testing and Pap smears in routine clinical practice. *Lancet Oncol* 2011;12:663-72. PMID: 21684207; PMCID:PMC3272857
 149. Schiffman M, Glass AG, Wentzensen N, Rush BB, **Castle PE**, Scott DR, Buckland J, Sherman ME, Lorincz AT, Wacholder S, Burk RD. A long-term prospective study of type-specific HPV infection and cervical cancer risk among 20,000 women in the Portland Kaiser Cohort Study. *Cancer Epi Biomarkers Prev* 2011;20:1398-409. PMID: 21602310; PMCID:PMC3156084

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

150. Yang HP, Walmer D, Merisier D, Gage JC, Bell L, Rangwala S, Shrestha N, Kobayashi L, Eder PS, **Castle PE**. A pilot analytic study of a prototype, low-cost human papillomavirus (HPV) 16, 18, and 45 test. *J Virol Methods* 2011;176:112-4. PMID: 21640138; PMCID:PMC3155880
151. Gage JC, Ghosh A, Borgonovo S, Follansbee S, Wentzensen N, Gravitt PE, Grabe N, Lahrmann B, **Castle PE**. A comparison of Dacron vs. flocked nylon swabs for anal specimen collection. *Acta Cytologica* 2011;55:364-7. PMID: 21791907; PMCID:PMC3150956
152. **Castle PE**, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Vaughan LM, Wheeler CM, Gravitt PE, Schiffman M. An evaluation of a new DNA test for carcinogenic human papillomavirus. *J Clin Microbiol* 2011;49:3029-32. PMID: 21632892; PMCID:PMC3147736
153. **Castle PE**, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM and the ATHENA Study Group. Performance of Carcinogenic Human Papillomavirus (HPV) and HPV16/18 Testing For Detection for Cervical Precancer and Cancer in 40,000 Women. *Lancet Oncol* 2011;12:880–90. PMID: 21865084
154. **Castle PE**, Gage JC, Wheeler CM, Schiffman M. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. *Obstet Gynecol* 2011;118:1222-9. PMID: 22105250; PMCID:PMC3229199
155. Gage JC, Scarinci I, Rausa A, Partridge EE, Walls T, Gravitt PE, Olivio V, Niwa S, Morrissey K, Tucker L, **Castle PE**. Comparative performance of human papillomavirus DNA testing using novel sample collection methods. *J Clin Microbiol* 2011;49:4185-9. PMID: 21998422; PMCID:PMC3232937
156. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage J, **Castle PE**. HPV testing in the prevention of cervical cancer. *J Natl Cancer Inst* 2011;103:368-83. PMID: 21282563; PMCID:PMC3046952
157. Gage JC, Sadorra M, LaMere BJ, Aldrich CA, Shaber R, Kinney W, Fetterman B, Lorey T, **Castle PE**. A comparison of the cobas(R) HPV test with Hybrid Capture 2 and Linear Array HPV DNA tests. *J Clin Microbiol* 2012 50:61-65. PMID: 22075592; PMCID:PMC3256696
158. Marks M, **Castle PE**, Schiffman M, Gravitt PE. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. *J Clin Microbiol* 2012;50:300-6. PMID: 22162556; PMCID:PMC3264159
159. Zhao FH, Lewkowitz A, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Li CQ, Ma JF, Li SM, Smith JS, Belinson JL, Qiao YL, **Castle PE**. A pooled analysis of self-collected cervicovaginal specimen and HPV DNA testing performance as primary screening test for cervical cancer in rural China. *J Natl Cancer Inst* 2012;104:178-88. PMID: 22271765; PMCID:PMC3274511
160. Katki HA, Li Y, Edelstein D, **Castle PE**. Estimating the agreement and diagnostic accuracy of two diagnostic tests when one test is conducted on only a subsample of specimens. *Stat Med* 2012;31:436-48. PMID: 22139832; PMCID:PMC3809897
161. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, Pretorius RG, BGI, **Castle PE**. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing.

- Int J Cancer* 2012;130:1855-60. PMID: 21630255
162. Plummer M, Peto J, Franceschi S, on behalf of the **International Collaboration of Epidemiological Studies of Cervical Cancer**. Time since first sexual intercourse and the risk of cervical cancer. *Int J Cancer* 2012;130:2638-44. PMID: 21702036; PMCID:PMC3982220
 163. Campos NC, Kim JJ, **Castle PE**, Ortendahl JD, O'Shea M, Sanchis MD, Goldie SJ. Health and economic impact of HPV16/18 vaccination and cervical cancer screening in Eastern Africa. *Int J Cancer* 2012 130:2672-84. PMID: 21717458; PMCID:PMC3314721
 164. D'Souza G, Burk RD, Zhong Y, Minkoff H, Massad LS, Xue X, Watts DH, Anastos K, Palefsky JM, Levine AM, Colie C, **Castle PE**, Strickler HD. Cervicovaginal HPV infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and non-oncogenic HPV types in a cohort of HIV-positive and HIV-negative women. *Int J Cancer* 2012;131:1472-8. PMID: 22120980; PMCID:PMC3321069
 165. Campos NG, **Castle PE**, Schiffman M, Kim JJ. Policy implications for adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. *Med Decis Making* 2012;32:400-27. PMID: 22147881; PMCID:PMC3647223
 166. Dinkelspiel H, Poitras N, Fetterman B, Kinney W, Cox JT, Lorey T, **Castle PE**. Screening History Preceding a Diagnosis of Cervical Cancer in Women Age 65 and Older. *Gynecol Oncol* 2012;126:203-6. PMID: 22561038
 167. **Castle PE**, Fetterman B, Poitras N, Lorey T, Kinney W. Safety against cervical precancer and cancer following negative human papillomavirus and Pap tests in HIV-infected women. *Arch Intern Med* 2012;172:1041-3. PMID: 22641193
 168. Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts HD, Levine AM, **Castle PE**, Colie C, Palefsky JM, Strickler HD. Cervical pre-cancer risk in cytologically normal HIV-infected women who tested negative for oncogenic human papillomavirus (HPV). *JAMA* 2012;308:362-9. PMID: 22820789; PMCID:PMC3556987
 169. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Stoler MH, Eder PS, Bell L, Shrestha N, Eklund C, Reilly M, Hutchinson ML, **Castle PE**, Burk RD, Schiffman M. Validation of a lower-cost rapid HPV DNA test in rural Nigeria. *Int J Cancer* 2012;131:2903-9. PMID: 22473652; PMCID:PMC3404249
 170. Wheeler CM, Hunt WC, Cuzick J, Ingersoll E, Pearse A, Montoya GD, Robertson M, Shearman C, **Castle PE**, For The New Mexico HPV Pap Registry Steering Committee. A population-based study of HPV genotype prevalence in the United States: the New Mexico HPV Pap Registry. *Int J Cancer* 2013;132:198-207. PMID: 22532127; PMCID:PMC3852415
 171. Guan YY, Wang S, Li B, Feng C, Ci B, Li X, Zhang W, Zhang X, **Castle PE**, Gravitt PE, Qiao YL. Acceptability of Self-Collection for HPV Testing Using FTA Cartridge. *Sex Trans Infect* 2012;88:490-4. PMID: 22645391
 172. Smith BC, McAndrew T, Chen Z, Harari A, Rodriguez AC, **Castle PE**, Schiffman M, Burk RD. Long-term serial sampling and methodological comparison of cervicovaginal microbiome analyses. *PLoS ONE* 2012;7:e40425. PMID: 22792313; PMCID:PMC3392218
 173. Darragh TM, Tokugawa D, **Castle PE**, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, LaMere BJ, Gage JC, Fetterman B, Lorey T, Wentzensen N. Inter-rater

- agreement for anal cytology. *Cancer Cytopathol* 2013;121:72-8. PMID: 22811048; PMCID:PMC3479324
174. Yang Y-S, Smith-McCune K, Darragh TM, Lai Y, Lin J-H, Chang T-C, Guo H-Y, Kesler T, Carter A, **Castle PE**, Cheng S. Direct HPV E6 Whole-Cell ELISA – Objective Measurement of E6 Oncoproteins in Cytology Samples. *Clin Vaccine Immunol* 2012;19:1474-9. PMID: 22815148; PMCID:PMC3428408
 175. **Castle PE**, Glass AG, Rush BB, Scott DR, Buckland J, Sherman ME, Rydzak G, Lorincz AT, Wentzensen N, Gage JC, Wacholder S. Clinical HPV detection forecasts cervical cancer risk over 18 years of follow-up in 20,000 women. *J Clin Oncol* 2012;30:3044-3050. PMID: 22851570; PMCID:PMC3732003
 176. **Castle PE**, Gravitt PE, Wentzensen N, Schiffman M. A descriptive analysis of prevalent versus incident cervical intraepithelial neoplasia grade 3. *Am J Clin Pathol* 2012 138:241-246. PMID: 22904136
 177. Pierce MC, Guan YY, Quinn MK, Wang S, Feng C, Zhang X, Zhang WH, Qiao Y-L, Gravitt PE, **Castle P**, Richards-Kortum R. A pilot study of low-cost, high-resolution microendoscopy as a tool for identifying women with cervical precancer. *Cancer Prev Res (Phila)*. 2012;5:1273-9. PMID: 22926339; PMCID:PMC3494281
 178. Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Darragh TM, Sahasrabudhe V, LaMere BJ, Gage JC, Fetterman B, Lorey T, **Castle PE**. Performance of HPV genotyping, HPV mRNA expression, and p16/ki67 cytology to detect anal cancer precursors in HIV-positive men. *AIDS* 2012;26:2185-92. PMID: 23018436
 179. Benard VB, Saraiya MS, **Castle PE**, Watson M. Cervical cancer incidence rates among young females in the United States. *Obstet Gynecol* 2012; 120:1117-23. PMID: 23090530; PMCID:PMC4540330
 180. Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, LaMere B, Clarke M, Lorincz AT, **Castle PE**, Schiffman M, Burk RD. Methylation of HPV18, HPV31, and HPV45 genomes is associated with cervical intraepithelial neoplasia grade 3. *J Natl Cancer Inst* 2012;104:1738-49. PMID: 23093560; PMCID:PMC3571257
 181. **Castle PE**, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, LaMere B, Gage J, Fetterman B, Rodriguez AC, Wentzensen N. A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancerous lesions among HIV-infected men who have sex with men. *Cancer Epidemiol Biomarkers Prev* 2013;22:42-9. PMID: 23155136; PMCID:PMC3538931
 182. Sahasrabudhe VV, **Castle PE**, Stephen Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, LaMere B, Gage J, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Wentzensen N. HPV genotype attribution to anal intraepithelial neoplasia among HIV-infected men who have sex with men. *J Infect Dis* 2013;207:392-401. PMID: 23162133
 183. Cox JT, **Castle PE**, Behrens CM, Sharma A, Wright TL, Wright TC, Jack Cuzick and the ATHENA (**Addressing THE Need for Advanced HPV Diagnostics**) HPV Study Group. Clinical outcomes of primary screening for cervical cancer with pooled hrHPV and HPV genotype 16/18: Results from the ATHENA HPV study. *Am J Obstet Gynecol* 2013;208:184.e1-184.e11. PMID: 23174289

184. **Castle PE**, Gage JC, Partridge EE, Rausa A, Gravitt PE, Scarinci I. Human papillomavirus genotypes in clinician-collected and self-collected specimens from women living in the Mississippi Delta. *BMC Infect Dis*. 2013;13:5. PMID: 23289357
185. Gage JC, Duggan MA, Nation JG, Gao S, **Castle PE**. Risk of cervical precancer following a CIN1 diagnosis by endocervical curettage versus biopsy. *J Lower Genit Tract Dis* 2013;17:137-41. PMID: 23343702; PMCID:PMC3608705.
186. Guan Y, Gravitt PE, Howard R, Eby YJ, Wang S, Li B, Feng C, Qiao YL, Castle PE. Agreement for HPV genotyping detection between self-collection specimens on a FTA cartridge and clinician-collected specimens. *J Virol Methods* 2013;189:167-71. PMID: 23370404; PMCID:PMC4763924
187. Litton A, **Castle PE**, Partridge EE, Scarinci I. Cervical cancer screening preferences among African American women in the Mississippi Delta. *J Health Care Poor Underserved* 2013;24:46-55. PMID: 23377716
188. LaMere BJ, **Castle PE**, Fetterman B, Poitras N, Stanley M, Shieh J, Lorey T, Kinney W, Shaber R, Schiffman M. A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting. *J Virol Methods* 2013;189:77-79. PMID: 23384678
189. Scarinci IC, Litton A, Garcés-Palacio I, Partridge EE, **Castle PE**. Acceptability and usability of self-collected sampling for HPV testing among African American women living in the Mississippi Delta. *Women's Health Issues* 2013;23:e123-30. PMID: 23410619; PMCID:PMC3596478
190. Gage JC, Schiffman M, Hunt WC, Joste N, Ghosh A, Wentzensen N, Wheeler CM; **New Mexico HPV Pap Registry Steering Committee**. Cervical histopathology variability among laboratories: a population-based statewide investigation. *Am J Clin Pathol* 2013;139:330-5. PMID: 23429369
191. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. *J Low Genit Tract Dis* 2013;17:S28-35. PMID: 23519302; PMCID:PMC3616419
192. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. *J Low Genit Tract Dis* 2013 Apr;17:S36-42. PMID: 23519303; PMCID:PMC3616508
193. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. *J Lower Genit Tract Dis* 2013;17:S43-9. PMID: 23519304; PMCID:PMC3637971
194. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. *J Lower Genit Tract Dis* 2013;17:S50-5. PMID: 23519305; PMCID:PMC3616447
195. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women who

- test Pap-negative but are HPV-positive. *J Lower Genit Tract Dis* 2013;17:S56-63. PMID: 23519306; PMCID:PMC3616446
196. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years. *J Lower Genit Tract Dis* 2013;17:S64-8. PMID: 23519307; PMCID:PMC3616448
 197. Katki HA, Gage JC, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Kinney WK. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. *J Lower Genit Tract Dis* 2013 Apr;17(5 Suppl 1):S69-77. PMID: 23519308; PMCID:PMC3616505
 198. Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras N, Lorey T, Cheung L, Raine-Bennett T, Gage JC, Kinney WK. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. *J Lower Genit Tract Dis* 2013;17:S78-84. PMID: 2351930; PMCID:PMC3616418
 199. Wilson L, Pawlita M, **Castle PE**, Waterboer T, Sahasrabudhe V, Gravitt P, Schiffman M, Wentzensen N. Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL triage study. *Int J Cancer* 2013;133:2172-81. PMID: 23588935; PMCID:PMC4238230
 200. Gage JC, Schiffman M, Solomon D, Wheeler CM, Gravitt PE, **Castle PE**, Wentzensen N. Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities. *Cancer Epidemiol Biomarkers Prev* 2013;22:1095-101. PMID: 23603204; PMCID:PMC3687215
 201. De Sanjose S, Wheeler CM, Quint W, Hunt WC, Alemany L, Bosch FX, Myers ER, **Castle PE**. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22:1313-8. PMID: 23632816; PMCID:PMC4306595
 202. Luhn P, Houldsworth J, Cahill L, Schiffman M, **Castle PE**, Zuna RE, Dunn ST, Gold MA, Walker JL, Wentzensen N. Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. *Gynecol Oncol* Gynecol Oncol. 2013;130:595-600. PMID: 23769811; PMCID:PMC3833871
 203. Zhao F-H, Jeronimo J, Qiao Y-L, Schweizer J, Chen W, Valdez M, Lu P, Kang L-L, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, **Castle PE**. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus (HPV) in rural China. *Cancer Prev Res (Phila)* 2013;6:938-48. PMID: 23878179
 204. Schwartz LM, **Castle PE**, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabudhe VV, LaMere BJ, Gage JC, Jay N, Berry JM, Darragh TM, Wentzensen N. Risk factors for anal HPV-infection and anal precancer in HIV-positive men who have sex with men. *J Infect Dis* 2013;208:1768-75. PMID: 23908478; PMCID:PMC3814839
 205. Walmer D, Eder PS, Bell L, Salim H, Kobayashi L, Ndirangu J, Tinfo N, **Castle PE**. Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, Haiti. *PLoS One* 2013;8:e76110. PMID: 24098429; PMCID:PMC3789741
 206. Dinkelspiel H, Poitras N, Fetterman B, Kinney W, Cox JT, Lorey T, **Castle PE**. Cervical cancer rates following the transition from annual Pap to 3-year HPV and Pap. *J Lower Genit Tract Dis* 2014;18:57-60. PMID: 24022057

207. Wentzensen N, Nason M, Schiffman M, Dodd L, Hunt WC, Wheeler CM; for **The New Mexico HPV Pap Registry Steering Committee**. No evidence for synergy between human papillomavirus genotypes for risk of HSIL in a large population-based study. *J Infect Dis* 2014;209:855-64. PMID: 24179110; PMCID:PMC3935473
208. Sahasrabudde VV, Gravitt PE, Dunn TS, Brown D, Allen RA, Smith K, Zuna RE, Zhang RR, Gold ML, Schiffman M, Walker JL, **Castle PE**, Wentzensen N. Comparison of HPV detection in urine, vulvar, and cervical samples from women attending a colposcopy clinic. *J Clin Microbiol* 2014;52:187-92. PMID: 24197879; PMCID:PMC3911475
209. Wheeler CM, Hunt WC, Cuzick J, Ingersoll E, Pearse A, Montoya GD, Robertson M, **Castle PE**, For The New Mexico HPV Pap Registry Steering Committee. A population-based study of the human papillomavirus-specific three-year risk of cervical precancer and cancer. *Int J Cancer* 2014;135:624-34. PMID: 24226935; PMCID:PMC4020996
210. Qiao Y-L, Jeronimo J, Zhao F-H, Schweizer J, Chen W, Valdez M, Lu P, Kang L-L, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, **Castle PE**. Lower-cost strategies for triage of human papillomavirus DNA-positive women. *Int J Cancer* 2014;134:2891-901. PMID: 24248915; PMCID:PMC4232922
211. Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, **Castle PE**, Benard V, Wheeler CM, on behalf of the New Mexico HPV Pap Registry Steering Committee. Population-based cervical screening in the United States: the New Mexico experience 2008-2011. *Cancer Epi Biomark Prevent* 2014;23:765-73. [Epub ahead of print]. PMID: 24302677; PMCID:PMC4011954
212. Xue X, Kim MY, **Castle PE**, Strickler HD. A New Method to Address Verification Bias in Studies of Clinical Screening Tests: Cervical Cancer Screening Assays as an Example. *J Clin Epidemiol* 2014;67:343-53. PMID: 24332397; PMCID:PMC3946800
213. **Castle PE**, Hunt WC, Erika Ingersoll E, Wheeler CM. Three-Year Risk of cervical precancer and cancer following the detection of low-risk HPV genotypes targeted by a commercial test. *Obstet Gynecol* 2014;123:49-56. PMID: 24463663; PMCID:PMC3926945
214. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, Mirembe F, Byamugisha J, Poli UR, Satyanarayana L, Asthana S; **START-UP Study Group**. A multi-country evaluation of careHPV™ testing, visual inspection with Acetic Acid, and Pap testing for the detection of cervical precancer and cancer. *Int J Gynecol Cancer* 2014;24:576-85. PMID: 24557438; PMCID:PMC4047307
215. **Castle PE**, Qiao Y-L, Zhao F-H, Chen W, Valdez M, AVC, Kang L-L, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Jeronimo J. Clinical determinants of a positive visual inspection after acetic acid for cervical cancer screening. *BJOG* 2014;121:739-46. PMID: 24575872
216. Thomsen LT, Frederiksen K, Munk C, Junge J, **Castle PE**, Iftner T, Kjaer SK. Absolute risk of cervical intraepithelial neoplasia grade 3 or cervical cancer among women tested for high-risk and low-risk human papillomavirus. *Obstet Gynecol* 2014;123:57-64. PMID: 24463664
217. Kang L-N, **Castle PE**, Zhao F-H, Jeronimo J, Chen F, Bansil P, Li J, Chen W, Zhang X, Qiao Y-L. A prospective study of age trends of high-risk human papillomavirus infection in rural China. *BMC Infect Dis* 2014;14:96. PMID: 24559293; PMCID:PMC3936871
218. Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM; **For The New**

- Mexico HPV Pap Registry Steering Committee.** Cervical excisional treatment of young women: A population-based study in the United States. *Gynecol Oncol* 2014;132:628-35. PMID: 24395062; PMCID:PMC3992337
219. **Castle PE**, Hunt WC, Langsfeld E, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Three-year risk of cervical precancer and cancer after the detection of low-risk human papillomavirus genotypes targeted by a commercial test. *Obstet Gynecol* 2014;123:49-56. PubMed. PMID: 24463663; PubMed Central; PMCID:PMC3926945.
220. Wilson L, Pawlita M, **Castle PE**, Waterboer T, Sahasrabudde V, Gravitt PE, Schiffman M, Wentzensen N. Seroprevalence of eight oncogenic human papillomaviruses and acquired immunity against reinfection. *J Infect Dis* 2014;210:448-55. PMID: 24569064; PMCID:PMC4110458
221. Kang L-N, Jeronimo J, Qiao Y-L, Zhao F-H, Chen W, Valdez V, Zhang X, Bansil P, Paul P, Bai P, Peck R, Stoler MH, Li J, Chen F, Stoler MH, **Castle PE**. The optimal positive cutpoints of care HPV testing on clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China. *J Clin Microbiol* 2014;52:1954-61. PMID: 24671789; PMCID:PMC4042749
222. Einstein MH, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, Gray JH, Stoler MH, Wright TC, Ferenzly A, **Castle PE**. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in a colposcopy referral population. *J Clin Microbiol* 2014;52:2089-95. PMID: 24719440; PMCID:PMC4042758
223. Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabudde V, Chen J, Lorey T, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang S, Darragh TM, **Castle PE**. Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men. *J Clin Microbiol* 2014;52:2892-7. PMID: 24899025; PMCID:PMC4136172
224. Rosenbaum AJ, Gage JC, Alfaro K, Ditzian L, Maza M, Scarinci I, **Castle PE**, Villata S, Miranda E, Cremer M. Acceptability of self-collected vs. provider-collected sampling for human papillomavirus DNA testing among women in rural El Salvador. *Int J Gynecol Cancer* 2014;126:156-60. PMID: 24880188
225. Sahasrabudde VV, Gravitt PE, Dunn TS, Robbins D, Brown D, Allen RA, Eby YJ, Smith K, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, **Castle PE**, Wentzensen N. Evaluation of the clinical performance of a novel urine-based HPV detection assay. *J Clin Virol* 2014;60:414-7. PMID: 24881489; PMCID:PMC4146457
226. Cremer M, Ditzian L, Winkler J, Jeronimo J, Singleton J, Franco HV, Maza M, Conlisk E, Gage J, **Castle P**, Santos C. Comparison of depth of necrosis using cryotherapy by gas and number of freeze cycles. *J Lower Genit Tract Dis* 2015 2015;19:1-6. PMID: 24886871
227. Gage JC, Schiffman M, Katki H, **Castle PE**, Fetterman B, Wentzensen N, Poitras N, Lorey T, Cheung LC, Kinney WK. Evidence on the potential safety of stand-alone HPV testing from 1 million women undergoing HPV and Pap testing in routine cervical cancer screening since 2003. *J Natl Cancer Inst* 2014;106(8). PMID: 25038467; PMCID:PMC4111283
228. Gage JC, Katki HA, Schiffman M, **Castle PE**, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao F-H, Cuzick J, Yang ZH, Kinney WK. Is HPV-negative/ASC-US Pap a negative screening result? *Cancer Cytopathol* 2014;122:842-50.

PMID: 25045058

229. Mirabello L, Frimer M, Harari A, McAndrew T, Smith B, Chen Z, Wentzensen N, Wacholder S, **Castle PE**, Raine-Bennett T, Schiffman M, Burk RD. HPV16 methylation is a consistent biomarker of cervical precancer using both a novel next-generation sequencing method and pyrosequencing. *Int J Cancer* 2015;136:E146-53. PMID: 25081507; PMCID:PMC4262737
230. Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, **Castle PE**, Wood S, Stiernerling E, Poitras N, Lorey, Kinney W. Interobserver reproducibility and accuracy of p16/Ki-67 dual stain cytology. *Cancer Cytopath* 2014;122:914-20. PMID: 25132656
231. Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, **Castle PE**, Kinney WK. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. *Int J Cancer* 2015; 136:1665-71. PMID: 25136967; PMCID:PMC4314342
232. Liao GD, Chen W, Qiao Y-L, Zhang X, Kang L-N, Zhao F-H, Stoler MH, Mills A, **Castle PE**. P16 immunohistochemistry interpretation by non-pathologists as an alternative method for diagnosing cervical precancer in low-and middle-income countries. *J Lower Genital Tract Dis* 2015;19:207-11. PMID: 25171105; PMCID: PMC5463559
233. Jeronimo J, Bansil P, Valdez M, Kang L-N, Zhao F-H, Qiao Y-L, Chen W, Zhang X, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, **Castle PE**. Relationship of human papillomavirus types on the visualization of cervical precancer and cancer. *J Lower Genital Tract Dis* 2015;19:220-3. PMID: 25279978
234. Schiffman M, Burk R, Boyle S, Raine-Bennett T, Katki H, Gage J, Wentzensen N, Korngay Aldrich C, Tam T, Erlich H, Apple R, Befano B, **Castle PE**. A study of genotyping for the management of human papillomavirus-positive, cytology-negative cervical cancer screening results. *J Clin Microbiol* 2015;53:52-9. PMID: 25339396; PMCID:PMC4290932
235. Joste NE, Ronnett BM, Hunt WC, Pearse A, Langsfeld E, Leete T, Jaramillo M, Stoler MH, **Castle PE**, Wheeler CM, New Mexico HPV Pap Registry Steering Committee. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. *Cancer Epidemiol Biomarkers Prev* 2015;24:230-40. PMID: 2536363; PMCID:PMC4294978
236. Cuzick J, Myers O, Hunt C, Saslow D, **Castle PE**, Kinney W, Waxman A, Robertson M, Wheeler CM, on behalf of the New Mexico HPV Pap Registry Steering Committee. Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. *Int J Cancer*. 2015;136:2854-63. PMID: 25447979; PMCID:PMC4737644
237. Chen W, Jeronimo J, Zhao F-H, Qiao Y-L, Valdez M, Zhang X, Kang L-N, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, **Castle PE**. The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. *J Clin Virol* 2014;61:553-557. PMID: 25453572
238. **Castle PE**, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, Gray JH, Stoler MH, Wright TC, Ferenzy A, Einstein MH. Reliability of the Xpert HPV Assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. *Am J Clin Pathol* 2015;143:126-33. PMID: 25511151

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

239. **Castle PE**, Cuzick J, Reid JL, Dockter J, Giachetti C, Getman D. Detection of HPV16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. *Am J Clin Pathol* 2015;143:160-7. PMID: 25596241
240. Mills AM, Paquette C, **Castle PE**, Stoler MH. The Risk Stratification By p16 Immunostaining of CIN1 Biopsies: A Retrospective Study of Patients from the Quadrivalent HPV Vaccine Trials *Am J Surg Pathol* 2015;39:611-7. PMID: 25602791
241. Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM; **For the New Mexico HPV Pap Registry Steering Committee**. The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. *Am J Surg Pathol* 2015;39:729-36. PMID: 25602796; PMCID:PMC4428379
242. Campos NG, Cremer ML, Maza M, Alfaro K, Gage JC, **Castle PE**, Felix J, Lopez MEA, Kim JJ. The comparative and cost-effectiveness of cervical cancer screening algorithms in El Salvador *Int J Cancer* 2015 Aug 15;137:893-902. PMID: 25639903
243. **Castle PE**, Eaton B, Reid J, Getman D, Dockter J. A comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred to colposcopy for an ASC-US Pap cytology result. *J Clin Microbiol* 2015;53:1277-81. PMID: 25653409; PMCID:PMC4365215
244. Sinayobye JD, Sklar M, Hoover DR, Shi Q, Duzingize JC, Cohen M, Mutimura E, Asiiimwe-Kateera B, **Castle PE**, Strickler H, Anastos K. Prevalence and risk factors for high-risk human papillomavirus infection among HIV-infected and –uninfected Rwandan women. *Infect Agents Cancer* 2014;9:40. PMID: 25926864; PMCID:PMC4413542
245. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; **Broad Spectrum HPV Vaccine Study**. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015;372:711-23. PMID: 25693011
246. Campos NG, **Castle PE**, Wright TC, Kim JJ. Cervical cancer screening in resource-limited settings: A framework for evaluating tradeoffs between test performance and programmatic attributes. *Int J Cancer* 2015;137:2208-19. PMID: 25943074; PMCID: PMC4910518
247. Schiffman M, Boyle S, Raine-Bennett T, Katki H, Gage JC, Wentzensen N, Kornegay J, Apple R, Aldrich C, Tam T, Befano B, Burk RD, **Castle PE**. The role of human papillomavirus (HPV) genotyping in cervical cancer screening: A large-scale evaluation of the cobas HPV test. *Cancer Epidemiol Biomark Prev* 2015;24:1304-10. PMID: 26088703; PMCID:PMC4560647
248. Schiffman M, Vaughan L, Raine-Bennett TR, **Castle PE**, Katki HA, Gage JC, Befano B, Wentzensen N. A Study of HPV Typing for the Management of HPV-Positive ASC-US Cervical Cytologic Results. *Gynecol Oncol.* 2015;138:573-8. PMID: 26148763; PMCID:PMC4556538
249. **Castle PE**, Reid J, Dockter J, Getman D. Reliability of high-risk human papillomavirus and human papillomavirus genotypes by Aptima in a population of women with an ASC-US Pap *J Clin Virol* 2015;69:52-5. PMID: 26209379

250. Sultana F, Gertig DM, Wrede CD, English DR, Simpson JA, Drennan KT, Brotherton JML, Phillips G, Heley S, **Castle PE**, Saville M. A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. *J Clin Virol* 2015;69:210-3. PMID: 26209409
251. Reid JL, Wright TC, Stoler MH, Cuzick J, **Castle PE**, Dockter J, Getman D, Giachetti C. HPV Oncogenic mRNA testing for Cervical Cancer Screening; Baseline and Longitudinal Results from the CLEAR Study. *Am J Clin Pathol* 2015;144:473-83. PMID: 26276778
252. Wentzensen N, Fetterman B, **Castle PE**, Schiffman M, Wood S, Stiernerling D, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. *J Natl Cancer Inst* 2015;107(12). PMID: 26376685; PMCID:PMC4675094
253. Keller MJ, Burk RD, Massad LS, Eltoun IE, Hessol N, **Castle PE**, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Palefsky JM, Strickler HD. Cervical precancer risk in HIV-infected women who test positive for oncogenic human papillomavirus despite a normal Pap test. *Clin Infect Dis*. 2015 61:1573-81. PMID: 26187020; PMCID: PMC4614409
254. Cullen M, Boland JF, Schiffman M, Chen Z, Zhang X, Wentzensen N, Yang Q, Yu K, Mitchell J, Roberson D, Bass S, Burdette L, Machado M, Ravichandran S, Luke B, Machiela M, Andersen M, Osentoski M, Laptewicz M, Wacholder S, Raine-Bennett T, Lorey T, **Castle PE**, Yeager M, Burk RD, Mirabello L. High depth genome sequencing of HPV16: A new tool for exploring the carcinogenicity and natural history of HPV16 infection. *Papillomavirus Res* 2015;1;1:3-11. PMID: 26645052; PMCID:PMC4669577
255. Katki HA, Cheung LC, Fetterman B, **Castle PE**, Sundaram R,. A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening. *J R Stat Soc Ser A Stat Soc* 2015;178:903-923. PMID: 26556961; PMCID:PMC4635446
256. Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, **Castle PE**, Hunt C, Waxman A, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Costs and benefits of U.S. cervical cancer screening practice using population-based data: a model-based analysis. *Ann Intern Med* 2015;163:589-97. PMID: 26414147; PMCID: PMC5104349
257. Valdez M, Jeronimo J, Bansil P, Qiao Y-L, Zhao F-H, Schweizer J, Chen W, Lu P, Zhang X, Kang L-N, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, **Castle PE**. Effectiveness of novel, lower-cost molecular human papillomavirus-based tests for cervical cancer screening in rural China. *Int J Cancer* 2016;138:1453-61. PubMed. PMID: 26421807
258. **Castle PE**, Maza M. HPV Vaccination: Past, Present, and Future. *Epidemiol Infect* 2015 Oct 2:1-20. PMID: 26429676 (CORRIGENDUM: *Epidemiol Infect*. 2016;144:2472. PMID: 27125301)
259. Alfaro K, Gage JC, Rosenbaum AJ, Ditzian L, Maza M, Scarinci I, **Castle PE**, Cremer M. Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador. *BMC Public Health* 2015;15:1058. PMID: 26474762; PMCID:PMC4609068
260. Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; **Castle PE**; Wheeler CM for The New Mexico HPV Pap Registry Steering Committee. Risk

- stratification using human papillomavirus testing among women with equivocally abnormal cytology: results from a state-wide surveillance program. *Cancer Epidem Biomark Prev* 2016;25:36-42. PMID: 26518316; PMCID: PMC4852208
261. Grant B, Fregnani JHTG, Resende JP, Scapulatempo-Neto C, Macedo G, Quang T, Stoler MH, **Castle PE**, Schmeler K, Kortum-Richards R. High-resolution microendoscopy (HRME): a point-of-care diagnostic for cervical dysplasia. *Eur J Cancer Prev* 2017; 26:63-70.
 262. Buckley N, Huber A, Lo Y, **Castle PE**, Kemal K, Burk RD, Strickler HD, Einstein MH, Young M, Anastos K, Herold BC. Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors In HIV Infected Women. *Am J Reprod Immunol* 2016;75:146-54. PMID: 26685115; PMCID:PMC4715979
 263. Zhao F-H, Hu S-Y, Zhang Q, Chen W, Zhang X, Gage JC, Wentzensen N, **Castle PE**, Qiao Y-L, Katki HA, Schiffman M. Comparative study of single and combined cervical cancer screening methods in a large chinese population. *Int J Cancer* 2016; 138(11):2639-47. PMID: 26800481
 264. Cremer M, Maza M, Alfaro K, Kim JJ, Ditzian L, Villalta S, Alonzo TA, Felix J, **Castle PE**, Gage JC. Introducing a high-risk HPV test into a public sector screening program in El Salvador. *J Lower Genit Tract Dis* 2016;20:145-50. PMID: 26890683; PMCID:PMC4819528
 265. Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, Zhang Z, Yu K, Yang Q, Mitchell, Roberson D, Bass S, Xiao Y, Burdett L, Raine-Bennett T, Lorey T, **Castle PE**, Burk RD, Schiffman M. A 3,200-woman study of HPV16 whole genomes reveals strong associations of variants with histology-specific cancer risk modified by ethnicity. *J Natl Cancer Inst* 2016 Apr 29;108(9). pii: djw100. Print 2016 Sep. PMID: 27130930
 266. Schroeder L, Guarner J, Elbireer A, **Castle PE**, Amukele TK. A Model List of Essential Diagnostics. *N Engl J Med* 2016;374:2511-4. PMID: 27355530
 267. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Franco E, Lörincz A, Wheeler CM, **Castle PE**, Robles C, Lazcano E. HPV vaccination impact on cervical cancer screening program: broadening the scope of prevention for cervical cancer. *Salud Pública de México* 2016;58:211-219. PMID: 27557379
 268. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P, Mendiola-Pastrana I, Rudolph SE, León-Maldonado L, Hernández R, Barrios E, Gravitt P, Moscicki AB, Schmeler KM, Flores YN, Méndez-Hernández P, Salmerón J; FRIDA Study Group. *Salud Publica Mex.* 2016 Apr;58(2):197-210. PMID: 27557378
 269. McDonald YJ, Goldberg DW, Scarinci IC, **Castle PE**, Cuzick J, Robertson M, Schwind M, Wheeler CM, New Mexico HPV Pap Registry Steering Committee. Landscape of cervical cancer screening, diagnostic, and pre-cancerous treatment services in New Mexico, USA. *J Rural Health* 2017;33:382-392. PMID: 27557124; PMCID: PMC5939944
 270. Silver MI, Schiffman M, Fetterman B, Poitras N, Gage JC, Wentzensen N Lorey T, Kinney W, **Castle PE**. HPV/cytology cotesting at 3-year intervals reduces cervical cancer risk and results in reduced yield of precancer per screen over time. *Cancer* 2016;122:3682-3686. PMID: 27657992

271. Simms KT, Smith MA, Lew J-B, **Castle PE**, Canfell K. Cervical cancer screening in women offered next generation HPV vaccines. *Int J Cancer* 2016 139:2771-2780. PMID: 27541596
272. **Castle PE**, Aslam S, Behrens C. Cervical precancer and cancer risk by human papillomavirus status and cytologic interpretation: implications for risk-based management. *Cancer Epi Biomark Prev* 2016; 25:1595-1599. PMID: 27587789
273. Schiffman M, Hyun N, Raine-Bennett T, Katki H, Fetterman B, Gage JC, Cheung L, Befano B, Poitras N, **Castle PE**, Wentzensen N. A cohort study of cervical screening using HPV typing and cytology. *Int J Cancer* 2016;139:2606-15. PMID: 27509172
274. Grant B, Smith C, **Castle PE**, Schuerer M, Richards-Kortum R. A paper-based immunoassay to determine HPV vaccination status at the point-of-care. *Vaccine* 2016;34:5656-5663. PMID: 27667331; PMCID:PMC5075515
275. Benard VB, **Castle PE**, Jenison SA, Hunt WC, Kim JJ, Norville S, Cuzick J, Wheeler CM, for The New Mexico HPV Pap Registry Steering Committee. Population-based incidence rates of cervical intraepithelial neoplasia post-HPV vaccine era in New Mexico, 2007-2014. *JAMA Oncol* 2017;3:833-837 PMID: 27685805; PMCID: PMC5765871
276. Mills AM, Paquette C, Tatjana T, **Castle PE**, Stoler MH. CK7 immunohistochemistry as a predictor of CIN1 progression: a retrospective study of patients from the quadrivalent HPV vaccine trials. *Amer J Surg Pathol* 2017;41:143-152. PMID: 27680604
277. Jeronimo J, **Castle PE**, Temin S, Denny L, Gupta V, Kim J, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri S. Secondary Prevention of Cervical Cancer: An American Society of Clinical Oncology Resource Stratified Guideline Adaptation. *J Global Oncol* 2016;3:635-657. PMID: 29094101; PMCID: PMC5646891
278. Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Myers O, Cuzick J, Waxman A, Wentzensen N, Kinney W, **Castle PE***, Wheeler CM*, for The New Mexico HPV Pap Registry Steering Committee. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines. *Obstet Gynecol* 2016;128:1248-1257. PMID: 27824767; PMCID:PMC5247269 *Co-Senior Authors
279. Cremer M, Maza M, Alfaro K, Velado MM, Felix J, **Castle PE**, Kim J, Gage JC, Alonzo TA, Conlisk E. Scale-up of a HPV-based testing implementation program in El Salvador. *J Lower Genit Tract Dis* 2016;21:26-32. PMID: 27922905; PMCID:PMC5201413
280. Engesæter B, an Diermen Hidle B, Hansen M, Moltu P, Staby KM, Borchgrevink-Pedersen S, Vintermyr O, Eide ML, Lönnberg S, Nygård M, Janssen EAM, **Castle PE**, Christiansen IK. Inter-laboratory reproducibility of the Cobas 4800 HPV test: Quality assurance of HPV testing in the implementation of HPV primary screening in Norway. *BMC Infect Dis* 2016;16:698-705. PMID: 27881082; PMCID:PMC5122146
281. Maza M, Alfaro K, Garai J, Velado MM, Gage JC, Castle PE, Felix J, Luciani S, Campos N, Kim J, Masch R, Cremer M. Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. *Gynecol Oncol Rep* 2017;20:58-61. PMID: 28337474; PMCID:PMC5352717
282. Fokom Domgue J, Schiffman M, Wentzensen N, Gage J, **Castle PE**, Raine-Bennett T,

- Fetterman B, Lorey T, Poitras N, Befano B, Xie Y, Miachon L, Dean M. Assessment of a new lower-cost real-time PCR detection assay for high-risk HPV: Useful for cervical screening in limited resource settings? *J Clin Microbiol* 2017; 55:2348-55. PMID: 28515214; PMCID: PMC5527412
283. Burger EA, Kim JJ, Sy S, **Castle PE**. Age of acquiring causal human papillomavirus (HPV) infections: Leveraging simulation models to explore the natural history of HPV-induced cervical cancer *Clinical Infect Dis* 2017;65:893-899. PMID: 28531261; PubMed Central PMCID: PMC5850533
284. Campos NG, Jeronimo J, Tsu V, **Castle PE**, Mvundura M, Kim JJ. The cost-effectiveness of visual triage of human papillomavirus-positive women in three low- and middle-income countries. *Cancer Epi Biomark Prevent* 2017;26(10):1500-1510. PMID: 28710075
285. Canfell K, Caruana M, GebSKI V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett C, Farnsworth A, Tan J, Wrede D, **Castle PE**, Saville M. Primary HPV vs. cytology for cervical screening in a population offered HPV vaccination: First findings from COMPASS, a randomised open-label trial. *PLoS Med* 2017;14:e1002388. PMID: 28926579; PMCID:PMC5604935; PMCID: PMC5604935
286. Mirabello L, Yeager M, Yu K, Clifford G, Xiao Y, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Zhu B, Chen Z, Song L, Yang Q, Steinberg M, Roberson D, Bass S, Burdette, Lorey T, Franceschi S, **Castle PE**, Burk RD, Schiffman M. E7 genetic conservation is critical to HPV16 carcinogenesis. *Cell* 2017; 170:1164-74. PMID: 28886384; PMCID: PMC5674785
287. Cheung L, Pan Q, Hyun N, Schiffman M, Fetterman B, **Castle P**, Lorey T, Katki H. Mixture models for left-censored and irregularly interval-censored data: Applications to a cancer screening cohort assembled from electronic health record. *Stats Med* 2017; 36(22):3583-3595. PMID: 28660629; PMCID:PMC5583012.
288. Cuzick J, Myers O, Lee J-H, Shi Y, Gage GC, Hunt WC, Robertson M, Wheeler CM, on behalf of the **New Mexico HPV Pap Registry Steering Committee**. Benefits and harms of human papillomavirus testing among Women with cytology showing atypical squamous cells of undetermined significance (ASC-US). *JAMA Oncol* 2017;3:1327-34. PMID: 28655061; PMCID: PMC5710525
289. **Castle PE**, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler JE, Katki H, Schiffman M. Why does cervical cancer occur in a state-of-the-art screening program? *Gynecol Oncol* 2017;146:546-553. PMID: 28606721; PMCID: PMC5743197
290. DeMarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, **Castle PE***, Schiffman M*. Risks of CIN2+, CIN3+, and cancer by cytology and HPV status: the foundation of risk-based cervical screening guidelines. *J Lower Genit Tract Dis* 2017; 21:261-7. (*Contributed equally). PMID: 28953116; PMCID: PMC5625966
291. Eldridge RC, Pawlita M, Wilson L, **Castle PE**, Waterboer T, Gravitt PE, Schiffman M, Wentzensen N. Smoking and subsequent infection of HPV: a mediation analysis. *Annals Epidemiol* 2017 ;27:724-730.PMID: 29107447; PMCID: PMC5705255
292. Canfell K, Saville M, Caruana M, GebSKI V, Darlington-Brown J, Brotherton J, Heley, **Castle PE**. Protocol for Compass: A randomised controlled trial of primary HPV testing

- versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25 to 69 years, living in Australia. *BMJ Open* 2018;8:e016700. PMID: 29374658
PMCID: PMC5829592
293. Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler JE, Katki H, **Castle PE**. Screening history prior to cervical cancer diagnoses in a cohort of 1 million women undergoing triennial HPV and cytology cotesting. *J Natl Cancer Inst* 2018;110:501-508. PMID: 29145648; PMCID: PMC6279277
 294. Taxa L, Jeronimo J, Alvarez M, Alonzo TA, Gage J, **Castle PE**, Cremer M, Felix JC. Depth of cervical intraepithelial neoplasia Grade 3 (CIN 3) in cervical tissue in a low-resource setting population. *J Lower Genit Tract Dis* 2018;22:27-30. PMID: 29271853; PMCID: PMC5745048
 295. Colon-Lopez V, Shiels MS, Machin M, Ortiz AP, Strickler HD, **Castle PE**, Pfeiffer RM, Engels EA. Anal cancer risk among HIV-infected people in the United States. *J Clin Oncol* 2018;36:68-75. PMID: 29140774; PMCID: PMC5791846
 296. **Castle PE**, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao F-H, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki H, Schiffman M. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. *Ann Intern Med* 2018;168:20-29. PMID: 29181509
 297. Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Fetterman B, Poitras NE, Lorey T, **Castle PE**, Sasieni PD, Katki HA. Risk estimation in the era of mining electronic health-records: the example of cervical cancer screening tests. *Prev Med* 2018;111:429-435. PMID: 29222045; PMCID: PMC5930038
 298. **Castle PE**, Pierz A, Stoler MH. A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. *Gynecol Oncol* 2018;148:422-429. PMID: 29248196
 299. Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, **Castle PE**. Adherence patterns to extended cervical cancer screening intervals in women undergoing HPV and cytology cotesting: A population-based study in routine clinical practice. *Prev Med* 2018;109:44-50. PMID: 29288782
 300. Clarke MA, Fetterman B, Cheung LC, Kinney WK, Gage JC, Katki HA, Befano B, Demarco M, Lorey TS, Poitras NE, Raine-Bennett T, Schussler J, Wentzen N, **Castle PE***, Schiffman*. Evidence that increased body weight increases risk of cervical cancer by decreased detection of precancer. *J Clin Oncol* 2018;36:1184-1191. PMID: 29356609 (*Contributed equally); PMCID: PMC5908221
 301. Leinonen MK, Schee K, Jonassen C, Lie K, Furlund C, Rangberg A, Furre I, Tropé A, Sjøborg K, Kristensen G, **Castle PE**, Nygård M. Human papillomavirus testing of self-collected cervical specimens is safe and acceptable for detection of cervical cancer and high-grade lesions: a clinical trial of two cervicovaginal self-collection methods (SESAM) in Norway. *J Clin Virol* 2017;99-100:22-30. PMID: 29289814
 302. Clarke MA, Gradismo A, Schiffman M, Lam J, Sollecito C, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, **Castle PE**, Wentzensen N, Burk RD. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. *Clin Cancer Res*

- 2018;24:2194-2202. PMID: 29420222; PMCID: PMC5932258
303. Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett TR, Kinney WK, **Castle PE**. Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in 2,417 women ages 21-39 years. *Cancer Prev Res (Phila)* 2018 ;11:165-170. PMID: 29437696
 304. Demarco M, Carter-Pokras O, Hyun M, **Castle PE**, He X, Dallal C, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M. Validation of a HPV DNA cervical screening test that provides expanded HPV typing. *J Clin Microbiol* 2018 Apr 25;56(5). PMID: 29491018; PMCID: PMC5925726
 305. **Castle PE**, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. *Prev Med* 2018;111:177-179. PMID: 29548787; PMCID: PMC5930058
 306. Demarco M, Cheung L, Kinney WK, Wentzensen N, Lorey T, Fetterman B, Poitras N, Befano B, **Castle PE**, Schiffman M. Low Risk of cervical cancer/precancer among most women undergoing post-colposcopy surveillance. *J Low Genit Tract Dis* 2018;22:97-103. PMID: 29570564; PMCID: PMC5895141
 307. Doubeni CA, Skinner C, Wheeler CM, **Castle PE**, Werni, Halm E, Corley, Weaver D, Beaber E, Tosteson A, Mao C, Chubak J, Armstrong K, Schall M. Follow-up of positive or abnormal cancer screening results: recommendations of the PROSPR cancer screening consortium. *CA Cancer J Clinic* 2018; 68:199-216. PMID: 29603147; PMCID: PMC5980732
 308. In H, Langon-Embry M, Gordon L, Dauer M, Schechter C, Wylie-Rosett J, **Castle PE**, Kemeny M, Rapkin B. A pilot case control study: could a gastric cancer risk screening tool help identify high risk patients for endoscopic screening in the US? *J Surg Res* 2018; 227:246-256. PMID: 29622399; PMCID: PMC5972059
 309. Hunt B, Fregnani JHT, Schwarz RA, Pantano N, Tesoni S, Possati-Resende JC, Antoniazzi M, de Oliveira Fonseca B, de Macedo Matsushita G, Scapulatempo-Neto C, Kerr L, **Castle PE**, Schmeler K, Richards-Kortum R. Diagnosing cervical cancer precursor lesions in rural Brazil using in vivo microscopy in a mobile van versus a central hospital: A cluster-randomized community trial. *Cancer Prev Res (Phila)* 2018;11:359-370. PMID: 29618459; PMCID: PMC5984709
 310. Yu K, Hyun NR, Fetterman B, Lorey T, Raine-Bennett T, Zhang H, Stamps RE, Poitras N, Wheeler B, Befano B, **Castle PE**, Wentzensen N, Schiffman M. Proof-of-principle of automated cervical screening and triage, based on HPV partial typing and computer-interpreted cytology. *J Natl Cancer Inst* 2018;110:1222-28. PMID: 29659930; PMCID: PMC6454428
 311. Kienen N, Bittencourt L, Pelloso SM, Consolaro MEL, **Castle PE**, Partridge EE, Silva VRS, Scarinci IC. Cervical Cancer Screening among Under-/Un-screened Brazilian Women: Training Community Health Workers to be Change Agents. *Prog Community Health Partnersh* 2018;12(1S):111-119. PMID: 29755054
 312. Murenzi G, Dusingize J-C, Rurangwa T, Sinayobye JD, Munyaneza A, Murangwa A, Zawadi T, Hebert T, Mugenzi P, Adedimeji A, Mutesa L, Anastos K, **Castle PE**. A study of cervical cancer screening technologies in human immunodeficiency virus-infected women

- living in Rwanda. *BMJ Open* 2018 Aug 5;8(8):e020432. PMID: 30082342; PMCID: PMC6078254
313. Maza M, Melendez M, Masch R, Alfaro K, Soler M, Conzuelo G, Gage JC, Alonzo TA, **Castle PE**, Felix JC, Cremer M. Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. *Prev Med* 2018;114:149-155. PMID: 29958860
 314. Pantano N, Hunt B, Schwarz R, Humberto-Fregnani J, Parra S, Possate-Resende J, Longatto A, **Castle PE**, Schmeler K, Richards-Kortum R. Is proflavine exposure associated with disease progression in women with cervical dysplasia? A brief report. *Photochem Photobiol.* 2018;94:1308-1313. PMID: 29981148; PMCID: PMC6282608
 315. **Castle PE**, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki H, Schiffman M. Impact of multiple negative rounds of HPV and cytology cotesting on cervical cancer risk following a positive screen. *J Natl Cancer Inst* 2019;111:820-827. PMID: 30576462; PMCID: PMC6695308
 316. Gibson EG, Gage J, **Castle PE**, Scarinci IC. Perceived susceptibility to cervical cancer among African-American women in the Mississippi Delta: does adherence to screening matter? *Women's Health Issues* 2019; 29(1):38-47. PMID: 30401612
 317. **Castle PE**, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, Wentzensen N, Strickler HD, Schiffman M. Impact of human papillomavirus vaccination on the meaning of cervical screening results. *Prev Med* 2019; 118:44-50. PMID: 30316878
 318. Clarke MA, Cheung LC, **Castle PE**, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N. Five-year risk of CIN2+ following p16/Ki-67 dual stain triage of HPV-positive women. *JAMA Oncol* 2019;5:181-186. PMID: 30325982; PMCID: PMC6439556
 319. Arbyn M, Smith S, Temin S, Sultana F, **Castle PE**, on behalf of the Collaboration on Self-Sampling and HPV Testing. HPV testing on vaginal self-samples or urine: As good as on samples taken by a clinician? More effective in reaching women who do not participate in cervical cancer screening programmes – a meta-analysis. *BMJ* 2018;363:k4823. PMID: 30518635; PMCID: PMC6278587
 320. Clarke MA, Cheung LC, Lorey L, Hare B, Landy R, Tokugawa D, Gage J, Darragh T, **Castle PE**, Wentzensen N. 5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. *Clin Infect Dis* 2019;69:631-638. PMID: 30418518; PMCID: PMC6669293
 321. Adedimeji AA, Sinayobye JD, Chaudhry J, Assimwe-Kateera B, Businge L, Gitembagara A, Murenzi G, Mugenzi P, Patel V, **Castle PE**, Mutesa L, Palefski J, Anastos KM. Social contexts and sexual behaviors of Rwandan men who have sex with men: Implications for HIV and STI acquisition. *PLoS One* 2019;14:e0211099. PMID: 30657797; PMCID: PMC6338414
 322. **Castle PE**, Silva VRS, Consolaro MEL, Kienen N, Bittencourt L, Pelloso SM, Partridge EE, Pierz A, Scarcini IC. A study of participation in cervical screening by self-collection and HPV testing, Pap, or a choice of either in Brazil. *Cancer Prev Res (Phila)* 2019;12:159-170. PMID: 30651294 NIHMSID:NIHMS1519131.
 323. Nguyen DNT, Simms K, Nguyen HQV, Tran TV, Nguyen NH, Huy PQ, LaMontagne S,

- Castle P**, Canfell K. The burden of cervical cancer in Vietnam: a synthesis of the evidence. *Cancer Epidemiol* 2019;59:83-103. PMID: 30710841
324. Campos NG, Maza M, Alfaro K, Gage JC, **Castle PE**, Felix J, Masch R, Cremer M, Kim JJ. The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. *Int J Gynecol Obstet* 2019;145:40-46. PMID: 30702142; PMCID: PMC6988124
325. Grant B, Quang T, Resende JCP, Scapulatempo-Neto C, Matsushita GM, Mauad EC, Stoler MH, **Castle PE**, Fregnani JHTG, Schmeler K, Richards-Kortum R. A mobile-phone based high-resolution microendoscope to image cervical precancer. *PLoS One* 2019;14:e0211045. PMID: 30726252; PMCID: PMC6364962
326. Simms KT, Caruana M, Smith MA, Lew J-B, **Castle PE**, Bray F, Canfell K. Timeline to global elimination of cervical cancer: projections of the impact of HPV vaccination and cervical screening in 181 countries; 2020-2099. *Lancet Oncol* 2019;20:394-407. PMID: 30795950
327. Landy R, Sasieni PD, Schiffman M, Cheung LC, Katki HA, Rydzak G, Wentzensen N, Poitras NE, Lorey T, Kinney WK, **Castle PE**. Absolute risks of cervical precancer among women who fulfil existing guidelines based on HPV and cytology cotesting. *Int J Cancer* 2020;146:617-626. PMID: 30861114
328. Velentzis LS, Smith MA, Simms KT, Lew J-B, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Lawrence B, Brotherton J, Skinner R, Brand A, Heley S, Carter J, Bateson D, Frazer I, Garland S, Guy R, Hammond I, Grogan P, Arbyn M, **Castle PE**, Saville M, Armstrong BK, Canfell K. Pathways to a cancer-free future: a protocol for modelled evaluations to maximize the future impact on cervical cancer in Australia. *Gynecol Oncol* 2019;152:465-471. PMID: 30876490
329. Ruiz-López T, Sen S, Jakobsen E, Tropé A, **Castle PE**, Hansen BT, Nygård, M. FightHPV: Design and evaluation of a mobile game to raise HPV awareness and nudge people to take action against cervical cancer. *JMIR Serious Games* 2019;7:e8540. PMID: 30958271; PMCID: PMC6475825
330. Wentzensen N, Clarke M, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, **Castle PE**, Schiffman M, Kingery J, Grewal KK, Locke A, Kinney W, Lorey TS. p16/Ki-67 dual stain and HPV16/18 genotyping for triage of HPV-positive women: Clinical validation in a large organized screening program. *JAMA Intern Med* 2019;179:881-888. PMID: 31081870; PMCID: PMC6515572
331. Dawson ET, Wagner S, Roberson D, Yeager M, Boland J, Garrison E, Chanock S, Schiffman M, Raine-Bennett T, Lorey T, **Castle PE**, Mirabello L, Durbin R. Viral coinfection analysis using a MinHash toolkit. *BMC Bioinformatics*. 2019;20(1):389. PMID: 31299914
332. Cremer M, Alfaro K, Garai, J, Salinas, M, Maza M, Zevallos A, Taxa L, Díaz AC, **Castle P**, Alonzo TA, Masch R, Soler M, Conzuelo G, Gage, J, Felix JC. Evaluation of two alternative ablation treatments for cervical pre-cancer against standard gas-based cryotherapy: a randomized non-inferiority study. *Int J Gynecol Cancer* 2019 May 3. pii: ijgc-2018-000148. doi: 10.1136/ijgc-2018-000148. [Epub ahead of print]. PMID: 31055452
333. León-Maldonado L, Cabral A, Brown B, Ryan GW, Maldonado A, Salmerón J, Allen-Leigh B, Lazcano-Ponce E; **FASTER Study Group**. Feasibility of a combined strategy of HPV vaccination and screening in Mexico: the FASTER-Tlalpan Study experience. *Hum Vaccin Immunother* 2019;15:1986-94. PMID: 31184976

334. Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM, for the **New Mexico HPV Pap Registry (NMHPVPR)** Steering Committee. Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia. *Cancer Epidemiol Biomarkers Prev* 2019;28:1816-1824
335. Knapp GC, Sharma A, Olopade B, Alatishe O, Olasehinde, O, Arije OO, Castle PE, Kingham TP. An exploratory analysis of fecal immunochemical test performance for colorectal cancer screening in nigeria. *World J Surg* 2019;43:2674-2680. PMID: 31407091
336. Nguyen DNT, Hughes S, Egger S, Simms K, **Castle PE**, Canfell. Systemic review and meta-analysis of childhood mortality related to maternal death in lower-resource settings: implications for cervical cancer prevention. *BMC Public Health*. 2019;19:1281. PMID: 31601205; PMCID: PMC6788023
337. Cheung LC, Berg CD, **Castle PE**, Katki HA, Chaturvedi AK. Benefit-based versus risk-based selection of individuals for cancer screening: Application to lung-cancer screening for US smokers. *Ann Intern Med* 2019 Oct 22. doi: 10.7326/M19-1263. [Epub ahead of print]. PMID: 31634914
338. **Castle PE**, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, Stoler MH, Ronnett BM, Joste NE, Darragh TM, Gravitt PE, Schiffman M, Hunt WC, Kinney WK, Wheeler CM, on behalf of the New Mexico HPV Pap Registry Steering Committee and for the p16 IHC Study Panel. Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology. *Arch Pathol Lab Med*. 2019 Nov 13. doi: 10.5858/arpa.2019-0241-OA. [Epub ahead of print]. PMID: 31718233
339. Campos NG, Alfaro K, Maza M, Sy S, Melendez M, Masch R, Soler M, Conzuelo-Rodriguez, G, Gage JC, Alonzo TA, **Castle PE**, Felix JC, Cremer M, Kim JJ. The cost-effectiveness of cervical HPV self-collection among screening non-attenders in El Salvador. *Prev Med* 2019 Nov 22:105931. doi: 10.1016/j.ypmed.2019.105931. [Epub ahead of print]. PMID: 31765712
340. **Castle PE**, Burk RD, Massad LS, Eltoun I-E, Hessor NA, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Fischl MA, Palefsky JM, Strickler HD. Epidemiologic evidence that human papillomavirus (HPV) types differ in their ability to evade immune surveillance: results from a large cohort of HIV-infected and HIV-uninfected women. *Int J Cancer*. 2019 Oct 2. doi: 10.1002/ijc.32693. [Epub ahead of print]
341. Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, Hammer A, Campos N, Kinney, Gage JC, Befano B, Perkins R, He X, Dallal C, Chen J, Poitras N, Mayrand M-H, Coutlee F, Burk RD, Lorey T, **Castle PE**, Wentzensen N, Schiffman MA study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs (*EClinicMed*, in Press)
342. Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki A-B, Mahmud, SM, Wheeler, CM, Rivera-Paredes, B, Hernández-López, R, León-Maldonado L, Jorge Salmerón, **for the FRIDA Study Group**. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico. *JAMA Netw Open*. 2019 Nov 1;2(11):e1915781. doi: 10.1001/jamanetworkopen.2019.15781. PMID: 31747033
343. Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, Goldberg

- DW, Scarinci IC, Cuzick J, Wheeler CM, **for the New Mexico HPV Pap Registry Steering Committee**. Impact of screening on cervical cancer incidence in New Mexico. A nested case-control study. *Int J Cancer* 2019 Dec 13. doi: 10.1002/ijc.32826. [Epub ahead of print]. PMID: 31837006; PMCID: PMC6742586
344. Zhu B, Xiao Y, Yeager M, Clifford G, Wentzensen N, Cullen M, Boland JF, Burk RD, Bass S, Steinberg M, Raine-Bennett T, Nelson CW, Pinheiro, M, Burdett L, Yu K, Wu H-H, Song L, Dean M, Roberson D, Lorey T, Franceschi S, **Castle PE**, Walker J, Zuna R, Schiffman M, Mirabello L. APOBEC3-induced mutations of HPV16 are diminished in cervical precancer-cancer cases and contribute to viral evolution. *Nature Commun* 2020; 11:886. PMID: 32060290; PMCID: PMC7021686
345. **Castle PE**, Varallo JE, Betram MM, Ratshaa B, Kitheka M, Rammipi K, Pheto T. High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana. *PLoS One* 2020;15:e0229086. PMID: 32053659 ; PMCID: PMC7018080
346. Usyk M, **Castle PE**, Befano B, Porras C, Herrero R, Gradissimo A, Hildesheim A, Safaeian M, Kreimer A, Schiffman M, Burk RD. Role of the cervical microbiome in the HPV natural history. *PLoS Pathol* 2020;16(3):e1008376. PMID: 32214382 PMCID: PMC7098574.
347. Murenzi G, Kanyabwisha F, Murangwa A, Kubwimana G, Mutesa L, Burk RD, Anastos K, **Castle PE**. Twelve-year trend in the prevalence of high-risk human papillomavirus infection among Rwandan women living with HIV. *J Infect Dis* 2020 Feb 12. pii: jiaa065. doi: 10.1093/infdis/jiaa065. [Epub ahead of print]. PMID: 3205002
348. Hashim D, Engesæter B, Skare GB, **Castle PE**, Bjørge T, Røysland K, Andreassen T, Trope A, Nygård M. Real world data on cervical cancer risk stratification by cytology and HPV results to inform the management of HPV-positive women in routine cervical screening. *Brit J Cancer* 2020 Apr 3. doi: 10.1038/s41416-020-0790-1. [Epub ahead of print] PMID: 32242098
349. Wentzensen N, Lahrmann B, Clarke M, Kinney W, Tokugawa D, Poitras N, Bartels L, Krauthoff A, Walker J, Zuna R, Grewal KK, Goldhoff PE, Kingery JD, **Castle PE**, Schiffman M, Lorey T, Grabe N. Deep learning-based evaluation of dual stain cytology improves efficiency of cervical cancer screening. (*J Natl Cancer Instit*, in Press)
350. Hammer A, Demarco M, Campos N, Befano B, Gravitt PE, Cheung L, Lorey TS, Poitras N, Wentzensen N, **Castle PE**, Schiffman. Results of a 15-Year Experience with HPV-Based Cervical Screening for Detection of CIN3+ among 1.5 Million Women at Kaiser Permanente Northern California *Int J Cancer* 2020 Mar 6. doi: 10.1002/ijc.32950. [Epub ahead of print]. PMID: 32141607
351. In H, Solsky I, **Castle PE**, Schlecter C, Parides M, Friendmann P, Wylie-Rosett J, Kemeny MM, Rapkin. Utilizing cultural and ethnic variables in screening models to identify individuals at high risk for gastric cancer. *Cancer Prev Res* 2020; May 14. pii: canprevres.0490.2019. doi: 10.1158/1940-6207.CAPR-19-0490. [Epub ahead of print] PMID: 32409594
352. Murenzi G, Kim H-Y, Munyaneza A, Tuyisenge P, Zawadi T, Buteera A, Adedimeji A, Mutesa L, **Castle PE**, Anastos K, Palefsky JM. Anogenital human papillomavirus and HIV infection in Rwandan men who have sex with men. (*JAIDS*, in Press)

353. Alfaro K, Maza M, Felix J, Gage JC, **Castle PE**, Alonzo TA, Chacón A, González E, Soler M, Conzuelo-Rodriguez G, Masch R, Cremer M. Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen and Treat Program in El Salvador. (*J Global Oncol*, Accepted)
354. Perkins RB, Guido RL, **Castle PE**, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim J, Moscicki A-B, Nayar R, Saraiya M, Sawaya G, Wentzensen N, Schiffman, for the 2019 ASCCP Risk-Based Management Consensus Guidelines Conference. 2019 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors: ASCCP Risk-Based Management Consensus Guidelines. *J Low Genit Tract Dis* 2020 24:102-131. PMID: 32243307
355. Egemen D, Cheung LC, Chen X, Demarco M, Kinney W, Poitras N, Befano B, Locke A, Perkins R, Guido R, Wiser AL, Gage J, Katki HA, Wentzensen N, **Castle PE**, Schiffman M, Lorey T. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. *J Low Genit Tract Dis* 2020;24:132-143. PMID: 32243308
356. DeMarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, Lorey TS, Chen X, Gage JC, **Castle PE**, Wentzensen N, Perkins RB, Guido RS, Schiffman M. A Study of Partial HPV Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. *J Low Genit Tract Dis* 2020;24:144-147. PMID: 32243309
357. Pinheiro M, Schiffman M, Clifford G, Chen Z, Yeager M, Cullen M, Boland JF, Raine-Bennett T, Steinberg M, Bass S, Gage J, Xiao Y, Vanessa Tenet V, Wentzensen N, Yu K, Zhu B, Burdett L, Turan S, Lorey T, **Castle PE**, Burk RD, Mirabello L. HPV35 A2 sublineage confers increased risks of cervical precancer/cancer in women of African ancestry. *Int J Cancer* 2020 May 4. doi: 10.1002/ijc.33033. [Epub ahead of print] PMID: 32363580
358. Adedimeji A, Ajeh R, Pierz A, Nkeghe R, Ndekeh J, Fuhngwa N, Nsame D, Dzudie A, Anastos KM, **Castle PE**. Challenges and opportunities to reduce the burden of cervical cancer in a low income, high HIV prevalence context. (*BMC Women's Health*, Accepted)
359. Adedimeji A, Ajeh R, Dzudie A, Kendowo E, Fuhngwa N, Nsame D, Orock E, Hebert TM, Pierz A, Murokora D, Anastos KM, **Castle PE**. Cervical human papillomavirus DNA detection in HIV-infected and HIV-uninfected women living in Limbe, Cameroon. (*J Clin Virol*, in Press)
360. Keller MJ, Hessel N, Eltoun I-E, Einstein MH, **Castle PE**, Massad LS, Flowers L, Rahangdale K, Atrio JM, Ramirez C, Minkoff H, Adimora AA, Ofotokun I, Colie C, Huchko M, Fischl M, Wright R, D'Souza G, Hennessy M, Leider J, Diaz O, Sanchez-Keeland L, Watts H, Shrestha S, Wrenn A, Xie X, Xue X, Anastos K, Palefsky J, Burk RD, Strickler HD. Primary HPV and Molecular Cervical Cancer Screening in Women Living with HIV. (*Clin Infect Dis*, Accepted)
361. Baena A, Agudelo MC, Lopez C, Ramírez AT, Castañeda M, Riveros M, Posada G, Buitrago CA, Suescun D, Gomez LJ, Ochoa JC, Stoler M, Gage J, **Castle PE**, Sasieni P, Almonte M, Herrero R, Sanchez GI; for the ASCUS-COL Trial Group* Comparison of immediate colposcopy, repeat conventional cytology and hrHPV testing for the management of ASC-US cytology in routine health services of Medellín, Colombia: The ASCUS-COL Trial (*Int J Cancer*, Accepted)
362. Pierz AJ, Randall TC, Ingabire CM, Uwinkindi F, **Castle PE**, Murenzi G. A Scoping

Review: Facilitators and Barriers of Cervical Cancer Screening and Early Diagnosis of Breast Cancer in Sub-Saharan African Health Settings. (*Gynecol Oncol Report*, Accepted)

363. **Castle PE**, Pierz AJ, Adcock A, Aslam S, Austin J, Basu P, Belinson JL, Cuzick J, El-Zein-M, Ferrecio C, Firnhaber C, Franco EL, Gravitt PE, Isidean SD, Lin J, Mahmud S, Monsonogo J, Muwonge R, Ratman S, Safaeian M, Schiffman M, Smith JS, Swarts A, Wright TC, Van De Wyngard V, Xi L-F. A pooled analysis to compare the clinical characteristics of human papillomavirus-positive and -negative cervical precancers. (*Cancer Prev Res*, Accepted)
364. Torres SM, Wentzensen N, Stoler MH, Darragh TM, Gravitt PE, Schiffman M, Ronnett BM, Joste NE, Torrez-Martinez N, Adcock R, Cuzick J, Wheeler CM, For the p16 Study Panel and the **New Mexico HPV Pap Registry Steering Committee**. Estimating the benefits and harms of p16 utilization on cervical biopsy interpretation in routine clinical practice. (*APLM*, Accepted)

XIX.B. Non-Peer Reviewed Articles (Chapters, Reviews, or Commentaries)

XIX.B.1. Reviews and Guidelines

1. **Castle PE**, Dean J. Molecular genetics of the zona pellucida: implications for immunocontraceptive strategies. *J Reprod Fertil Suppl* 1996;50:1-8. PMID: 8984171
2. **Castle PE**, Dean J. Manipulating the genome to study reproduction. Mice with 'humanized' zonae pellucidae. *Hum Reprod* 1999;14:1927-39. PMID: 10438400
3. Schiffman M, **Castle PE**. Human papillomavirus: epidemiology and public health. *Arch Pathol Lab Med* 2003;127:930-4. PMID: 12873163
4. **Castle PE**, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors. *J Natl Cancer Inst Monogr* 2003;31:29-34. PMID: 12807942
5. Solomon D, **Castle PE**. ALTS: Impact on cervical cytology screening, triage and patient management. *Pathol Case Rev* 2005;10:128-37.
6. Meijer CJM, Snijders PJF, **Castle PE**. Clinical utility of HPV genotyping. *Gynecol Oncol* 2006;103:12-7. PMID: 16934860
7. Saslow D, **Castle PE**, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, Gynecologic Cancer Advisory Group, Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA Cancer J Clin* 2007;57:7-28. PMID: 17237032
8. Safaeian M, Solomon D, **Castle PE**. Cervical cancer prevention--cervical screening: science in evolution. *Obstet Gynecol Clin North Am* 2007;34:739-60. PMID: 18061867; PMCID:PMC2762353
9. **Castle PE**. The potential utility of HPV genotyping in screening and clinical management. *J Natl Compr Canc Netw* 2008;6:83-95. PMID: 18267061
10. **Castle PE**, Solomon D, Saslow D, Schiffman M. Predicting the effect of successful human

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- papillomavirus vaccination on existing cervical cancer prevention programs in the United States. *Cancer* 2008;113(10 Suppl):3031-5. PMID: 18980285
11. HPV Vaccines I, II, and III. UpToDate (http://www.uptodate.com/home/clinicians/toc.do?tocKey=table_of_contents/-1/8) (2009-2017).
 12. Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam S, Cain J, Kinney W, Garcia FAR, Moriarty A, Waxman A, Wilbur D, Wentzensen N, Downs L, Spitzer M, Moscicki AB, Saraiya M, Franco EL, Stoler MS, Schiffman M, **Castle PE**[†], Evan R. Myers[†]; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology Screening Guideline for the Prevention of Cervical Cancer. ([†]Co-senior authors) *CA Cancer J Clin* 2012;62:147-72. PMID: 22422631; *Am J Clin Pathol* 2012;137:516-42. PMID: 22431528; *J Lower Gen Tract Dis* 2012;16:175-204. PMID: 22418039
 13. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Wilbur DC, **For Members of the LAST Project Work Groups**. The HPV-associated Lower Anogenital Squamous Terminology Project of the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology Terminology: Background and Consensus Recommendations. *J Lower Gen Tract Dis* 2012;16:205-242. PMID: 22820980; *Arch Pathol Lab Med.* 2012;136:1266-97. PMID: 22742517; *Int J Gynecol Pathol* 2013 Jan;32(1):76-115;. PMID: 23202792
 14. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson, **on behalf of the 2012 ASCCP Consensus Guidelines Conference**. Updating guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *J Lower Genit Tract Dis* 2013;17:S1-S27. PMID: 23519301
 15. **Castle PE**, Cremer M. HPV Testing in Cervical Cancer Screening. *Obstet Gynecol Clin North Am* 2013;40:377-90. PMID: 23732037
 16. **Castle PE**, de Sanjose S, Qiao Y-L, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of HPV DNA screening in the world: 15 years of experience In: The need for professional information on HPV and the novel options for cancer prevention. Monograph series on HPV and cancer. *Vaccine* 2012; Volume 30, Supplement 5, F117-22. PMID: 23199954
 17. Bosch FX, Broker TR, David Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, **Castle PE**, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJLM, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. *Vaccine* 2013;31 Suppl 5:F1-F31. doi: 10.1016/j.vaccine.2013.10.001. PMID: 24331745; Suppl 6:G1-G31. doi: 10.1016/j.vaccine.2013.10.002. PMID: 24331817; Suppl 7:H1-H31. doi: 10.1016/j.vaccine.2013.10.003. PMID: 24332295.
 18. Jeronimo J, **Castle PE**, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. *J Oncol Pract* 2016 Nov 15;JOP2016017889. [Epub ahead of print] No abstract available. PMID: 27845871

19. **Castle PE**, Temin S, Shastri SS, Jeronimo J. Screening To Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. *J Clin Oncol* 2017;35:1250-1252. PMID: 28135111
20. **Castle PE**, Murokora D, Perez C, Alvarez M, Quek SC, Campbell C. Treatment of cervical intraepithelial lesions. *Int J Gynecol Cancer* 2017;138 Suppl 1:20-25. PMID: 28691333
21. **Castle PE**, Pierz A. (At least) Once in her lifetime. *Obstet Gynecol Clin North Am* 2019;46:107-123. PMID: 30683258

XIX.B.2. Commentaries

22. Schiffman M, **Castle PE**. Commentary on “Persistent HPV infection is associated with a greater risk of developing cervical lesions than a single positive test.” *Evidence-Based Obstet Gynecol* 2002;4:148-9.
23. **Castle PE**, Schiffman M. Commentary on “Management of women who test positive for high-risk types of human papillomavirus: the HART study.” *Evidence-Based Obstet Gynecol* 2004;6:150-1.
24. **Castle PE**. Review of: Rohan T, Shah K (eds.). Cervical cancer: from etiology to prevention. *Cancer Causes Control* 2004;15:435.
25. Pfeiffer RM, **Castle PE**. With or without a gold standard. *Epidemiology* 2005;16:595-7. PMID: 16135933
26. Schiffman M, **Castle PE**. The promise of global cervical-cancer prevention. *N Engl J Med* 2005;353:2101-4. PMID: 16291978
27. Schiffman M, **Castle PE**. When to test women for human papillomavirus. *BMJ* 2006;332:61-2. PMID: 16410556
28. **Castle PE**. Commentary: Hormonal contraceptives and the risk of cervical precancer. *Salud(i)Ciencia*, 2006.
29. **Castle PE**. “Does contraceptive use impact cervical cancer risk?” *Contraceptive Technology Update*, March 2006:31-32.
30. Stoler MH, **Castle PE**, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. *Am J Clin Pathol* 2007;127:335-7. PMID: 17276947
31. Stoler M, **Castle P**, Solomon D, Schiffman M. Re.: The expanded use of human papillomavirus testing in gynecologic practice. *Am J Clin Pathol* 2007;128:883-6. PMID: 17276947
32. **Castle PE**. Invited commentary: is monitoring human papillomavirus infection for viral persistence ready for use in cervical cancer screening? *Am J Epidemiol* 2008;168:138-44. PMID: 18483124; PMCID:PMC2443359
33. Cox JT, Moriarty AT, **Castle PE**. Commentary on: Statement on HPV DNA Test Utilization. *Am J Clin Pathol* 2009;131:770-773, *Diagn Cytopathol* 2009;37:471-4, *J Low Genit Tract Dis* 2009;13:131-4; *Arch Pathol Lab Med* 2009;133:1192-4. PMID: 19550208 and. PMID: 19459174
34. **Castle PE**. The evolving definition of carcinogenic human papillomavirus. *Infect Agent*

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

- Cancer* 2009;4:7. PMID: 19432962
35. **Castle PE**, Katki HA. Benefits and risks of HPV testing in cervical cancer screening. *Lancet Oncol* 2010;11:214-5. PMID: 20089448
 36. **Castle PE**. HPV testing for cervical cancer: the good, the bad, and the ugly. *Nature Rev Clin Oncol* 2010;7:364-5. PMID: 20592711
 37. Kinney W, Stoler MH, **Castle PE**. Special commentary: Patient safety and the next generation of HPV DNA tests. *Am J Clin Pathol* 2010;134:193-199. PMID: 20660320
 38. Gage JC, **Castle PE**. Preventing cervical cancer globally by acting locally: If not now, when. *J Natl Cancer Inst* 2010;102:1524-7. PMID: 20884892; PMCID:PMC2957431
 39. Ghosh A, **Castle PE**. Invited Commentary: Comparing Effectiveness of Markers. *Am J Epidemiol* 2011;173:1388-90. PMID: 21571873
 40. **Castle PE**. Abuses in HPV testing. *Obstet Gynecol* 2011;118:1-3. PMID: 21691156
 41. **Castle PE**, Zhao F-H. Editorial on HPV Vaccination of Boys. *J Infect Dis* 2011;204:335-7. Erratum in: *J Infect Dis*. 2011;204:1149. PMID: 21742829
 42. **Castle PE**. More Evidence for Supporting Human Papillomavirus Testing. *Nature Rev Clin Oncol* 2012;9:131-2. PMID: 22330684
 43. Roberts DJ, Wilson ML, Nelson AM, Adesina AM, Fleming KA, Milner D, Guarner J, Rebbeck TR, **Castle P**, Lucas S. RE: The good news about cancer in developing countries – *Pathology answers the call*. *Lancet* 2012; 379:712. PMID: 22364759
 44. **Castle PE**, Schmeler KM. Optimizing cervical cancer prevention in the United States. *Gynecol Oncol* 2012;127:437-9. PMID: 23140752
 45. **Castle PE**. A LASTing Impression: Incorporating p16 immunohistochemistry into routine diagnosis of cervical neoplasia. *Pathology Case Rev* 2013; 18:154-7.
 46. **Castle P**. Current status and future trends in cervical cancer screening. *Womens Health (Lond)* 2014; 10:129-33. PMID: 24147567
 47. **Castle PE**. The new standard of care: high-risk human papillomavirus testing for cervical cancer screening. *Nature Rev Clin Oncol* 2015; Apr;12:194-6. PMID: 25707625
 48. Arbyn M, **Castle PE**. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening programme. *Cancer Epidemiol Biomarkers Prev* 2015;24:769-72. PMID: 25713024
 49. **Castle PE**. Understanding the limitations of cytology for screening. *HPV Today*
 50. **Castle PE**. Cervical Cancer Prevention in 21st Century in Norway. *Cancer in Norway 2015*
 51. Waxman AG, Buenconsejo-Lum LE, Cremer M, Feldman S, Ault KA, Cain JM, Diaz ML; **Expert Panel on Cervical Cancer Screening in the US Territories Pacific Island Jurisdictions**. Cervical Cancer Screening in the United States-Affiliated Pacific Islands: Options and Opportunities. *J Low Genit Tract Dis* 2016;20:97-104. PMID: 26704332
 52. Khan MJ, Massad LS, Kinney W, Gold MH, Mayeaux EJ, Darragh TM, **Castle PE**, Chelmow, Lawson HW, Huh WK. A common clinical dilemma: management of abnormal vaginal cytology and HPV testing. *J Lower Genit Tract Dis* 2016;20:119-25. PMID: 26901279; *Gynecol Oncol* 2016 141(2):364-370. PMID: 26915529; PMCID:PMC4977828

53. **Castle PE**, Katki HA. A Risk-Based Framework to Decide Who Benefits from Cancer Screening. *Nat Rev Clin Oncol* 2016;13:531-2. PMID: 27323876; PMCID:PMC5505517
54. **Castle PE**, Burger EA. Age of HPV Vaccination? *Lancet Infect Dis* 2016;16:1091-3. PMID: 27373899
55. **Castle PE**. When less is more. *J Natl Cancer Inst.* 2017;109:. PMID: 27756809
56. Schiffman M, Wentzensen N, Khan MJ, **Castle PE**, Chelmow D, Huh WK, Moscicki AB, Stockdale CK, Darragh TM, Silver M, Guido RS. Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. *J Low Genit Tract Dis.* 2017; 21:87-90. PMID: 28244885; PMCID: PMC5365374
57. **Castle P**, Feldman S, Perkins R. The next generation of cervical cancer screening: should guidelines focus on best practices for the future or current screening capacity? *J Low Genit Tract Dis* 2018;22:91-96. PMID: 29570563; PMCID: PMC5895142.
58. **Castle PE**. Time for Risk-Based Screening Guidelines for the Prevention of Anal Cancer? *Clinic Infect Dis*

XIX.B.3. Letters

59. Gravitt PE, **Castle PE**. Chlamydia trachomatis and cervical squamous cell carcinoma. *JAMA* 2001;285:1703-4. PMID: 11277819
60. **Castle PE**. Could multiple low-affinity bonds mediate primary sperm-zona pellucida binding? *Reproduction* 2002;124:29-32. PMID: 12090915
61. **Castle P**. Cervical cancer screening among women without a cervix. *JAMA* 2004;292:1550-1; author reply 1551-2. PMID: 15467050
62. Schiffman M, **Castle PE**, Solomon D, Stoler ME, Wheeler C. Response to Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. *J Natl Cancer Inst* 2005;97:938-41. PMID: 15956659
63. **Castle PE**. Human papillomavirus (HPV) genotype 84 infection of the male genitalia: further evidence for HPV tissue tropism? *J Infect Dis* 2008;197:776-8. PMID: 18419356
64. **Castle PE**. How does tobacco smoke contribute to cervical carcinogenesis? *J Virol* 2008;82:6084-5. PMID: 18497423; PMCID:PMC2395121
65. **Castle PE**. Cervical cancers after HPV vaccination. *Obstet Gynecol* 2009;114:174. PMID: 19546791
66. Sasieni P, **Castle PE**, Cuzick J. Further analysis of the ARTISTIC trial. *Lancet Oncol* 2009;10:841-2. PMID: 19717086
67. Katki HA, Wacholder S, Solomon D, **Castle PE**, Schiffman M. Risk estimation for the next generation of prevention programmes for cervical cancer. *Lancet Oncol* 2009;10:1022-3. PMID: 19767237
68. **Castle PE**, Scarinci I. Should HPV vaccine be given to men? *BMJ* 2009;339:b4127. PMID: 19815585
69. Solomon D, **Castle P**, Hildesheim A, Schiffman M, Wacholder S. HPV vaccination in women aged 24-45 years. *Lancet* 2009; 374:1239. PMID: 19819386

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

70. Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, **Castle PE**. Reply to Comment re: Detection of cervical precancer by HPV genotype. *Cancer Res* 2010;70:2136. PMID: 20179199
71. **Castle PE**, Carreon JD. Letter to the Editor. Re: Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. *J Low Genit Tract Dis* 2010;14:238-40. PMID: 20592562
72. Kinney W, Stoler MH, **Castle PE**. Response to Letter to the Editor re. Special commentary: Patient safety and the next generation of HPV DNA tests (*Am J Clin Pathol* 2010;134:193-199). *Am J Clin Pathol* 2011;135:481-3. PMID: 20660320
73. **Castle PE**, Gage JC. Response to Letter to the Editor re. Preventing cervical cancer globally by acting locally: If not now, when (*J Natl Cancer Inst* 2010;102:1524-7). *J Natl Cancer Inst* 2011;103:612-3.
74. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage J, **Castle PE**. Response to Letter to the Editor re. HPV testing in the prevention of cervical cancer. *J Natl Cancer Inst* 2011 103:1483-1484 (*J Natl Cancer Inst* 2011;103:368-83.).
75. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, **Castle PE**. Premature conclusions on HPV-only testing---Author's reply. *Lancet Oncol* 2011:993. PMID: 21968223
76. Myers E, **Castle P**, Saslow D. In reply. *J Low Genit Tract Dis* 2012;16:483-5.
77. **Castle PE**. Letter to the Editor (RE: RE: Population-Level Impact of the Bivalent, Quadrivalent, and Candidate Nonavalent Human Papillomavirus Vaccines: A Comparative Model-Based Analysis.) *J Natl Cancer Inst* 2013;105:1254. PMID: 23907339
78. **Castle PE**. A teaching moment: why promising biomarkers do not always translate into clinically useful tests (RE: Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer). *J Clin Oncol* 2014;32:359-61. PMID: 24366935
79. **Castle PE**. The Interpretation of LSIL-H. *Am J Clin Pathol* 2014;142:278-9. PMID: 25015874
80. **Castle PE**, Schmeler KS. HPV vaccination: for women of all ages? *Lancet* 2014 Sep 1. pii: S0140-6736(14)61230-7. doi: 10.1016/S0140-6736(14)61230-7. [Epub ahead of print]. PMID: 25189357
81. **Castle PE**. The new era of primary HPV screening for prevention of cervical cancer. *Cancer Forum* 2014;38:209-14
82. Kim JJ and **Castle PE**. Letter to the editor regarding Firnhaber et al.'s Evaluation of a Cervicography-Based Program to Ensure Quality of Visual Inspection of the Cervix in HIV-Infected Women in Johannesburg, South Africa. *J Lower Genit Tract Dis* 2015;19:e45-6. PMID: 25811272
83. Gage JC, Schiffman M, Katki H, **Castle PE**, Fetterman B, Wentzensen N, Poitras N, Lorey T, Cheung LC, Kinney WK. Responses Letter re. Evidence on the potential safety of stand-alone HPV testing from 1 million women undergoing HPV and Pap testing in routine cervical cancer screening since 2003 (*J Natl Cancer Inst* 2014;106(8)). *J Natl Cancer Inst* 2014; 107:390. PMID: 25542966

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

84. **Castle PE.** Prostate-Specific Antigen Testing for Prostate Cancer Screening: *Lancet Oncol* 2015 Jan;16:e2-3. PMID: 25638549
85. **Castle PE,** Konno R, Bosch X. HPV vaccination: Just the facts. *Intern Med.* 2015;54:1829. PMID: 26179547
86. **Castle PE.** Letter to the Editor. *Cancer Epi Biomark Prev* 2015;24:1295. PMID: 26240171
87. **Castle PE.** Letter to the Editor. *Cancer Cytopath* 2015;123:566. PMID: 26179787
88. Wentzensen N, Fetterman B, Castle P, Schiffman M, Wood S, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W. Response. *J Natl Cancer Inst* 2016;108. PMID: 26711869; PMCID: PMC4862437.
89. **Castle PE.** Letter to the Editor. *Prev Med* 2017;105:356. PMID: 28939142
90. **Castle PE.** Charting the Future of Cancer Health Disparities Research-Letter. *Cancer Res* 2018;78:1883-1885. PMID: 29506973
91. Jeronimo J, Temin S, **Castle PE,** Shastri SS. Reply to M. Swanson *et al.* *J Glob Oncol.* 2018;(4):1-2. PMID: 30241216; PMCID: PMC6180766
92. Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, **Castle PE,** Bray F, Canfell K. Towards global elimination of cervical cancer in all groups of women - Authors' reply. *Lancet Oncol* 2019 May;20(5):e239. PMID: 31044714

XIX.B.4. Chapters

93. Alberts DS, Barakat RR, Daly M, Method MW, Benbrook DM, Boggess JF, Brewer MA, Brinton LA, **Castle PE,** Davanipour Z, Garcia FAR, Hanly MG, Hess LM, Hines JF, Kelaghan J, Lucci J, Minasian L, Muller C, Mutter GL, Rader JS, Rodríguez G, Sobel E, Walker JL. Prevention of gynecologic malignancies. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G, eds. *Gynecologic cancer: controversies in management.* Philadelphia: Elsevier Science, 2004;883-919.
94. Kitchener HC, **Castle PE,** Cox T. Chapter 7: Achievements and limitations of cervical cytology screening. In: *HPV vaccines and screening for cervical cancer prevention.* *Vaccine* 2006;24 Suppl 3:S3/63-70. PMID: 16950019
95. Konduri N, Quick J, Gralow J, Samiei M, **Castle P,** Guerrero R. Chapter 7, PART III: Access to affordable medicines, vaccines, and health technologies. *Closing The Cancer Divide: An Equity Imperative.* 2012

Preparation/Submitted

- Torres SM, Wentzensen N, Stoler MH, Darragh TM, Gravitt PE, Schiffman M, Ronnett BM, Joste NE, Torrez-Martinez N, Adcock R, Cuzick J, Wheeler CM, For the p16 Study Panel and the **New Mexico HPV Pap Registry Steering Committee**. Estimating the benefits and harms of p16 utilization on cervical biopsy interpretation in routine clinical practice. (*APLM*)
- Adedimeji A, Murenzi G, Sinayobye JD, Munyaneza A, Hoover DR, Kim H-Y, Shi Q, Gasana J, Mivumbi J-P, **Castle PE**, Mutesa L, Palefsky J, Anastos K. Cohort description and baseline participant characteristics: A study of HPV and HIV incidence and prevalence in Rwandan men who have sex with men.
- Pierz AJ, Randall TC, Ingabire CM, Uwinkindi F, **Castle PE**, Murenzi G. A Scoping Review: Facilitators and Barriers of Cervical Cancer Screening and Early Diagnosis of Breast Cancer in Sub-Saharan African Health Settings. (*Gynecol Oncol Report*)
- **Castle PE**, Kinney WK, Chen L, Kim J, Jenison S, Rossi G, Cuzick J, Wheeler CM, on behalf of the New Mexico HPV Pap Registry (NMHPVPR) Steering Committee. The impact of changing national guidelines on cervical screening adherence: a population-based evaluation from New Mexico.
- Munyaneza A, Kim H-Y, Ross J, Murenzi G, Kabahizi J, Gasana J, Nsengiyumva B, Kubwimana G, Muhoza B, Ingabire, Mutesa L, Adedimeji A, **Castle PE**, Palefsky JM, Anastos KM, Patel VV. Awareness and willingness to use HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Rwanda.
- **Castle PE**, Pierz AJ, Adcock A, Aslam S, Austin J, Basu P, Belinson JL, Cuzick J, El-Zein-M, Ferrecio C, Firnhaber C, Franco EL, Gravitt PE, Isidean SD, Lin J, Mahmud S, Monsonogo J, Muwonge R, Ratman S, Safaeian M, Schiffman M, Smith JS, Swarts A, Wright TC, Van De Wyngard V, Xi L-F. A Limitation of Using Verification-Bias Adjustment in Estimating the Performance of Human Papillomavirus Testing for Detection of Cervical Precancer and Cancer. (*Cancer Epi Biomark Prev*)
- Savas LS, Atkinson JA, Figueroa-Solis E, Valdez A, Morales P, **Castle PE**, Fernandez ME. Evaluation of a Lay Health Worker Intervention to Improve Breast and Cervical Cancer Screening among Latinas in El Paso, Texas: Unidas Por Vida Y Salud. (*Amer J Prev Med*)
- Pierz A, Awoh AR, Fuhngwa N, Nasah J, Dzudie A, Nkeng R, Anastos K, **Castle PE**, Adedimeji A. Acceptability of Self-Sampling for Cervical Cancer Screening Among Women Living with HIV and HIV-Negative Women in Limbé, Cameroon.
- Pinheiro M, Harari A, Schiffman M, Clifford GM, Chen Z, Yeager M, Cullen M, Boland JF, Raine-Bennett T, Steinberg M, Bass S, Xiao Y, Tenet V, Wentzensen N, Yu K, Zhu B, Burdett L, Turan S, Lorey T, Castle PE, Burk RD, Mirabello LM. Characterization of viral genomic variation and methylation of the human papillomavirus type 31: a study of 2,228 viral genomes. (*J Virol*)
- Hunt B, Schwarz RA, Borba K, Andrade V, Silva E, Loami L, Pantano N, Brenes D, Carns J, Cherry K, Salcedo M, Cury F, Possati-Resende JC, Antoniazzi M, de Oliveira Fonseca B, de Macêdo Matsushita G, Kerr L, Santana I, Fregnani JHTG, **Castle PE**, Schmeler K, Richards-Kortum R. The CLARA Study – Cervical lesion assessment using real-time

Philip Edward Castle, Ph.D., M.P.H.
 NCI Division of Cancer Prevention
 9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
 240-276-7120; philip.castle@nih.gov

microendoscopy image analysis: a validation study.

- Mayrand MH, Ndiaye C, Trottier H, Coutlee F, Schiffman M, Wentzensen N, Gage JC, Lorey TS, Poitras N, Raine-Bennett TR, Befano B, Burk RD, **Castle PE**. Age and risk of cervical high-grade intraepithelial lesion following high-risk HPV infection. (*Amer J Obstet Gynecol*)
- Landy R, Mathews C, Robertson M, Wiggins CL, McDonald YJ, Goldberg DW, Scarinci IC, Cuzick J, Sasieni PD, Wheeler CM, **for the New Mexico HPV Pap Registry Steering Committee**. A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. (*Int J Cancer*)
- Knapp GC, Alatise O, Olopade B, Samson M, Olasehinde O, Wuraola F, Akinwunmi AO, Arije OO, **Castle PE**, Smith J, Weiser MR, Kingham TP. Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal screening in Nigeria.
- 211
- Cameroon
- Cotesting vs. HPV for Endo/Ovarian
- Nygård M, Engesæter B, **Castle PE**, Berland J, Eide ML, Iversen OE, Jonassen C, Christiansen IK, Vintermyr OK, Trope A. Randomized introduction of high-risk human papillomavirus testing within existing organized cervical cancer screening program in Norway.
- Engesæter B: Cancers
- Scarinci: Delta
- Salcedo MP, Oliveira C, Andrade V, Mariano AAN, Changule D, Rangeiro R, Monteiro ECS, Baker E, Phoolcharoen N, Varon ML, Matos T, Thomas JP, Castle PE, Fregnani JHTG, Lorenzoni C, Schmeler KM. The Capulana study: A prospective evaluation of cervical cancer screening using primary human papillomavirus (HPV) testing in Mozambique. (*Int J Gynecol Cancer*)
- 2nd Capulana manuscript
- Fight PV
- Parra S, Carns J, Schwartz R, Smith C, Felix J, Ramalingam P, **Castle PE**, Schmeler K, Richards-Kortum R. Evaluation of screening and triage strategies incorporating VIA, HPV DNA testing, and high-resolution microendoscopy to identify women needing immediate treatment for high-grade cervical abnormalities in El Salvador. (*Int J Cancer*)
- Murenzi G, Tuyisenge P, Kanyabwisha F, Munyaneza A, Muhoza B, Kubwimana G, Murangwa A, Mutesa L, Anastos K, **Castle PE**. Type-specific persistence, incidence and clearance of high-risk HPV among screen-positive Rwandan women living with HIV (*Infect Agent Cancer*)
- Marcus JZ, Abedin Y, Taveras Y, Parmar H, Sollecito CC, Pierz AJ, Burk RD, **Castle PE**. A pilot study of HPV detection in urine using the Xpert HPV Test. (*J Appl Lab Med*)
- **Castle PE**, Ajeh R, Dzudie A, Kendowo E, Fuhngwa N, Nsame D, Orock E, Hebert TM, Pierz AJ, Murokora D, Anastos A, Adedimeji A. A Comparison of Screening Tests for

Detection of High-Grade Cervical Abnormalities in Women Living with HIV from Cameroon
(*Infect Agent Cancer*)

Philip Edward Castle, Ph.D., M.P.H.
NCI Division of Cancer Prevention
9609 Medical Center Drive, Room 5E410, Bethesda, MD 20892
240-276-7120; philip.castle@nih.gov